细胞株Cell Lines 56-BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心http://www.biovector.net
- 价 格：¥19200
- 货 号：NTCC-CV56
- 产 地：北京
- BioVector NTCC典型培养物保藏中心
- 联系人：Dr.Xu, Biovector NTCC Inc.
电话：400-800-2947 工作QQ:1843439339 (微信同号)
邮件：Biovector@163.com
手机：18901268599
地址：北京
- 已注册
细胞株Cell Lines-BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心
ID JM8A1.N3
AC CVCL_J958
WW https://www.komp.org/pdf.php?cloneID=236746
WW https://www.komp.org/pdf/Culturing_protocol_for_JM8A-Agouti.pdf
CC Breed/subspecies: C57BL/6N.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_J957 ! JM8
SX Male
CA Embryonic stem cell
//
ID JM8A3
AC CVCL_J959
RX PubMed=19525957;
WW https://www.komp.org/pdf.php?cloneID=236747
WW https://www.komp.org/pdf/Culturing_protocol_for_JM8A-Agouti.pdf
CC Breed/subspecies: C57BL/6N.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_J957 ! JM8
SX Male
CA Embryonic stem cell
//
ID JM8A3.N1
AC CVCL_J960
WW https://www.komp.org/pdf.php?cloneID=236745
WW https://www.komp.org/pdf/Culturing_protocol_for_JM8A-Agouti.pdf
CC Breed/subspecies: C57BL/6N.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_J959 ! JM8A3
SX Male
CA Embryonic stem cell
//
ID JM8.F6
AC CVCL_J961
RX PubMed=19525957;
WW https://www.komp.org/pdf.php?cloneID=11959
WW https://www.komp.org/pdf/Culturing_and_media_conditions_for_KOMP_CSD_JM8_and_JM8_F6_ES_cell_clones_Protocol.pdf
CC Breed/subspecies: C57BL/6N.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_J957 ! JM8
SX Male
CA Embryonic stem cell
//
ID JM8.N4
AC CVCL_J962
RX PubMed=19525957;
WW https://www.komp.org/pdf.php?cloneID=8669
WW https://www.komp.org/pdf/Culturing_and_media_conditions_for_KOMP_CSD_JM8_N4_ES_cell_clones_Protocol.pdf
CC Breed/subspecies: C57BL/6N.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_J957 ! JM8
SX Male
CA Embryonic stem cell
//
ID JMA
AC CVCL_HA40
DR BCRJ; 0124
RX PubMed=23257665;
ST Source(s): BCRJ
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 12
ST D16S539: 8,12
ST D18S51: 13,15
ST D19S433: 14,15.2
ST D21S11: 28,32.2
ST D2S1338: 16,23
ST D3S1358: 16,17
ST D5S818: 11
ST D7S820: 8,12
ST D8S1179: 11,14
ST FGA: 24,25
ST TH01: 7
ST TPOX: 8,12
ST vWA: Not_detected
DI NCIt; C9142; Adult T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID JMAR
AC CVCL_1Q86
DR BioSample; SAMN03151990
RX PubMed=12907203;
RX PubMed=21868764;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Parent cell line (Tu 167) has been shown to be a UM-SCC-1 derivative (PubMed=21868764).
ST Source(s): PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 10,12,13
ST D13S317: 8,11,12
ST D16S539: 8,9,12,13
ST D5S818: 10,12,13
ST D7S820: 9,10,12
ST TH01: 6,8
ST TPOX: 8,10,11
ST vWA: 15,16,18
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4912 ! Tu 167
SX Male
CA Cancer cell line
//
ID JME/CF 12
AC CVCL_IN69
SY JME/CF12
RX PubMed=1701980;
CC Characteristics: Heterozygous for the CFTR p.Phe508del mutation.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
DI NCIt; C2975; Cystic fibrosis
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID JME/CF 15
AC CVCL_IN70
SY JME/CF15
RX PubMed=1701980;
RX PubMed=15463957;
RX PubMed=19584307;
CC Characteristics: Homozygous for the CFTR p.Phe508del mutation.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
DI NCIt; C2975; Cystic fibrosis
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID JMN
AC CVCL_M005
DR Cosmic; 733818
DR Cosmic; 1522776
DR Cosmic; 1541210
DR GEO; GSM726271
RX PubMed=3334988;
RX PubMed=7106748;
RX PubMed=21642991;
CC Omics: SNP array analysis.
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JMN-1B
AC CVCL_M006
SY JMN 1B; JMN1B
RX PubMed=2787682;
RX PubMed=15920167;
CC Omics: Transcriptome analysis.
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M005 ! JMN
SX Male
CA Cancer cell line
//
ID JMRD3
AC CVCL_D592
RX PubMed=7994044;
RX PubMed=8635507;
CC Selected for resistance to: ChEBI; CHEBI:73558; Vitamin D3.
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D591 ! RWLeu-4
CA Cancer cell line
//
ID JMSU-1
AC CVCL_2081
SY JMSU1
DR CLO; CLO_0050846
DR BioSample; SAMN03472026
DR BioSample; SAMN03473570
DR CCLE; JMSU1_URINARY_TRACT
DR Cosmic; 1285120
DR Cosmic; 2050446
DR Cosmic; 2057451
DR Cosmic; 2444245
DR DSMZ; ACC-505
DR GEO; GSM887187
DR GEO; GSM888260
DR RCB; RCB2227
RX PubMed=7483139;
RX PubMed=22460905;
RX PubMed=24367658;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Characteristics: Has lost chromosome Y.
CC Doubling time: 32 hours (PubMed=7483139); ~30 hours (DSMZ).
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Ascites.
ST Source(s): DSMZ; RCB
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 8,12 (DSMZ)
ST D13S317: 8 (RCB)
ST D16S539: 9,11
ST D5S818: 11
ST D7S820: 8
ST TH01: 6,9
ST TPOX: 8
ST vWA: 14,18 (DSMZ)
ST vWA: 14,19 (RCB)
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JMU-RTK-1
AC CVCL_4W57
RX PubMed=19383826;
CC Doubling time: ~9 hours (PubMed=19383826).
DI NCIt; C8715; Rhabdoid tumor of the kidney
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JMU-RTK-2
AC CVCL_4W58
DR JCRB; JCRB1484
RX PubMed=19383826;
CC Problematic cell line: Possibly misidentified. Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile).
CC Doubling time: ~18 hours (PubMed=19383826).
CC Derived from metastatic site: Cerebrospinal fluid.
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 8,10
ST D16S539: 9,11
ST D5S818: 11
ST D7S820: 9,12
ST TH01: 7,10
ST TPOX: 8,11
ST vWA: 14,18
DI NCIt; C8715; Rhabdoid tumor of the kidney
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JN-DSRCT-1
AC CVCL_9W68
SY JN-DSRCT
DR Cosmic; 1718818
RX PubMed=12218078;
RX PubMed=15782132;
CC Miscellaneous: So far it is the only DSCRCT cell line available.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C27372; Childhood desmoplastic small round cell tumor
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JN-M
AC CVCL_0C15
RX PubMed=1311980;
RX PubMed=7736387;
RX PubMed=9815546;
RX PubMed=10100721;
CC Derived from metastatic site: Bone marrow.
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JNU-hES-01
AC CVCL_X171
RX PubMed=24159464;
CC From: Jeju National University Stem Cell Research Center; South Korea.
CC Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010049.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID JNU-hES-02
AC CVCL_X172
RX PubMed=24159464;
CC From: Jeju National University Stem Cell Research Center; South Korea.
CC Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010050.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID JNUBK-3
AC CVCL_AP73
SY Jeju National University Bovine Kidney-3
RX DOI=10.13041/jpvm.2014.38.1.15;
CC Transfected with: HGNC; 11730; TERT.
CC Miscellaneous: Breed from personal communication of Hwang K.-K.
CC Breed/subspecies: Hanwoo.
OX NCBI_TaxID=9913; ! Bos taurus
OI CVCL_AP74 ! JNUBK-4
SX Female
CA Telomerase immortalized cell line
//
ID JNUBK-4
AC CVCL_AP74
SY Jeju National University Bovine Kidney-4
RX DOI=10.13041/jpvm.2014.38.1.15;
CC Transfected with: HGNC; 11730; TERT.
CC Miscellaneous: Breed from personal communication of Hwang K.-K.
CC Breed/subspecies: Hanwoo.
OX NCBI_TaxID=9913; ! Bos taurus
OI CVCL_AP73 ! JNUBK-3
SX Female
CA Telomerase immortalized cell line
//
ID JNUCK-1
AC CVCL_AP71
SY Jeju National University Canine Kidney-1
RX DOI=10.12729/jbr.2015.16.1.006;
CC Transfected with: HGNC; 11730; TERT.
CC Breed/subspecies: Mixed breed.
OX NCBI_TaxID=9615; ! Canis lupus familiaris
OI CVCL_AP72 ! JNUCK-2
SX Sex undetermined
CA Telomerase immortalized cell line
//
ID JNUCK-2
AC CVCL_AP72
SY Jeju National University Canine Kidney-2
RX DOI=10.12729/jbr.2015.16.1.006;
CC Transfected with: HGNC; 11730; TERT.
CC Breed/subspecies: Mixed breed.
OX NCBI_TaxID=9615; ! Canis lupus familiaris
OI CVCL_AP71 ! JNUCK-1
SX Sex undetermined
CA Telomerase immortalized cell line
//
ID Jo Cav
AC CVCL_U675
DR ATCC; CRL-1387
CC Discontinued: ATCC; CRL-1387; true.
DI NCIt; C118636; Stiff skin syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID Jo Per
AC CVCL_3320
DR CLO; CLO_0007032
DR ATCC; CRL-1332
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID Jo Vid
AC CVCL_U676
SY XP16BE
DR ATCC; CRL-1307
CC Discontinued: ATCC; CRL-1307; true.
DI NCIt; C3452; Xeroderma pigmentosum
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID Jo Zan
AC CVCL_U779
DR ATCC; CRL-1197
CC Discontinued: ATCC; CRL-1197; true.
DI NCIt; C34807; Marfan syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID JO-E
AC CVCL_0C16
DR Cosmic; 2239099
RX PubMed=1311980;
RX PubMed=7736387;
RX PubMed=9559344;
RX PubMed=9815546;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JO1-1
AC CVCL_G197
SY JO1.1
DR CLO; CLO_0007033
DR ATCC; HB-8638
OX NCBI_TaxID=10090; ! Mus musculus
CA Hybridoma
//
ID Joey-HSA
AC CVCL_0C98
SY JOEY
RX PubMed=19461996;
CC Breed/subspecies: Rottweiler.
DI NCIt; C122783; Canine hemangiosarcoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Male
CA Cancer cell line
//
ID JOG-9
AC CVCL_0P35
RX PubMed=2424598;
DI NCIt; C8107; Ovarian yolk sac tumor
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JOK-1 [Human gastric epithelial]
AC CVCL_9813
RX PubMed=10852347;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID JOK-1 [Human hairy cell leukemia]
AC CVCL_M706
DR Cosmic; 999765
RX CelloPub=CLPUB00061;
RX PubMed=7141737;
RX PubMed=11060441;
DI NCIt; C7402; Hairy cell leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JON
AC CVCL_M891
SY JO'N; J'O.N.; J.O.N.; JO N; JO-N; J ON
DR Cosmic; 715706
DR Cosmic; 760472
DR Cosmic; 845567
DR Cosmic; 1016891
DR Cosmic; 1285121
DR Cosmic; 1285999
DR Cosmic; 2037948
DR Cosmic; 2050447
DR Cosmic; 2057452
DR Cosmic; 2444249
DR GEO; GSM763025
RX PubMed=2903136;
RX PubMed=16885334;
RX PubMed=24018021;
RX PubMed=24367658;
RX PubMed=25997541;
RX PubMed=26621286;
CC Part of: BLA-40 bladder carcinoma cell line panel.
CC Part of: UBC-40 urothelial bladder cancer cell line index.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID JoN
AC CVCL_D785
RX PubMed=2156601;
RX PubMed=2713809;
RX PubMed=2903136;
DI NCIt; C9192; Ovarian carcinosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JoN HDF
AC CVCL_D786
RX PubMed=2903136;
DI NCIt; C9192; Ovarian carcinosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D785 ! JoN
SX Female
CA Cancer cell line
//
ID JoN LDF
AC CVCL_D787
RX PubMed=2903136;
DI NCIt; C9192; Ovarian carcinosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D785 ! JoN
SX Female
CA Cancer cell line
//
ID Jones
AC CVCL_DN28
SY JONES
DR GEO; GSM1974791
RX PubMed=26842912;
RX PubMed=27197945;
RX PubMed=27257868;
CC Part of: FACC canine tumor cell line panel.
CC Omics: Transcriptome analysis.
DI NCIt; C120298; Canine melanoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
CA Cancer cell line
//
ID JoPaca-1
AC CVCL_S507
SY JOPACA-1
DR DSMZ; ACC-744
RX PubMed=23152778;
CC Doubling time: ~3-4 days (DSMZ).
ST Source(s): DSMZ
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 9,12
ST D16S539: 10
ST D5S818: 11
ST D7S820: 9,10
ST TH01: 9,9.3
ST TPOX: 8
ST vWA: 15,18
DI NCIt; C9120; Pancreatic ductal adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Josh 4
AC CVCL_8248
SY JOSH-4
RX PubMed=6256462;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C3822; X-linked agammaglobulinemia
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_8249 ! Josh 7
CA Transformed cell line
//
ID Josh 7
AC CVCL_8249
SY JOSH-7
RX PubMed=230517;
RX PubMed=6256462;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C3822; X-linked agammaglobulinemia
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_8248 ! Josh 4
CA Transformed cell line
//
ID JOSK-I
AC CVCL_2082
DR CLO; CLO_0007034
DR CLDB; cl2951
DR BioSample; SAMN03151980
DR Cosmic; 787438
DR Cosmic; 919120
DR DSMZ; ACC-155
RX PubMed=3486043;
RX PubMed=10508494;
RX PubMed=12592342;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a U-937 derivative (PubMed=10508494, PubMed=12592342, PubMed=20143388).
CC Doubling time: ~28-35 hours (DSMZ).
ST Source(s): DSMZ
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 10,12
ST D16S539: 12
ST D5S818: 12
ST D7S820: 9,11
ST TH01: 6,9.3
ST TPOX: 8,11
ST vWA: 14,15
DI NCIt; C8263; Adult acute monocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0007 ! U-937
SX Male
CA Cancer cell line
//
ID JOSK-K
AC CVCL_8141
DR BioSample; SAMN03151981
DR Cosmic; 919121
RX PubMed=3486043;
RX PubMed=10508494;
RX PubMed=12592342;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a U-937 derivative (PubMed=10508494, PubMed=12592342, PubMed=20143388).
DI NCIt; C8263; Adult acute monocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0007 ! U-937
SX Male
CA Cancer cell line
//
ID JOSK-M
AC CVCL_2083
DR CLO; CLO_0007035
DR CLDB; cl2952
DR BioSample; SAMN03151982
DR BioSample; SAMN03473345
DR Cosmic; 787439
DR Cosmic; 999773
DR DSMZ; ACC-30
RX PubMed=3486043;
RX PubMed=10508494;
RX PubMed=12592342;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a U-937 derivative (PubMed=10508494, PubMed=12592342, PubMed=20143388).
CC Doubling time: ~30-40 hours (DSMZ).
ST Source(s): DSMZ
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 10,12
ST D16S539: 12
ST D5S818: 13
ST D7S820: 9,11
ST TH01: 6,9.3
ST TPOX: 8,11
ST vWA: 14,15
DI NCIt; C8263; Adult acute monocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0007 ! U-937
SX Male
CA Cancer cell line
//
ID JOSK-S
AC CVCL_8142
DR BioSample; SAMN03151983
RX PubMed=3486043;
RX PubMed=10508494;
RX PubMed=12592342;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a U-937 derivative (PubMed=10508494, PubMed=12592342, PubMed=20143388).
DI NCIt; C8263; Adult acute monocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0007 ! U-937
SX Male
CA Cancer cell line
//
ID Journey-HSA
AC CVCL_0C99
SY JOURNEY
RX PubMed=19461996;
CC Breed/subspecies: Golden Retriever.
DI NCIt; C122783; Canine hemangiosarcoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID JOV675
AC CVCL_8250
DR Cosmic; 845148
RX PubMed=9625810;
DI NCIt; C4908; Ovarian carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JP165
AC CVCL_N326
DR ATCC; HB-8280
RX Patent=US4643971;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID JPKO
AC CVCL_6F54
DR IMGT/HLA; 15828
RX PubMed=16702430;
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID JPX-9
AC CVCL_0D86
SY Jpx-9; JPX9; JPX 9-4
RX PubMed=2501514;
RX PubMed=2784206;
CC Transfected with: UniProtKB; P03409; HTLV-1 Tax.
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID JR 1
AC CVCL_L880
DR CLO; CLO_0007036
DR CLDB; cl2953
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JR-1
AC CVCL_J063
SY JR1
DR Cosmic; 687952
RX PubMed=3730258;
RX PubMed=23882450;
CC Doubling time: ~29 hours (PubMed=3730258).
CC Derived from metastatic site: Lung.
DI NCIt; C8971; Embryonal rhabdomyosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JR-2(82)
AC CVCL_5298
SY JR-2-82; JR-2
RX PubMed=3110293;
RX PubMed=6306101;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=JR-2-82
CC Characteristics: Partially IL4 dependent. Only dies in the absence of IL4 if seeded at 1 X 1000 cells per well or less.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID JR-St
AC CVCL_0365
AS CVCL_W525
SY JRST; JR-1
DR MCCL; MCC:0000259
DR Cosmic; 877045
DR Cosmic; 918494
RX PubMed=1848829;
RX PubMed=2562403;
CC Doubling time: 72 hours, at 20th passage (PubMed=2562403); 35 hours, at 30th passage (PubMed=1848829).
CC Derived from metastatic site: Cerebrospinal fluid.
DI NCIt; C5250; Signet ring cell gastric adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JR8
AC CVCL_5780
SY IR8; IR-8
DR BTO; BTO:0002969
DR CLO; CLO_0007037
DR CLDB; cl2955
CC Caution: It seems that JR8 has been mistransposed to IR8 in some publications.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID JRO1-27
AC CVCL_V087
DR CLO; CLO_0007038
DR CLDB; cl2956
DR IHW; IHW8026
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID JS
AC CVCL_E718
DR dbMHC; 48914
DR ECACC; 94022532
DR IHW; IHW9228
DR IMGT/HLA; 10872
WW http://bioinformatics.hsanmartino.it/ecbr/cl228.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID JS-73
AC CVCL_9711
CC From: Van Valen F.; University of Munster; Germany.
DI NCIt; C4817; Ewing sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JS-E
AC CVCL_0C17
DR Cosmic; 2239092
RX PubMed=7736387;
RX PubMed=9559344;
RX PubMed=9815546;
CC Derived from metastatic site: Pericardial effusion.
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID JSa1
AC CVCL_6E04
SY Jaw Sparus aurata 1
RX DOI=10.1111/j.1439-0426.2010.01411.x;
CC Group: Fish cell line.
OX NCBI_TaxID=8175; ! Sparus aurata
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID JSC-1
AC CVCL_3728
AS CVCL_B054
SY JSC1
DR CLO; CLO_0007039
DR ATCC; CRL-2769
DR ATCC; JHU-32
DR BioSample; SAMN03471783
DR Cosmic; 1588564
DR Cosmic-CLP; 1327769
DR GDSC; 1327769
DR GEO; GSM634739
DR GEO; GSM710424
DR GEO; GSM710440
DR GEO; GSM827379
DR GEO; GSM1669964
RX PubMed=11024147;
RX PubMed=15613351;
RX PubMed=21685375;
RX PubMed=27397505;
CC Doubling time: 48 hours (PubMed=11024147).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Misspelling: Occasionally 'JCS-1'.
CC Discontinued: ATCC; CRL-2769; true.
CC Discontinued: ATCC; JHU-32; true.
ST Source(s): ATCC; Cosmic-CLP
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 9,14
ST D16S539: 11,12
ST D5S818: 12
ST D7S820: 9
ST TH01: 6,9
ST TPOX: 8,11
ST vWA: 14,18
DI NCIt; C6915; Primary effusion lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JSKG
AC CVCL_R910
SY Japanese Striped Knifejaw Gonad
RX DOI=10.1577/1548-8667(1993)005<0127:COTCCL>2.3.CO;2;
RX DOI=10.3147/jsfp.28.27;
CC Group: Fish cell line.
OX NCBI_TaxID=163134; ! Oplegnathus fasciatus
SX Male
CA Spontaneously immortalized cell line
//
ID JSQ-3
AC CVCL_L892
SY JSQ3
RX PubMed=2004949;
RX PubMed=3417487;
RX PubMed=9054521;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID JSQ-3B
AC CVCL_V281
RX PubMed=2004949;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_L892 ! JSQ-3
CA Cancer cell line
//
ID JT1
AC CVCL_GY09
RX PubMed=7108207;
OX NCBI_TaxID=9606; ! Homo sapiens
CA Spontaneously immortalized cell line
//
ID JT1-1D7
AC CVCL_9U14
SY JT-1-1D7; JT1-D7
DR CCRID; 3142C0001000000426
RX Patent=US5180660;
RX Patent=US5217895;
CC Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1685.
CC Monoclonal antibody target: UniProtKB; P01730; Human CD4.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID JT1-1F3
AC CVCL_9U15
DR CCRID; 3142C0001000000421
DR ECACC; 87062501
RX Patent=US5180660;
RX Patent=US5217895;
CC Monoclonal antibody target: UniProtKB; P01730; Human CD4.
CC Discontinued: ECACC; 87062501; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID JT1-1F3-E5
AC CVCL_9U16
DR CCRID; 3142C0001000000420
DR ECACC; 87062502
RX Patent=US5180660;
RX Patent=US5217895;
CC Monoclonal antibody target: UniProtKB; P01730; Human CD4.
CC Discontinued: ECACC; 87062502; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID JT2-N15
AC CVCL_9U17
DR CCRID; 3142C0001000000425
RX Patent=US5180660;
RX Patent=US5217895;
CC Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1684.
CC Monoclonal antibody target: UniProtKB; P01730; Human CD4.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID JT4C12
AC CVCL_9U18
DR ATCC; HB-9387
RX Patent=US5180660;
RX Patent=US5217895;
CC Monoclonal antibody target: UniProtKB; P01730; Human CD4.
CC Discontinued: ATCC; HB-9387; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID JT4C16
AC CVCL_9U19
DR ATCC; HB-9386
DR CCRID; 3142C0001000000424
RX Patent=US5180660;
RX Patent=US5217895;
CC Monoclonal antibody target: UniProtKB; P01730; Human CD4.
CC Discontinued: ATCC; HB-9386; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID JT4C8
AC CVCL_9U20
DR ATCC; HB-9385
RX Patent=US5180660;
RX Patent=US5217895;
CC Monoclonal antibody target: UniProtKB; P01730; Human CD4.
CC Discontinued: ATCC; HB-9385; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID JTC-1
AC CVCL_M884
SY Japanese Tissue Culture-1
RX PubMed=4358144;
RX PubMed=4361510;
CC Derived from metastatic site: Ascites.
DI NCIt; C60505; Rat sarcoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_4367 ! AH130
CA Cancer cell line
//
ID JTC-11
AC CVCL_5299
SY Ehrlich-Lettre ascites strain K; Japanese Tissue Culture-11
DR JCRB; JCRB0424
RX CelloPub=CLPUB00234;
RX CelloPub=CLPUB00367;
RX PubMed=3983491;
RX PubMed=14497414;
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_3873 ! Ehrlich-Lettre ascites strain E
SX Female
CA Cancer cell line
//
ID JTC-12
AC CVCL_3631
SY MK; Monkey Kidney; Japanese Tissue Culture-12
DR CLO; CLO_0050517
DR CLO; CLO_0050518
DR RCB; RCB0456
DR RCB; RCB1485
RX PubMed=4328993;
RX PubMed=13984589;
CC Group: Non-human primate cell line.
OX NCBI_TaxID=9541; ! Macaca fascicularis
SX Female
CA Spontaneously immortalized cell line
//
ID JTC-12.P3
AC CVCL_5483
SY MK.P3; Japanese Tissue Culture-12.P3
DR JCRB; JCRB0607.1
DR JCRB; NIHS0354
RX PubMed=4328993;
CC Group: Non-human primate cell line.
CC Discontinued: JCRB; NIHS0354; true.
OX NCBI_TaxID=9541; ! Macaca fascicularis
HI CVCL_3631 ! JTC-12
SX Female
CA Spontaneously immortalized cell line
//
ID JTC-12.P3(F)
AC CVCL_5484
SY MK.P3(F)
DR JCRB; JCRB0607
CC Group: Non-human primate cell line.
OX NCBI_TaxID=9541; ! Macaca fascicularis
HI CVCL_3631 ! JTC-12
SX Female
CA Spontaneously immortalized cell line
//
ID JTC-13
AC CVCL_IN85
SY Japanese Tissue Culture-13
RX PubMed=4181158;
DI NCIt; C21603; Mouse sarcoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID JTC-14
AC CVCL_IN86
SY Japanese Tissue Culture-14
RX PubMed=4157883;
DI NCIt; C21603; Mouse sarcoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID JTC-15
AC CVCL_2084
SY Japanese Tissue Culture-15
DR BTO; BTO:0000455
DR CLO; CLO_0007040
DR CLO; CLO_0050814
DR CLO; CLO_0050816
DR DSMZ; ACC-329
DR RCB; RCB0063
DR RCB; RCB1461
RX PubMed=4312683;
RX PubMed=4358144;
CC Doubling time: ~30 hours (DSMZ).
CC Transformant: ChEBI; CHEBI:17903; 4-(dimethylamino)azobenzene (Methyl yellow).
CC Derived from metastatic site: Ascites.
DI NCIt; C60505; Rat sarcoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_4368 ! AH66-TC
CA Cancer cell line
//
ID JTC-16
AC CVCL_8360
SY JTC16; Japanese Tissue Culture-16
RX PubMed=4312683;
RX PubMed=4328993;
RX PubMed=4358144;
CC Derived from metastatic site: Ascites.
DI NCIt; C60505; Rat sarcoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_F989 ! AH7974-TC
CA Cancer cell line
//
ID JTC-16.P3
AC CVCL_8361
SY JTC-16-P3; JTC-16 P3; JTC 16P3; AH-7974.P3; Japanese Tissue Culture-16.P3
DR JCRB; JCRB0714
DR JCRB; JCRB0714.1
DR JCRB; NIHS0368
RX PubMed=4328993;
CC Discontinued: JCRB; NIHS0368; true.
CC Derived from metastatic site: Ascites.
DI NCIt; C60505; Rat sarcoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_8360 ! JTC-16
CA Cancer cell line
//
ID JTC-17
AC CVCL_8362
SY Japanese Tissue Culture-17
DR BioSample; SAMN03151728
RX PubMed=20143388;
WW http://cellbank.nibiohn.go.jp/legacy/cellbank/qualitycontrol/identification/summary.htm
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=20143388).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID JTC-19
AC CVCL_3632
SY JTC19; Japanese Tissue Culture-19; RLG-1
DR CLO; CLO_0007041
DR CLO; CLO_0050817
DR CLO; CLO_0050818
DR CLDB; cl2957
DR ECACC; 87111902
DR JCRB; JCRB0608
DR RCB; RCB0074
DR RCB; RCB1486
RX PubMed=6085955;
CC Breed/subspecies: JAR-1.
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Female
CA Spontaneously immortalized cell line
//
ID JTC-2
AC CVCL_M885
SY Japanese Tissue Culture-2
RX PubMed=4358144;
RX PubMed=4361510;
CC Derived from metastatic site: Ascites.
DI NCIt; C60505; Rat sarcoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_4367 ! AH130
CA Cancer cell line
//
ID JTC-20.P3
AC CVCL_IN91
SY RTH-1.P3; Japanese Tissue Culture-20.P3
RX PubMed=4328993;
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Spontaneously immortalized cell line
//
ID JTC-21.P3
AC CVCL_IN87
SY RLH-1.P3; Japanese Tissue Culture-21.P3
RX PubMed=4328993;
CC Breed/subspecies: JAR-1.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Spontaneously immortalized cell line
//
ID JTC-22.P3
AC CVCL_IN88
SY RLH-2.P3; Japanese Tissue Culture-22.P3
RX PubMed=4328993;
CC Breed/subspecies: JAR-1.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Spontaneously immortalized cell line
//
ID JTC-23.P3
AC CVCL_IN89
SY RLH-3.P3; Japanese Tissue Culture-23.P3
RX PubMed=4328993;
CC Breed/subspecies: JAR-1.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Spontaneously immortalized cell line
//
ID JTC-24.P3
AC CVCL_IN90
SY RLH-4.P3; Japanese Tissue Culture-24.P3
RX PubMed=4328993;
CC Breed/subspecies: JAR-1.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Spontaneously immortalized cell line
//
ID JTC-25.P3
AC CVCL_M886
SY JTC-25-P3; JTC-25P3; RLH-5.P3; Japanese Tissue Culture-25.P3
RX PubMed=240686;
RX PubMed=4328993;
RX PubMed=4358144;
RX PubMed=4359557;
CC Breed/subspecies: JAR-1.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Spontaneously immortalized cell line
//
ID JTC-27
AC CVCL_2085
SY AH601(JTC27); AH-601(JTC-27); Japanese Tissue Culture-27
DR BTO; BTO:0000528
DR CLO; CLO_0007042
DR CLO; CLO_0050813
DR CLO; CLO_0050815
DR CLDB; cl2958
DR CLDB; cl4942
DR DSMZ; ACC-330
DR ECACC; 94042255
DR ICLC; ATL98013
DR JCRB; JCRB0132.1
DR JCRB; NIHS0227
DR RCB; RCB0065
DR RCB; RCB1479
RX PubMed=4340679;
RX PubMed=4358144;
CC Doubling time: ~37 hours (DSMZ).
CC Transformant: ChEBI; CHEBI:82285; Ortho-aminoazotoluene.
CC Discontinued: JCRB; NIHS0227; true.
CC Breed/subspecies: Donryu.
DI NCIt; C60416; Rat hepatocellular carcinoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
OI CVCL_F993 ! AH601-TC
SX Female
CA Cancer cell line
//
ID JTC-29
AC CVCL_M876
SY Japanese Tissue Culture-29
RX PubMed=2607719;
RX PubMed=3938823;
RX PubMed=6684098;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JTC-3
AC CVCL_A034
SY Japanese Tissue Culture-3
DR BioSample; SAMN03151729
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=20143388).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID JTC-30
AC CVCL_M877
SY JTC30; Japanese Tissue Culture-30
RX PubMed=2607719;
RX PubMed=3938823;
RX PubMed=6684098;
RX PubMed=7474403;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JTC-31
AC CVCL_M878
SY Japanese Tissue Culture-31
RX PubMed=3938823;
RX PubMed=6684098;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JTC-32
AC CVCL_M879
SY JTC32; Japanese Tissue Culture-32
RX PubMed=2607719;
RX PubMed=3938823;
RX PubMed=6684098;
RX PubMed=7474403;
RX PubMed=10640149;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JTC-33
AC CVCL_M880
SY Japanese Tissue Culture-33
RX PubMed=3938823;
RX PubMed=6684098;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JTC-34
AC CVCL_M881
SY Japanese Tissue Culture-34
RX PubMed=3938823;
RX PubMed=6684098;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JTC-35
AC CVCL_4560
SY Japanese Tissue Culture-35
DR CLO; CLO_0050471
DR RCB; RCB2686
OX NCBI_TaxID=9913; ! Bos taurus
SX Female
CA Transformed cell line
//
ID JTC-4
AC CVCL_M883
SY JTC4; Japanese Tissue Culture-4
RX PubMed=13980350;
CC Breed/subspecies: Wistar.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Finite cell line
//
ID JTC-6
AC CVCL_IN92
SY Japanese Tissue Culture-6
RX PubMed=13774936;
CC Breed/subspecies: Wistar.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Finite cell line
//
ID JTG-1
AC CVCL_0P33
RX PubMed=2424598;
RX PubMed=6178868;
DI NCIt; C8000; Testicular yolk sac tumor
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JTK-LCL
AC CVCL_8724
DR CLO; CLO_0050226
DR BioSample; SAMN03472079
DR RCB; RCB1873
DR TKG; TKG 0585
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
ST Source(s): RCB; TKG
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8
ST D16S539: 9
ST D5S818: 10,12
ST D7S820: 8,11
ST TH01: 6,9
ST TPOX: 10,11
ST vWA: 14,19
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID JU77
AC CVCL_2536
DR CBA; CBA-0140
DR Cosmic; 1522780
DR Cosmic; 1963329
DR ECACC; 10092309
DR GEO; GSM726272
RX PubMed=1703129;
RX PubMed=21642991;
CC Doubling time: 25 hours (PubMed=1703129).
CC Omics: SNP array analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Jup-GFP, DSas-4 line 127
AC CVCL_Z867
SY DSas-4-/- line 127
DR DGRC; 215
RX PubMed=23519377;
CC Group: Insect cell line.
CC Knockout cell: Method=Null mutation; FlyBase; FBgn0011020; Sas-4.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Jup-GFP, DSas-4 line 131
AC CVCL_Z868
SY DSas-4-/- line 131
DR DGRC; 216
RX PubMed=23519377;
CC Group: Insect cell line.
CC Knockout cell: Method=Null mutation; FlyBase; FBgn0011020; Sas-4.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Jup-GFP, DSas-4 line 69
AC CVCL_Z869
SY DSas-4-/- line 69
DR DGRC; 211
RX PubMed=23519377;
CC Group: Insect cell line.
CC Knockout cell: Method=Null mutation; FlyBase; FBgn0011020; Sas-4.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Jup-GFP, DSas-4 line 70
AC CVCL_Z870
SY DSas-4-/- line 70
DR DGRC; 212
RX PubMed=23519377;
CC Group: Insect cell line.
CC Knockout cell: Method=Null mutation; FlyBase; FBgn0011020; Sas-4.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Jup-GFP, DSas-4 line 84
AC CVCL_Z871
SY DSas-4-/- line 84
DR DGRC; 213
RX PubMed=23519377;
CC Group: Insect cell line.
CC Knockout cell: Method=Null mutation; FlyBase; FBgn0011020; Sas-4.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Jup-GFP, DSas-4 line 96
AC CVCL_Z872
SY DSas-4-/- line 96
DR DGRC; 214
RX PubMed=23519377;
CC Group: Insect cell line.
CC Knockout cell: Method=Null mutation; FlyBase; FBgn0011020; Sas-4.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Jupiter
AC CVCL_Z785
DR DGRC; 178
RX PubMed=16518797;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Jurkat
AC CVCL_0065
SY JURKAT; JM; JM-Jurkat; Jurkat-FHCRC; Jurkat FHCRC; FHCRC-11; FHCRC subclone 11; FCCH1024
DR BTO; BTO:0000661
DR CLO; CLO_0007029
DR CLO; CLO_0007043
DR CLO; CLO_0050978
DR CLO; CLO_0050993
DR CLO; CLO_0051001
DR EFO; EFO_0002796
DR MCCL; MCC:0000503
DR CLDB; cl2950
DR CLDB; cl2959
DR CLDB; cl2960
DR CLDB; cl2961
DR CLDB; cl5212
DR BioSample; SAMN03472181
DR BioSample; SAMN03472286
DR BioSample; SAMN03473341
DR CCLE; JURKAT_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CCRID; 3111C0001CCC000347
DR ChEMBL-Cells; CHEMBL3307526
DR ChEMBL-Targets; CHEMBL397
DR Cosmic; 683539
DR Cosmic; 721707
DR Cosmic; 755289
DR Cosmic; 801727
DR Cosmic; 850196
DR Cosmic; 913426
DR Cosmic; 919152
DR Cosmic; 922675
DR Cosmic; 933540
DR Cosmic; 991544
DR Cosmic; 998737
DR Cosmic; 999757
DR Cosmic; 1012072
DR Cosmic; 1037693
DR Cosmic; 1115592
DR Cosmic; 1118463
DR Cosmic; 1118464
DR Cosmic; 1127262
DR Cosmic; 1130236
DR Cosmic; 1132774
DR Cosmic; 1175129
DR Cosmic; 1191689
DR Cosmic; 1224368
DR Cosmic; 1226860
DR Cosmic; 1330489
DR Cosmic; 1375588
DR Cosmic; 1483364
DR Cosmic; 1524798
DR Cosmic; 1639637
DR Cosmic; 1641380
DR Cosmic; 1664522
DR Cosmic; 1760524
DR Cosmic; 1811157
DR Cosmic; 2039520
DR Cosmic; 2165713
DR Cosmic; 2301569
DR Cosmic; 2361366
DR Cosmic-CLP; 998184
DR DSMZ; ACC-282
DR ECACC; 86010201
DR GDSC; 998184
DR GEO; GSM1991
DR GEO; GSM236783
DR GEO; GSM236819
DR GEO; GSM482494
DR GEO; GSM887188
DR GEO; GSM888261
DR GEO; GSM1040307
DR GEO; GSM1040377
DR GEO; GSM1374580
DR GEO; GSM1669965
DR ICLC; HTL01002
DR IZSLER; BS CL 131
DR KCB; KCB 94018YJ
DR Lonza; 142
DR MeSH; D019169
DR NCBI_Iran; C120
DR NIH-ARP; 4668-165
DR PRIDE; PRD000008
DR PRIDE; PRD000013
DR PRIDE; PRD000787
DR PRIDE; PXD000426
DR PRIDE; PXD001428
DR PRIDE; PXD002091
DR PRIDE; PXD002395
DR RCB; RCB0537
DR RCB; RCB0806
DR RCB; RCB3052
DR TKG; TKG 0209
DR TOKU-E; 3710
DR Wikidata; Q1632589
RX PubMed=68013;
RX PubMed=3165345;
RX PubMed=8547074;
RX PubMed=9685479;
RX PubMed=9738977;
RX PubMed=9933131;
RX PubMed=10071127;
RX PubMed=11021758;
RX PubMed=15028022;
RX PubMed=16408098;
RX PubMed=17117183;
RX PubMed=19608861;
RX PubMed=22278370;
RX PubMed=22460905;
RX PubMed=22675565;
RX PubMed=23325432;
RX PubMed=24618588;
RX PubMed=26074081;
RX PubMed=27397505;
WW https://en.wikipedia.org/wiki/Jurkat_cells
WW http://www.cells-talk.com/index.php/page/copelibrary?key=Jurkat
WW http://141.61.102.20/mxdb/project/show/9191407937500
WW http://genome.ucsc.edu/ENCODE/protocols/cell/human/Jurkat_protocol.pdf
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/j/cell-lines-detail-7.html
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: ENCODE project common cell types; tier 3.
CC Doubling time: ~25-35 hours (DSMZ).
CC Microsatellite instability: Instable (MSI-high) (Sanger).
CC Omics: Acetylation analysis by proteomics.
CC Omics: Deep exome analysis.
CC Omics: Deep phosphoproteome analysis.
CC Omics: Deep proteome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Omics: Virome analysis using proteomics.
CC Discontinued: ICLC; HTL01002; true.
ST Source(s): COG; Cosmic-CLP; DSMZ; ECACC; RCB; TKG
ST Amelogenin: X,Y
ST CSF1PO: 11,12 (COG; TKG)
ST CSF1PO: 10,11 (Cosmic-CLP; DSMZ)
ST CSF1PO: 10,12 (ECACC)
ST CSF1PO: 9,10,11 (RCB_RCB0537)
ST CSF1PO: 11 (RCB_RCB0806)
ST D13S317: 8,11 (COG; Cosmic-CLP; DSMZ; ECACC; RCB_RCB0537)
ST D13S317: 8,11,12 (RCB_RCB0806)
ST D13S317: 8,10,11 (TKG)
ST D16S539: 11 (COG; Cosmic-CLP; DSMZ; RCB_RCB0806; TKG)
ST D16S539: 10,11 (ECACC; RCB_RCB0537)
ST D18S51: 13,21
ST D19S433: 13,15.2
ST D21S11: 31.2,32.2
ST D2S1338: 19,23
ST D3S1358: 15,16,17
ST D5S818: 9
ST D7S820: 8,10 (COG; ECACC; RCB_RCB0537; TKG)
ST D7S820: 8,10,11 (Cosmic-CLP; DSMZ; RCB_RCB0806)
ST D8S1179: 12,14,15
ST FGA: 20,22
ST TH01: 6,9.3
ST TPOX: 8,10 (COG; Cosmic-CLP; DSMZ; ECACC; RCB_RCB0806; TKG)
ST TPOX: 8,9,10 (RCB_RCB0537)
ST vWA: 17,18,19 (COG; DSMZ)
ST vWA: 18,19,20 (Cosmic-CLP)
ST vWA: 16,17,19,20 (ECACC)
ST vWA: 16,17,18 (RCB_RCB0537; RCB_RCB0806)
ST vWA: 18,20 (TKG)
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Jurkat 1G4
AC CVCL_IR10
SY Jurkat-1G4
DR PRIDE; PXD001410
RX PubMed=23177477;
CC Transfected with: T-cell receptor 1G4 (TCR 1G4).
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat clone 77-6.8
AC CVCL_HE54
SY J77-6.8; J77.6.8
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_DS01 ! Jurkat J77
SX Male
CA Cancer cell line
//
ID Jurkat D1.1
AC CVCL_3502
SY D1.1; D1-1
DR CLO; CLO_0002658
DR ATCC; CRL-10915
DR BioSample; SAMN03471307
DR Cosmic; 683659
DR GEO; GSM827149
RX Patent=US6331433;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=D1.1
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 8,11
ST D16S539: 10,11
ST D5S818: 9
ST D7S820: 8,10
ST TH01: 6,9.3
ST TPOX: 8,10
ST vWA: 18,19,20
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat E6.1
AC CVCL_0367
SY JurkatE6-1; Jurkat E6-1; Jurkat, Clone E6-1; Jurkat Clone E6-1; Jurkat (clone E6-1); JURKAT E-6.1; JURKAT E-61; Jurkat-E6; Jurkat E6; J.E6-1; E6-1
DR BTO; BTO:0001948
DR CLO; CLO_0007045
DR MCCL; MCC:0000260
DR CLDB; cl2962
DR ATCC; TIB-152
DR BCRC; 60424
DR BCRJ; 0125
DR BioSample; SAMN03472194
DR CCRID; 3111C0001CCC000075
DR CCRID; 3111C0001CCC000348
DR CCRID; 3111C0002000000049
DR CCRID; 3131C0001000700123
DR CCRID; 3142C0001000000080
DR CLS; 300223/p849_Jurkat_E61
DR Cosmic; 913419
DR ECACC; 88042803
DR ENCODE; ENCBS407ENC
DR ENCODE; ENCBS429ENC
DR ENCODE; ENCBS550BVM
DR ENCODE; ENCBS551ZKL
DR GEO; GSM472928
DR GEO; GSM510511
DR GEO; GSM827151
DR GEO; GSM923424
DR GEO; GSM945267
DR GEO; GSM945268
DR KCB; KCB 94008YJ
DR KCLB; 40152
DR NCBI_Iran; C121
DR NIH-ARP; 177-450
DR PRIDE; PXD000148
DR PRIDE; PXD000589
DR PRIDE; PXD002871
DR TOKU-E; 2081
RX PubMed=8316623;
RX PubMed=10468210;
RX PubMed=25485619;
RX PubMed=25894527;
RX PubMed=26546556;
WW http://www.nibsc.org/Default.aspx?pageid=597&id=0027&theme=default
CC Doubling time: 20.7 +- 2.2 hours (PubMed=10468210).
CC Omics: Cell surface proteome.
CC Omics: Deep phosphoproteome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: H3K4me3 ChIP-seq epigenome analysis.
CC Omics: SNP array analysis.
ST Source(s): ATCC; CLS; ECACC; KCLB; PubMed=11416159; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 8,12
ST D16S539: 11
ST D18S51: 13,21
ST D21S11: 31.2,33.2
ST D3S1358: 15,17 (CLS; PubMed=25877200)
ST D3S1358: 15 (KCLB)
ST D5S818: 9
ST D7S820: 8,12 (ATCC; KCLB; PubMed=25877200)
ST D7S820: 8,10 (CLS; ECACC)
ST D8S1179: 13,14
ST FGA: 20,21
ST Penta D: 11,13
ST Penta E: 10,12
ST TH01: 6,9.3
ST TPOX: 8,10
ST vWA: 18
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat J6
AC CVCL_4530
DR CLO; CLO_0007044
DR CLDB; cl5213
DR IZSLER; BS TCL 110
RX PubMed=18842727;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat J77
AC CVCL_DS01
SY Jurkat/J77; J77
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0367 ! Jurkat E6.1
SX Male
CA Cancer cell line
//
ID Jurkat J77 cl20
AC CVCL_DS02
SY Jurkat J77cl20; J77 clone 20; J77cl20; J77.20
DR PRIDE; PXD001549
RX PubMed=7759540;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_DS01 ! Jurkat J77
SX Male
CA Cancer cell line
//
ID Jurkat NucLight Red
AC CVCL_DF51
WW http://www.essenbioscience.com/essen-products/reagents-and-consumables/incucyte-jurkat-nuclight-red-cells-cat-no-4613/
CC Characteristics: Stably expresses a non-perturbing nuclear restricted red fluorescent label.
CC Transfected with: mKate2; a bright red fluorescent protein derived from eqFP578.
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0367 ! Jurkat E6.1
SX Male
CA Cancer cell line
//
ID Jurkat R3.25
AC CVCL_EG05
SY R3.25
RX PubMed=9300530;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat Tet-On 3G
AC CVCL_V356
WW http://www.clontech.com/US/Products/Inducible_Systems/Tetracycline-Inducible_Expression/Tet-On_3G_Cell_Lines
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat tet-on clone 1
AC CVCL_W813
RX DOI=10.1007/BF02887100;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat tet-on clone 2
AC CVCL_W814
RX DOI=10.1007/BF02887100;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat Wurzburg
AC CVCL_0584
SY Wurzburg; Jurkat JR; JR
DR MCCL; MCC:0000490
RX PubMed=7526398;
RX PubMed=10468210;
CC Doubling time: 16.6 +- 2 hours (PubMed=10468210).
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-111
AC CVCL_U326
SY Jurkat 111; J-111
DR ATCC; CRL-8129
DR BioSample; SAMN03471193
RX Patent=EP0142268A1;
RX Patent=US5795777;
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 8,10,11
ST D16S539: 11,12
ST D5S818: 9
ST D7S820: 8,10,11
ST TH01: 6,9.3
ST TPOX: 8,10
ST vWA: 18,19
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-522 F/Y
AC CVCL_1G47
DR NIH-ARP; 3955-94
RX PubMed=8627650;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-7/3 STOP
AC CVCL_1G48
DR NIH-ARP; 3956-101
RX PubMed=8627650;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-77
AC CVCL_6925
SY JURKAT-77; Jurkat 77; Jurkat77
DR CCRID; 3111C0001CCC000162
RX PubMed=6600440;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-99
AC CVCL_U323
SY Jurkat 99; J-99
DR ATCC; CRL-8131
CC Discontinued: ATCC; CRL-8131; probable.
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-A2
AC CVCL_X703
SY Jurkat A2; JA2
RX PubMed=2477484;
CC Transfected with: HGNC; 4931; HLA-A (allele HLA-A2).
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-deltaKS
AC CVCL_1G46
DR NIH-ARP; 3954-102
RX PubMed=8627650;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-Dual
AC CVCL_X593
WW http://www.invivogen.com/jurkat-dual
CC Transfected with: HGNC; 439; ALPP.
CC Transfected with: Lucia luciferase; a synthetic gene designed on natural secreted luciferase genes from marine copepods.
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-FADD-/-
AC CVCL_HF44
SY E1
RX PubMed=10616904;
RX PubMed=15637111;
CC Transformant: ChEBI; CHEBI:23994; Ethyl methanesulfonate (Methylsulfonic acid ethyl ester; MSEE).
ST Source(s): PubMed=15637111
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 8,11
ST D16S539: 10,11
ST D18S51: 13,22
ST D21S11: 31.2,33.2
ST D3S1358: 15,17
ST D5S818: 9
ST D7S820: 8,9.3
ST D8S1179: 12,14
ST FGA: 19,22
ST Penta D: 11
ST Penta E: 10,12
ST TH01: 6.9.3
ST TPOX: 8,10
ST vWA: 17,18
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1061 ! A3
SX Male
CA Cancer cell line
//
ID Jurkat-HXBc2(4)
AC CVCL_1F94
DR NIH-ARP; 3952-323
RX PubMed=8627650;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-HXBc2(6)
AC CVCL_1F95
DR NIH-ARP; 3953-96
RX PubMed=8627650;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-JMN
AC CVCL_B332
SY Jurkat JMN; JMN
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-TAg
AC CVCL_C831
SY Jurkat TAg; Jurkat Tag
RX PubMed=8428966;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat-tat
AC CVCL_X692
DR NIH-ARP; 1399-85
RX Patent=US4981790;
RX PubMed=2156043;
CC Doubling time: 25 hours (NIH-ARP).
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID Jurkat/A4
AC CVCL_AR84
SY Jurkat-A4
RX CelloPub=CLPUB00316;
RX PubMed=20693966;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0065 ! Jurkat
SX Male
CA Cancer cell line
//
ID JURL-MK1
AC CVCL_2086
DR BTO; BTO:0005909
DR BioSample; SAMN03473526
DR CCLE; JURLMK1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 9214-4
DR Cosmic; 1012073
DR Cosmic; 1078719
DR Cosmic-CLP; 1327771
DR DSMZ; ACC-532
DR GDSC; 1327771
DR GEO; GSM887189
DR GEO; GSM888262
DR GEO; GSM1669966
RX PubMed=9305612;
RX PubMed=16408098;
RX PubMed=22460905;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~48 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 11
ST D16S539: 11,12
ST D5S818: 12
ST D7S820: 10,13
ST TH01: 8
ST TPOX: 8,11
ST vWA: 18
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_2087 ! JURL-MK2
SX Male
CA Cancer cell line
//
ID JURL-MK2
AC CVCL_2087
DR BTO; BTO:0005910
DR BioSample; SAMN03473527
DR CGH-DB; 9219-4
DR DSMZ; ACC-533
RX PubMed=9305612;
CC Doubling time: ~72 hours (DSMZ).
ST Source(s): DSMZ
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 11
ST D16S539: 11,12
ST D5S818: 12
ST D7S820: 10,13
ST TH01: 8
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_2086 ! JURL-MK1
SX Male
CA Cancer cell line
//
ID JVC
AC CVCL_R734
RX PubMed=6437669;
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID JVE015
AC CVCL_EG16
SY JVE-015
DR DSMZ; ACC-786
RX PubMed=26894854;
CC Doubling time: ~3-4 days (DSMZ).
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 11,12
ST D16S539: 9
ST D21S11: 30,32.2
ST D5S818: 11,12
ST D7S820: 9,11
ST TH01: 6,9.3
ST TPOX: 8,11
ST vWA: 17,18
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JVE044
AC CVCL_EG17
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 13,14
ST D13S317: 13,14
ST D16S539: 9,10
ST D21S11: 30
ST D5S818: 11
ST D7S820: 9,11
ST TH01: 9.3
ST TPOX: 11
ST vWA: 18
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JVE059
AC CVCL_EG18
RX PubMed=26894854;
CC Microsatellite instability: Instable (MSI-high) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 12
ST D16S539: 12
ST D21S11: 29,30.2
ST D5S818: 11,12
ST D7S820: 11,12
ST TH01: 6,7
ST TPOX: 8
ST vWA: 14,15
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JVE103
AC CVCL_EG19
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
CC Derived from metastatic site: Liver.
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 13
ST D21S11: 28,31
ST D5S818: 11,12
ST D7S820: 8,11
ST TH01: 6,9.3
ST TPOX: 11
ST vWA: 14,15
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JVE109
AC CVCL_EG20
RX PubMed=26894854;
CC Microsatellite instability: Instable (MSI-high) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 9,12
ST D16S539: 11
ST D21S11: 28
ST D5S818: 11,12
ST D7S820: 9
ST TH01: 7,9.3
ST TPOX: 8
ST vWA: 16,22
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JVE114
AC CVCL_EG21
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
CC Derived from metastatic site: Liver.
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 11,12
ST D16S539: 11,13
ST D21S11: 29,30
ST D5S818: 12
ST D7S820: 8,9
ST TH01: 7,9.3
ST TPOX: 8,11
ST vWA: 15,17
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JVE127
AC CVCL_EG22
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X,Y
ST CSF1PO: 11
ST D13S317: 8,13
ST D16S539: 12,13
ST D21S11: 30
ST D5S818: 13
ST D7S820: 8,12
ST TH01: 7
ST TPOX: 11
ST vWA: 16,18
DI NCIt; C7966; Colon mucinous adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JVE187
AC CVCL_EG23
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
CC Derived from metastatic site: Liver.
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 9,11
ST D16S539: 11,13
ST D21S11: 31,32.2
ST D5S818: 11,12
ST D7S820: 9
ST TH01: 6,9
ST TPOX: 11
ST vWA: 14,16
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JVE192
AC CVCL_EG24
RX PubMed=26894854;
CC Microsatellite instability: Instable (MSI-high) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 9,10,13
ST D13S317: 10,11
ST D16S539: 10,12,14
ST D21S11: 31,33.2
ST D5S818: 10,11
ST D7S820: 9,10
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 14,16
DI NCIt; C7966; Colon mucinous adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JVE207
AC CVCL_EG25
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 12,13
ST D16S539: 11
ST D21S11: 28
ST D5S818: 12
ST D7S820: 9,12
ST TH01: 7,9
ST TPOX: 8,9
ST vWA: 15,17
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JVE222
AC CVCL_EG26
RX PubMed=26894854;
CC Microsatellite instability: Instable (MSI-high) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 11,12
ST D16S539: 9,12
ST D21S11: 29,32.2
ST D5S818: 9,11
ST D7S820: 10,11
ST TH01: 7,9.3
ST TPOX: 11
ST vWA: 16
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JVE241
AC CVCL_EG27
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 11,14
ST D13S317: 10,11
ST D16S539: 13
ST D21S11: 29,30.2
ST D5S818: 13,14
ST D7S820: 9,10
ST TH01: 6,9.3
ST TPOX: 8
ST vWA: 16,18
DI NCIt; C7966; Colon mucinous adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JVE253
AC CVCL_EG28
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
CC Derived from metastatic site: Liver.
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11,13
ST D16S539: 11,14
ST D21S11: 31,32.2
ST D5S818: 11
ST D7S820: 8,10
ST TH01: 7,9.3
ST TPOX: 11,12
ST vWA: 18,19
DI NCIt; C7966; Colon mucinous adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JVE367
AC CVCL_EG29
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 9
ST D16S539: 13
ST D21S11: 33.2
ST D5S818: 12
ST D7S820: 9,11
ST TH01: 6,9.3
ST TPOX: 10
ST vWA: 21
DI NCIt; C96157; Colorectal large cell neuroendocrine carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JVE371
AC CVCL_EG30
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
CC Derived from metastatic site: Liver.
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 9,14
ST D16S539: 11,12
ST D21S11: 33.2
ST D5S818: 10
ST D7S820: 9,12
ST TH01: 8,10
ST TPOX: 9,11
ST vWA: 18
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JVE528
AC CVCL_EG31
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 11,14
ST D13S317: 12
ST D16S539: 9,11
ST D21S11: 28,31
ST D5S818: 11,12
ST D7S820: 8,10
ST TH01: 6,9.3
ST TPOX: 8
ST vWA: 15,17
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JVE774
AC CVCL_EG32
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 11,12
ST D16S539: 9,12
ST D21S11: 28,29
ST D5S818: 12
ST D7S820: 8
ST TH01: 9.3
ST TPOX: 8,9
ST vWA: 17
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID JVM
AC CVCL_E719
SY GM06819
DR CLO; CLO_0036527
DR Coriell; GM06819
DR dbMHC; 48916
DR ECACC; 85051629
DR IHW; IHW9039
DR IMGT/HLA; 10879
WW http://bioinformatics.hsanmartino.it/ecbr/cl39.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID JVM-13
AC CVCL_1318
SY JVM 13; JVM13
DR CLO; CLO_0007046
DR CLDB; cl2964
DR CLDB; cl5073
DR ATCC; CRL-3003
DR BioSample; SAMN01821571
DR BioSample; SAMN01821641
DR BioSample; SAMN03471707
DR DSMZ; ACC-19
DR ECACC; 96090516
RX PubMed=3262465;
RX PubMed=25315077;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 58 hours (PubMed=25315077); ~70 hours (DSMZ).
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): ATCC; DSMZ; ECACC
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 9,11
ST D16S539: 11
ST D5S818: 11
ST D7S820: 9
ST TH01: 6,7
ST TPOX: 10,11
ST vWA: 16,18
DI NCIt; C4337; Mantle cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID JVM-14
AC CVCL_B333
RX PubMed=3262465;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C3163; Chronic lymphocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID JVM-2
AC CVCL_1319
SY JVM2
DR CLO; CLO_0007047
DR EFO; EFO_0005476
DR CLDB; cl2965
DR ATCC; CRL-3002
DR BioSample; SAMN03471706
DR CCLE; JVM2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR ChEMBL-Cells; CHEMBL3308530
DR ChEMBL-Targets; CHEMBL2366359
DR Cosmic; 907269
DR Cosmic; 2088017
DR Cosmic; 2296995
DR Cosmic-CLP; 907269
DR DSMZ; ACC-12
DR ECACC; 96090515
DR GDSC; 907269
DR GEO; GSM115805
DR GEO; GSM887190
DR GEO; GSM888263
DR GEO; GSM907524
DR GEO; GSM1374581
DR GEO; GSM1669967
DR Lonza; 1399
RX PubMed=3093393;
RX PubMed=3262465;
RX PubMed=7849311;
RX PubMed=16183118;
RX PubMed=16448697;
RX PubMed=16960149;
RX PubMed=22460905;
RX PubMed=25315077;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 48 hours (PubMed=25315077); ~50-70 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Misspelling: Occasionally 'JUM2'.
ST Source(s): ATCC; Cosmic-CLP; DSMZ; ECACC
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 11,13
ST D16S539: 12,13
ST D5S818: 11,12
ST D7S820: 10,11
ST TH01: 6,9
ST TPOX: 8,11
ST vWA: 17
DI NCIt; C4337; Mantle cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID JVM-3
AC CVCL_1320
SY JVM3
DR CLO; CLO_0007048
DR EFO; EFO_0002214
DR CLDB; cl2966
DR BioSample; SAMN03473365
DR CCLE; JVM3_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR ChEMBL-Cells; CHEMBL3308203
DR ChEMBL-Targets; CHEMBL2366372
DR Cosmic; 907270
DR Cosmic-CLP; 907270
DR DSMZ; ACC-18
DR GDSC; 907270
DR GEO; GSM887191
DR GEO; GSM888264
DR GEO; GSM1374582
DR GEO; GSM1669968
DR IGRhCellID; JVM3
RX PubMed=3093393;
RX PubMed=3262465;
RX PubMed=22460905;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~30 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 13
ST D16S539: 11,12
ST D5S818: 11
ST D7S820: 10
ST TH01: 9,9.3
ST TPOX: 8,9
ST vWA: 17,19 (Cosmic-CLP)
ST vWA: 17,18,19 (DSMZ)
DI NCIt; C4753; B-cell prolymphocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID JW152
AC CVCL_W354
DR ATCC; PTA-9657
RX Patent=US9243235;
RX PubMed=20346410;
CC Discontinued: ATCC; PTA-9657; probable.
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID JW183/5/1
AC CVCL_M108
DR ECACC; 87080703
RX PubMed=3500259;
CC Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP).
OX NCBI_TaxID=9606; ! Homo sapiens
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3949 ! J558L
CA Hybridoma
//
ID JW184/2/1
AC CVCL_M109
DR ECACC; 87080704
RX PubMed=3500259;
CC Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP).
OX NCBI_TaxID=9606; ! Homo sapiens
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3949 ! J558L
CA Hybridoma
//
ID JW393/A
AC CVCL_M110
DR ECACC; 87080702
RX PubMed=3500259;
CC Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP).
OX NCBI_TaxID=9606; ! Homo sapiens
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3949 ! J558L
CA Hybridoma
//
ID JW8/5/13
AC CVCL_M111
DR ECACC; 87080706
RX PubMed=3500259;
CC Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP).
OX NCBI_TaxID=9606; ! Homo sapiens
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3949 ! J558L
CA Hybridoma
//
ID JX-G
AC CVCL_M085
RX PubMed=8287127;
DI NCIt; C4162; Juxtaglomerular cell tumor
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID JY
AC CVCL_0108
SY JY-S
DR BTO; BTO:0003044
DR ChEMBL-Cells; CHEMBL3308061
DR ChEMBL-Targets; CHEMBL613833
DR dbMHC; 48917
DR ECACC; 94022533
DR IHW; IHW9287
DR IMGT/HLA; 10882
DR PRIDE; PXD000394
DR Wikidata; Q6109290
RX PubMed=23619976;
RX PubMed=25576301;
WW https://en.wikipedia.org/wiki/JY_cell_line
WW http://bioinformatics.hsanmartino.it/ecbr/cl287.html
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/j/cell-lines-detail-50.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Omics: HLA class I peptidome analysis by proteomics.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID Jyg-MC(A)
AC CVCL_H216
SY JygMC(A); JYG-MC A; JYG-MC type A; JYG-A
DR CLO; CLO_0050966
DR RCB; RCB0526
RX PubMed=2071538;
RX PubMed=7757963;
CC Breed/subspecies: JYG.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_H217 ! Jyg-MC(B)
SX Female
CA Cancer cell line
//
ID Jyg-MC(B)
AC CVCL_H217
SY JygMC(B); JYG-MC B; JYG-MC type B; JYG-B
DR CLO; CLO_0050965
DR RCB; RCB0527
RX PubMed=2071538;
RX PubMed=7757963;
CC Breed/subspecies: JYG.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_H216 ! Jyg-MC(A)
SX Female
CA Cancer cell line
//
ID K 114
AC CVCL_G225
SY K114; K1114; M-16
DR CLO; CLO_0007049
DR ATCC; HB-8444
RX Patent=US4806628;
RX Patent=US4808704;
CC Discontinued: ATCC; HB-8444; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID K-1034
AC CVCL_8251
SY K-1034 RPE; K1034
DR BTO; BTO:0002899
RX PubMed=7933691;
OX NCBI_TaxID=9606; ! Homo sapiens
CA Spontaneously immortalized cell line
//
ID K-104
AC CVCL_M719
SY SYM-I (clone K-104)
RX PubMed=6208314;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M718 ! SYM-I
CA Cancer cell line
//
ID K-119
AC CVCL_6292
RX PubMed=7689076;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=K-119__REFERENCES
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID K-1.fl
AC CVCL_F499
DR CLO; CLO_0050785
DR RCB; RCB0559
RX PubMed=1071084;
CC Breed/subspecies: DDD.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4312 ! T-3-Cl-2
SX Male
CA Cancer cell line
//
ID K-22
AC CVCL_6D68
SY K22
RX PubMed=162864;
RX PubMed=6865990;
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Male
CA Finite cell line
//
ID K-231
AC CVCL_F959
DR TKG; TKG 0129
CC Breed/subspecies: ACI/N.
DI NCIt; C60416; Rat hepatocellular carcinoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Female
CA Cancer cell line
//
ID K-251
AC CVCL_5141
DR CLO; CLO_0050616
DR RCB; RCB2859
DR TKG; TKG 0130
CC Breed/subspecies: ACI/N.
DI NCIt; C60416; Rat hepatocellular carcinoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Female
CA Cancer cell line
//
ID K-562
AC CVCL_0004
SY K562; K 562
DR BTO; BTO:0000664
DR CLO; CLO_0007050
DR CLO; CLO_0007059
DR CLO; CLO_0050123
DR CLO; CLO_0050124
DR CLO; CLO_0050126
DR EFO; EFO_0002067
DR MCCL; MCC:0000261
DR CLDB; cl2967
DR CLDB; cl2969
DR CLDB; cl2970
DR CLDB; cl2971
DR CLDB; cl2972
DR CLDB; cl2973
DR CLDB; cl2974
DR CLDB; cl2976
DR CLDB; cl2978
DR CLDB; cl2979
DR CLDB; cl2980
DR CLDB; cl2981
DR CLDB; cl2982
DR CLDB; cl2984
DR ATCC; CCL-243
DR BCRC; 60007
DR BCRJ; 0126
DR BioSample; SAMN03472111
DR BioSample; SAMN03473172
DR BioSample; SAMN03473407
DR CCLE; K562_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CCLV; CCLV-RIE 0439
DR CCRID; 3111C0001CCC000039
DR CCRID; 3111C0002000000026
DR CCRID; 3131C0001000700029
DR CCRID; 3142C0001000000037
DR CCRID; 3153C0001000000012
DR CGH-DB; 9215-4
DR ChEMBL-Cells; CHEMBL3308378
DR ChEMBL-Targets; CHEMBL385
DR CLS; 300224/p473_K-562
DR Cosmic; 683655
DR Cosmic; 755290
DR Cosmic; 759897
DR Cosmic; 760646
DR Cosmic; 787495
DR Cosmic; 798223
DR Cosmic; 798664
DR Cosmic; 851999
DR Cosmic; 875864
DR Cosmic; 897450
DR Cosmic; 905940
DR Cosmic; 919127
DR Cosmic; 922682
DR Cosmic; 924039
DR Cosmic; 932771
DR Cosmic; 949095
DR Cosmic; 974253
DR Cosmic; 991559
DR Cosmic; 994173
DR Cosmic; 998760
DR Cosmic; 999774
DR Cosmic; 1012074
DR Cosmic; 1019830
DR Cosmic; 1026565
DR Cosmic; 1037680
DR Cosmic; 1044253
DR Cosmic; 1067445
DR Cosmic; 1070699
DR Cosmic; 1078718
DR Cosmic; 1089521
DR Cosmic; 1092608
DR Cosmic; 1107181
DR Cosmic; 1118473
DR Cosmic; 1127251
DR Cosmic; 1175856
DR Cosmic; 1176584
DR Cosmic; 1191694
DR Cosmic; 1226862
DR Cosmic; 1305338
DR Cosmic; 1312324
DR Cosmic; 1319552
DR Cosmic; 1325761
DR Cosmic; 1465965
DR Cosmic; 1516632
DR Cosmic; 1523829
DR Cosmic; 1524846
DR Cosmic; 1601068
DR Cosmic; 1779132
DR Cosmic; 1998450
DR Cosmic; 2009516
DR Cosmic; 2024372
DR Cosmic; 2089675
DR Cosmic; 2301564
DR Cosmic-CLP; 905940
DR DSMZ; ACC-10
DR ECACC; 89121407
DR ENCODE; ENCBS001TOZ
DR ENCODE; ENCBS004ALC
DR ENCODE; ENCBS005AIZ
DR ENCODE; ENCBS005ZXA
DR ENCODE; ENCBS007IVF
DR ENCODE; ENCBS007ZNT
DR ENCODE; ENCBS008XYP
DR ENCODE; ENCBS010SYB
DR ENCODE; ENCBS011IBX
DR ENCODE; ENCBS013BQD
DR ENCODE; ENCBS013ENT
DR ENCODE; ENCBS013GDO
DR ENCODE; ENCBS013VIB
DR ENCODE; ENCBS014ZBK
DR ENCODE; ENCBS014ZUQ
DR ENCODE; ENCBS016BTC
DR ENCODE; ENCBS016SET
DR ENCODE; ENCBS016SXN
DR ENCODE; ENCBS016YMK
DR ENCODE; ENCBS017GMY
DR ENCODE; ENCBS017IKU
DR ENCODE; ENCBS017YLT
DR ENCODE; ENCBS018CRO
DR ENCODE; ENCBS019QZZ
DR ENCODE; ENCBS020IUG
DR ENCODE; ENCBS021PJN
DR ENCODE; ENCBS022LAM
DR ENCODE; ENCBS023DBL
DR ENCODE; ENCBS023ECI
DR ENCODE; ENCBS023EVI
DR ENCODE; ENCBS023XVB
DR ENCODE; ENCBS023YVH
DR ENCODE; ENCBS024UMN
DR ENCODE; ENCBS024ZBK
DR ENCODE; ENCBS025CUE
DR ENCODE; ENCBS025ONJ
DR ENCODE; ENCBS026DNX
DR ENCODE; ENCBS026IRF
DR ENCODE; ENCBS026LKC
DR ENCODE; ENCBS027GJN
DR ENCODE; ENCBS029GNW
DR ENCODE; ENCBS031HYV
DR ENCODE; ENCBS031YPZ
DR ENCODE; ENCBS036OIX
DR ENCODE; ENCBS038KVF
DR ENCODE; ENCBS038TWG
DR ENCODE; ENCBS039ENC
DR ENCODE; ENCBS039FPC
DR ENCODE; ENCBS040EUG
DR ENCODE; ENCBS040IKC
DR ENCODE; ENCBS044UVO
DR ENCODE; ENCBS044WJW
DR ENCODE; ENCBS048GNZ
DR ENCODE; ENCBS049QOP
DR ENCODE; ENCBS049ZAC
DR ENCODE; ENCBS051ELN
DR ENCODE; ENCBS053JIZ
DR ENCODE; ENCBS055ZTI
DR ENCODE; ENCBS056HKT
DR ENCODE; ENCBS058KXV
DR ENCODE; ENCBS058MBJ
DR ENCODE; ENCBS058XGI
DR ENCODE; ENCBS060HRB
DR ENCODE; ENCBS061SQD
DR ENCODE; ENCBS061XBB
DR ENCODE; ENCBS063NCT
DR ENCODE; ENCBS063ROH
DR ENCODE; ENCBS065RXZ
DR ENCODE; ENCBS070OMK
DR ENCODE; ENCBS071UNK
DR ENCODE; ENCBS073JAL
DR ENCODE; ENCBS074HIZ
DR ENCODE; ENCBS078NQM
DR ENCODE; ENCBS078OYF
DR ENCODE; ENCBS079AJY
DR ENCODE; ENCBS079MXX
DR ENCODE; ENCBS081NLE
DR ENCODE; ENCBS082JRQ
DR ENCODE; ENCBS083ACT
DR ENCODE; ENCBS083CLD
DR ENCODE; ENCBS084MBW
DR ENCODE; ENCBS086JQA
DR ENCODE; ENCBS087RNA
DR ENCODE; ENCBS088RNA
DR ENCODE; ENCBS089OTW
DR ENCODE; ENCBS091YRZ
DR ENCODE; ENCBS092VTJ
DR ENCODE; ENCBS093NNC
DR ENCODE; ENCBS099HZF
DR ENCODE; ENCBS101QRF
DR ENCODE; ENCBS103HEN
DR ENCODE; ENCBS106FRJ
DR ENCODE; ENCBS107DSY
DR ENCODE; ENCBS109ENC
DR ENCODE; ENCBS109VHI
DR ENCODE; ENCBS110VVJ
DR ENCODE; ENCBS111BRF
DR ENCODE; ENCBS111GYT
DR ENCODE; ENCBS111RFA
DR ENCODE; ENCBS113YMQ
DR ENCODE; ENCBS118YJZ
DR ENCODE; ENCBS119EVP
DR ENCODE; ENCBS119WDQ
DR ENCODE; ENCBS123DAX
DR ENCODE; ENCBS123QRB
DR ENCODE; ENCBS123YCA
DR ENCODE; ENCBS125ACM
DR ENCODE; ENCBS125WRA
DR ENCODE; ENCBS126AJR
DR ENCODE; ENCBS128EWC
DR ENCODE; ENCBS128UKH
DR ENCODE; ENCBS131FDE
DR ENCODE; ENCBS132EBC
DR ENCODE; ENCBS133VWK
DR ENCODE; ENCBS136ZNW
DR ENCODE; ENCBS138SLH
DR ENCODE; ENCBS139SNH
DR ENCODE; ENCBS140MLH
DR ENCODE; ENCBS140NYG
DR ENCODE; ENCBS143LJI
DR ENCODE; ENCBS143XSU
DR ENCODE; ENCBS144YDQ
DR ENCODE; ENCBS145IJT
DR ENCODE; ENCBS146WJY
DR ENCODE; ENCBS148ZBT
DR ENCODE; ENCBS149SJX
DR ENCODE; ENCBS151LUO
DR ENCODE; ENCBS152EMG
DR ENCODE; ENCBS152WCA
DR ENCODE; ENCBS152XKV
DR ENCODE; ENCBS153VBF
DR ENCODE; ENCBS154XYR
DR ENCODE; ENCBS155KGP
DR ENCODE; ENCBS158FRU
DR ENCODE; ENCBS158KSS
DR ENCODE; ENCBS159KYP
DR ENCODE; ENCBS159UIB
DR ENCODE; ENCBS162AGB
DR ENCODE; ENCBS162UQR
DR ENCODE; ENCBS164AGP
DR ENCODE; ENCBS164ITK
DR ENCODE; ENCBS165ART
DR ENCODE; ENCBS165NPS
DR ENCODE; ENCBS166BGG
DR ENCODE; ENCBS166SNL
DR ENCODE; ENCBS169BBI
DR ENCODE; ENCBS170ZQG
DR ENCODE; ENCBS171PLV
DR ENCODE; ENCBS172RAU
DR ENCODE; ENCBS173WPT
DR ENCODE; ENCBS174LOJ
DR ENCODE; ENCBS174YKM
DR ENCODE; ENCBS175JIH
DR ENCODE; ENCBS175LWC
DR ENCODE; ENCBS175LZM
DR ENCODE; ENCBS177FZX
DR ENCODE; ENCBS177LGN
DR ENCODE; ENCBS180BMC
DR ENCODE; ENCBS181AJG
DR ENCODE; ENCBS182ISG
DR ENCODE; ENCBS182RTT
DR ENCODE; ENCBS182SAO
DR ENCODE; ENCBS184UCR
DR ENCODE; ENCBS185RGL
DR ENCODE; ENCBS190TRO
DR ENCODE; ENCBS192SEZ
DR ENCODE; ENCBS193JEH
DR ENCODE; ENCBS193QNA
DR ENCODE; ENCBS193WKG
DR ENCODE; ENCBS195ZWQ
DR ENCODE; ENCBS198UTW
DR ENCODE; ENCBS198YII
DR ENCODE; ENCBS199SKB
DR ENCODE; ENCBS200VZF
DR ENCODE; ENCBS201EIP
DR ENCODE; ENCBS201LYR
DR ENCODE; ENCBS204NMW
DR ENCODE; ENCBS205QYW
DR ENCODE; ENCBS207UAM
DR ENCODE; ENCBS209TDT
DR ENCODE; ENCBS209TSR
DR ENCODE; ENCBS210WPX
DR ENCODE; ENCBS211WEE
DR ENCODE; ENCBS215KUV
DR ENCODE; ENCBS216WMI
DR ENCODE; ENCBS217DFO
DR ENCODE; ENCBS218LCA
DR ENCODE; ENCBS218QRN
DR ENCODE; ENCBS218ZAA
DR ENCODE; ENCBS220ZHX
DR ENCODE; ENCBS221UJD
DR ENCODE; ENCBS221YFO
DR ENCODE; ENCBS222CHH
DR ENCODE; ENCBS222QCU
DR ENCODE; ENCBS225YVR
DR ENCODE; ENCBS226YIA
DR ENCODE; ENCBS228CEB
DR ENCODE; ENCBS230JWL
DR ENCODE; ENCBS232KKV
DR ENCODE; ENCBS237BHV
DR ENCODE; ENCBS237MFM
DR ENCODE; ENCBS237RBH
DR ENCODE; ENCBS243YEC
DR ENCODE; ENCBS243YPN
DR ENCODE; ENCBS244ZUD
DR ENCODE; ENCBS245AME
DR ENCODE; ENCBS250CMV
DR ENCODE; ENCBS250HLF
DR ENCODE; ENCBS250IAJ
DR ENCODE; ENCBS252OWV
DR ENCODE; ENCBS253VOZ
DR ENCODE; ENCBS254JMT
DR ENCODE; ENCBS254KOX
DR ENCODE; ENCBS254WUV
DR ENCODE; ENCBS257HMY
DR ENCODE; ENCBS257PZA
DR ENCODE; ENCBS261MYX
DR ENCODE; ENCBS262OLW
DR ENCODE; ENCBS263GNB
DR ENCODE; ENCBS268LPU
DR ENCODE; ENCBS270GGH
DR ENCODE; ENCBS270OAE
DR ENCODE; ENCBS271BPH
DR ENCODE; ENCBS271WWU
DR ENCODE; ENCBS272SXA
DR ENCODE; ENCBS274WIM
DR ENCODE; ENCBS275HBP
DR ENCODE; ENCBS278ISQ
DR ENCODE; ENCBS278LNR
DR ENCODE; ENCBS280PHL
DR ENCODE; ENCBS283QAE
DR ENCODE; ENCBS283TEI
DR ENCODE; ENCBS284MJG
DR ENCODE; ENCBS285VBM
DR ENCODE; ENCBS287TWJ
DR ENCODE; ENCBS288EEL
DR ENCODE; ENCBS290OFW
DR ENCODE; ENCBS292NBI
DR ENCODE; ENCBS293BDC
DR ENCODE; ENCBS293ZDP
DR ENCODE; ENCBS298QZZ
DR ENCODE; ENCBS301EZU
DR ENCODE; ENCBS302IGJ
DR ENCODE; ENCBS305KEA
DR ENCODE; ENCBS306NPK
DR ENCODE; ENCBS311LNQ
DR ENCODE; ENCBS313HKT
DR ENCODE; ENCBS316CKF
DR ENCODE; ENCBS318IMK
DR ENCODE; ENCBS320BUL
DR ENCODE; ENCBS322JPK
DR ENCODE; ENCBS323NUL
DR ENCODE; ENCBS323WRW
DR ENCODE; ENCBS324XGY
DR ENCODE; ENCBS324YAG
DR ENCODE; ENCBS326ULG
DR ENCODE; ENCBS328LML
DR ENCODE; ENCBS330LHC
DR ENCODE; ENCBS331OZE
DR ENCODE; ENCBS333OTT
DR ENCODE; ENCBS334VOL
DR ENCODE; ENCBS339WIS
DR ENCODE; ENCBS340AMO
DR ENCODE; ENCBS341TAT
DR ENCODE; ENCBS344LIE
DR ENCODE; ENCBS344ZTN
DR ENCODE; ENCBS345PNA
DR ENCODE; ENCBS346YOL
DR ENCODE; ENCBS348UOE
DR ENCODE; ENCBS349ULG
DR ENCODE; ENCBS351GWD
DR ENCODE; ENCBS354VJM
DR ENCODE; ENCBS355BRH
DR ENCODE; ENCBS356NKY
DR ENCODE; ENCBS357GME
DR ENCODE; ENCBS358PHP
DR ENCODE; ENCBS359TRM
DR ENCODE; ENCBS360VVZ
DR ENCODE; ENCBS360YEH
DR ENCODE; ENCBS361MEX
DR ENCODE; ENCBS362YBS
DR ENCODE; ENCBS363HPO
DR ENCODE; ENCBS365DFQ
DR ENCODE; ENCBS366CLP
DR ENCODE; ENCBS368MWR
DR ENCODE; ENCBS370QIM
DR ENCODE; ENCBS370ZIR
DR ENCODE; ENCBS371NDR
DR ENCODE; ENCBS373HMN
DR ENCODE; ENCBS374DHY
DR ENCODE; ENCBS376UCQ
DR ENCODE; ENCBS378DFU
DR ENCODE; ENCBS379NWT
DR ENCODE; ENCBS380BDK
DR ENCODE; ENCBS380IYL
DR ENCODE; ENCBS380NDS
DR ENCODE; ENCBS383JPN
DR ENCODE; ENCBS383VKK
DR ENCODE; ENCBS388NGV
DR ENCODE; ENCBS388YAM
DR ENCODE; ENCBS388ZVM
DR ENCODE; ENCBS392QEL
DR ENCODE; ENCBS393YUA
DR ENCODE; ENCBS394LTC
DR ENCODE; ENCBS396JPQ
DR ENCODE; ENCBS396WFI
DR ENCODE; ENCBS397GXE
DR ENCODE; ENCBS397OLQ
DR ENCODE; ENCBS398SSI
DR ENCODE; ENCBS400CRG
DR ENCODE; ENCBS400HFL
DR ENCODE; ENCBS400IMH
DR ENCODE; ENCBS400MFJ
DR ENCODE; ENCBS402AEU
DR ENCODE; ENCBS403VZZ
DR ENCODE; ENCBS405GDI
DR ENCODE; ENCBS406BAI
DR ENCODE; ENCBS406RFF
DR ENCODE; ENCBS407GJQ
DR ENCODE; ENCBS409CCX
DR ENCODE; ENCBS409HCD
DR ENCODE; ENCBS410EIF
DR ENCODE; ENCBS411BWT
DR ENCODE; ENCBS413TJM
DR ENCODE; ENCBS413UCH
DR ENCODE; ENCBS415LMS
DR ENCODE; ENCBS415MYO
DR ENCODE; ENCBS416ZWV
DR ENCODE; ENCBS417FMB
DR ENCODE; ENCBS417QMS
DR ENCODE; ENCBS418OCT
DR ENCODE; ENCBS419NSL
DR ENCODE; ENCBS422KVR
DR ENCODE; ENCBS424RFS
DR ENCODE; ENCBS425EWY
DR ENCODE; ENCBS426MFA
DR ENCODE; ENCBS430DZA
DR ENCODE; ENCBS431YNM
DR ENCODE; ENCBS432FLT
DR ENCODE; ENCBS433HMF
DR ENCODE; ENCBS433OVV
DR ENCODE; ENCBS433WAM
DR ENCODE; ENCBS438DSC
DR ENCODE; ENCBS440DGS
DR ENCODE; ENCBS441PSF
DR ENCODE; ENCBS442NXE
DR ENCODE; ENCBS442VLY
DR ENCODE; ENCBS443DUP
DR ENCODE; ENCBS445GUZ
DR ENCODE; ENCBS448ECS
DR ENCODE; ENCBS449PYL
DR ENCODE; ENCBS450ITK
DR ENCODE; ENCBS451AJS
DR ENCODE; ENCBS452HCE
DR ENCODE; ENCBS453KQD
DR ENCODE; ENCBS455LFT
DR ENCODE; ENCBS456EWO
DR ENCODE; ENCBS456TNJ
DR ENCODE; ENCBS460WQH
DR ENCODE; ENCBS461TCT
DR ENCODE; ENCBS463ABO
DR ENCODE; ENCBS463GGK
DR ENCODE; ENCBS464DIX
DR ENCODE; ENCBS464YJN
DR ENCODE; ENCBS465MWC
DR ENCODE; ENCBS465RFQ
DR ENCODE; ENCBS468YAY
DR ENCODE; ENCBS472YQF
DR ENCODE; ENCBS474CTB
DR ENCODE; ENCBS474XLY
DR ENCODE; ENCBS476AUA
DR ENCODE; ENCBS476AXH
DR ENCODE; ENCBS476WAQ
DR ENCODE; ENCBS477JCG
DR ENCODE; ENCBS477MKD
DR ENCODE; ENCBS478TXQ
DR ENCODE; ENCBS478USZ
DR ENCODE; ENCBS482NAM
DR ENCODE; ENCBS484NBA
DR ENCODE; ENCBS486UBH
DR ENCODE; ENCBS487XCP
DR ENCODE; ENCBS488IUR
DR ENCODE; ENCBS489AXI
DR ENCODE; ENCBS489LOC
DR ENCODE; ENCBS489PTQ
DR ENCODE; ENCBS489ZOH
DR ENCODE; ENCBS491FIM
DR ENCODE; ENCBS492BQN
DR ENCODE; ENCBS492SXA
DR ENCODE; ENCBS494YUP
DR ENCODE; ENCBS495MNB
DR ENCODE; ENCBS497UCZ
DR ENCODE; ENCBS498NIQ
DR ENCODE; ENCBS499AAA
DR ENCODE; ENCBS499ZBY
DR ENCODE; ENCBS500AAA
DR ENCODE; ENCBS501AAA
DR ENCODE; ENCBS501AJP
DR ENCODE; ENCBS501VGA
DR ENCODE; ENCBS502AAA
DR ENCODE; ENCBS502SUO
DR ENCODE; ENCBS503AAA
DR ENCODE; ENCBS504AAA
DR ENCODE; ENCBS504EOJ
DR ENCODE; ENCBS504SHW
DR ENCODE; ENCBS505AAA
DR ENCODE; ENCBS505ILK
DR ENCODE; ENCBS506VSB
DR ENCODE; ENCBS508YPA
DR ENCODE; ENCBS509AAA
DR ENCODE; ENCBS510AAA
DR ENCODE; ENCBS511UGF
DR ENCODE; ENCBS511YCF
DR ENCODE; ENCBS512JXB
DR ENCODE; ENCBS515TJK
DR ENCODE; ENCBS516DKF
DR ENCODE; ENCBS517UIR
DR ENCODE; ENCBS517XSM
DR ENCODE; ENCBS519PER
DR ENCODE; ENCBS519VAI
DR ENCODE; ENCBS521FNT
DR ENCODE; ENCBS522JIE
DR ENCODE; ENCBS523GIC
DR ENCODE; ENCBS524AAA
DR ENCODE; ENCBS526FPZ
DR ENCODE; ENCBS526GWV
DR ENCODE; ENCBS528AAA
DR ENCODE; ENCBS530DUV
DR ENCODE; ENCBS530IBU
DR ENCODE; ENCBS530JOQ
DR ENCODE; ENCBS530MLH
DR ENCODE; ENCBS532KVA
DR ENCODE; ENCBS533ETT
DR ENCODE; ENCBS534MHY
DR ENCODE; ENCBS534VZR
DR ENCODE; ENCBS534WDC
DR ENCODE; ENCBS537KCG
DR ENCODE; ENCBS538WJZ
DR ENCODE; ENCBS540TUC
DR ENCODE; ENCBS540UNM
DR ENCODE; ENCBS543YEP
DR ENCODE; ENCBS544JRU
DR ENCODE; ENCBS548BNW
DR ENCODE; ENCBS549CBF
DR ENCODE; ENCBS549CIX
DR ENCODE; ENCBS551TRA
DR ENCODE; ENCBS552DXA
DR ENCODE; ENCBS552IDC
DR ENCODE; ENCBS552LNH
DR ENCODE; ENCBS555BIW
DR ENCODE; ENCBS555BYH
DR ENCODE; ENCBS555MCX
DR ENCODE; ENCBS556RPW
DR ENCODE; ENCBS559ZAU
DR ENCODE; ENCBS560YCY
DR ENCODE; ENCBS561DIS
DR ENCODE; ENCBS563BBS
DR ENCODE; ENCBS565ULH
DR ENCODE; ENCBS565XGU
DR ENCODE; ENCBS566AKW
DR ENCODE; ENCBS566NIL
DR ENCODE; ENCBS569AYK
DR ENCODE; ENCBS569WDT
DR ENCODE; ENCBS572YNK
DR ENCODE; ENCBS573CFY
DR ENCODE; ENCBS574JXP
DR ENCODE; ENCBS575FXP
DR ENCODE; ENCBS576EJU
DR ENCODE; ENCBS577JGM
DR ENCODE; ENCBS577QZL
DR ENCODE; ENCBS579CNZ
DR ENCODE; ENCBS588YDJ
DR ENCODE; ENCBS590KAM
DR ENCODE; ENCBS590PKD
DR ENCODE; ENCBS591LWJ
DR ENCODE; ENCBS593BIQ
DR ENCODE; ENCBS593CFU
DR ENCODE; ENCBS594GNK
DR ENCODE; ENCBS595QXS
DR ENCODE; ENCBS598STC
DR ENCODE; ENCBS599BAS
DR ENCODE; ENCBS600AAA
DR ENCODE; ENCBS600EDY
DR ENCODE; ENCBS601AAA
DR ENCODE; ENCBS601MXN
DR ENCODE; ENCBS602AAA
DR ENCODE; ENCBS602RSX
DR ENCODE; ENCBS602TPG
DR ENCODE; ENCBS603CUX
DR ENCODE; ENCBS603PMU
DR ENCODE; ENCBS609MYU
DR ENCODE; ENCBS611GYD
DR ENCODE; ENCBS613LBH
DR ENCODE; ENCBS614RYV
DR ENCODE; ENCBS615ZVR
DR ENCODE; ENCBS619KUS
DR ENCODE; ENCBS621XIY
DR ENCODE; ENCBS622KGA
DR ENCODE; ENCBS624RXT
DR ENCODE; ENCBS626KTH
DR ENCODE; ENCBS626OHB
DR ENCODE; ENCBS626TPH
DR ENCODE; ENCBS627GSN
DR ENCODE; ENCBS628JQT
DR ENCODE; ENCBS629DNR
DR ENCODE; ENCBS630MQK
DR ENCODE; ENCBS630NVQ
DR ENCODE; ENCBS630OAS
DR ENCODE; ENCBS631FGS
DR ENCODE; ENCBS632QPM
DR ENCODE; ENCBS636RQT
DR ENCODE; ENCBS637RKV
DR ENCODE; ENCBS638EYY
DR ENCODE; ENCBS638OEZ
DR ENCODE; ENCBS638QCL
DR ENCODE; ENCBS639AAA
DR ENCODE; ENCBS641AAS
DR ENCODE; ENCBS642DEU
DR ENCODE; ENCBS643CHR
DR ENCODE; ENCBS643OWK
DR ENCODE; ENCBS645RVR
DR ENCODE; ENCBS647KYQ
DR ENCODE; ENCBS649DTO
DR ENCODE; ENCBS649VHZ
DR ENCODE; ENCBS651RVZ
DR ENCODE; ENCBS652YOG
DR ENCODE; ENCBS654OPT
DR ENCODE; ENCBS654PMT
DR ENCODE; ENCBS654VZH
DR ENCODE; ENCBS655HQL
DR ENCODE; ENCBS656VZE
DR ENCODE; ENCBS657MGB
DR ENCODE; ENCBS657ZYP
DR ENCODE; ENCBS658KIL
DR ENCODE; ENCBS659SAO
DR ENCODE; ENCBS661YYO
DR ENCODE; ENCBS664AAA
DR ENCODE; ENCBS664AUV
DR ENCODE; ENCBS664VDB
DR ENCODE; ENCBS666SJB
DR ENCODE; ENCBS667AAA
DR ENCODE; ENCBS667PRV
DR ENCODE; ENCBS670KPG
DR ENCODE; ENCBS673MZQ
DR ENCODE; ENCBS674MPN
DR ENCODE; ENCBS674VNC
DR ENCODE; ENCBS675OVW
DR ENCODE; ENCBS676KLB
DR ENCODE; ENCBS677BWZ
DR ENCODE; ENCBS677GYI
DR ENCODE; ENCBS677HPS
DR ENCODE; ENCBS677KBE
DR ENCODE; ENCBS680QCR
DR ENCODE; ENCBS681CCH
DR ENCODE; ENCBS684JMW
DR ENCODE; ENCBS688EQJ
DR ENCODE; ENCBS688QTO
DR ENCODE; ENCBS688VYK
DR ENCODE; ENCBS690NWI
DR ENCODE; ENCBS691GWJ
DR ENCODE; ENCBS693EWC
DR ENCODE; ENCBS695KRB
DR ENCODE; ENCBS697QYY
DR ENCODE; ENCBS697XFI
DR ENCODE; ENCBS698AAA
DR ENCODE; ENCBS698ZKR
DR ENCODE; ENCBS699AAA
DR ENCODE; ENCBS700AAA
DR ENCODE; ENCBS701AAA
DR ENCODE; ENCBS701VZK
DR ENCODE; ENCBS702AAA
DR ENCODE; ENCBS703AAA
DR ENCODE; ENCBS703API
DR ENCODE; ENCBS704AAA
DR ENCODE; ENCBS704IXT
DR ENCODE; ENCBS704YXA
DR ENCODE; ENCBS708KJA
DR ENCODE; ENCBS709SOB
DR ENCODE; ENCBS709TUN
DR ENCODE; ENCBS713VDJ
DR ENCODE; ENCBS714PSX
DR ENCODE; ENCBS714TRH
DR ENCODE; ENCBS715AAA
DR ENCODE; ENCBS715BML
DR ENCODE; ENCBS715XGH
DR ENCODE; ENCBS718GJU
DR ENCODE; ENCBS719UQU
DR ENCODE; ENCBS719YVT
DR ENCODE; ENCBS720HYG
DR ENCODE; ENCBS720UTF
DR ENCODE; ENCBS721AAA
DR ENCODE; ENCBS721OCY
DR ENCODE; ENCBS722AAA
DR ENCODE; ENCBS723AAA
DR ENCODE; ENCBS723ZIW
DR ENCODE; ENCBS724AAA
DR ENCODE; ENCBS725AAA
DR ENCODE; ENCBS726AAA
DR ENCODE; ENCBS726ZFM
DR ENCODE; ENCBS728WBV
DR ENCODE; ENCBS729ELF
DR ENCODE; ENCBS729IGE
DR ENCODE; ENCBS730QNJ
DR ENCODE; ENCBS731EBS
DR ENCODE; ENCBS731WEZ
DR ENCODE; ENCBS731WGV
DR ENCODE; ENCBS732IZQ
DR ENCODE; ENCBS732XZP
DR ENCODE; ENCBS734NZL
DR ENCODE; ENCBS736PRC
DR ENCODE; ENCBS737CUP
DR ENCODE; ENCBS739ZIJ
DR ENCODE; ENCBS741EFJ
DR ENCODE; ENCBS741VGS
DR ENCODE; ENCBS744CXB
DR ENCODE; ENCBS745CIF
DR ENCODE; ENCBS745UXY
DR ENCODE; ENCBS746GKH
DR ENCODE; ENCBS746KYH
DR ENCODE; ENCBS746YXR
DR ENCODE; ENCBS747AAA
DR ENCODE; ENCBS748AAA
DR ENCODE; ENCBS748FCA
DR ENCODE; ENCBS749AAA
DR ENCODE; ENCBS749FNX
DR ENCODE; ENCBS750AAA
DR ENCODE; ENCBS751AAA
DR ENCODE; ENCBS751EBU
DR ENCODE; ENCBS751SXP
DR ENCODE; ENCBS751WKI
DR ENCODE; ENCBS752AAA
DR ENCODE; ENCBS753DCN
DR ENCODE; ENCBS753LXR
DR ENCODE; ENCBS757HMX
DR ENCODE; ENCBS764AAA
DR ENCODE; ENCBS765AAA
DR ENCODE; ENCBS766AAA
DR ENCODE; ENCBS767AAA
DR ENCODE; ENCBS767HRR
DR ENCODE; ENCBS767XGD
DR ENCODE; ENCBS768AAA
DR ENCODE; ENCBS769AAA
DR ENCODE; ENCBS770AAA
DR ENCODE; ENCBS770VHR
DR ENCODE; ENCBS771AAA
DR ENCODE; ENCBS771FYB
DR ENCODE; ENCBS771FYZ
DR ENCODE; ENCBS771NTZ
DR ENCODE; ENCBS772AAA
DR ENCODE; ENCBS772SKD
DR ENCODE; ENCBS774KGY
DR ENCODE; ENCBS775AAA
DR ENCODE; ENCBS775HUY
DR ENCODE; ENCBS776AAA
DR ENCODE; ENCBS776WTE
DR ENCODE; ENCBS777AAA
DR ENCODE; ENCBS778AAA
DR ENCODE; ENCBS779AAA
DR ENCODE; ENCBS782AAA
DR ENCODE; ENCBS782UIO
DR ENCODE; ENCBS783AAA
DR ENCODE; ENCBS783CHO
DR ENCODE; ENCBS783CHQ
DR ENCODE; ENCBS783PTA
DR ENCODE; ENCBS783WYV
DR ENCODE; ENCBS784AAA
DR ENCODE; ENCBS785AAA
DR ENCODE; ENCBS786AAA
DR ENCODE; ENCBS787AAA
DR ENCODE; ENCBS788AAA
DR ENCODE; ENCBS788CSD
DR ENCODE; ENCBS789AAA
DR ENCODE; ENCBS789DTV
DR ENCODE; ENCBS790AAA
DR ENCODE; ENCBS790JBM
DR ENCODE; ENCBS790YFX
DR ENCODE; ENCBS791AAA
DR ENCODE; ENCBS792SRL
DR ENCODE; ENCBS797SGL
DR ENCODE; ENCBS798HJU
DR ENCODE; ENCBS799TLB
DR ENCODE; ENCBS800RVX
DR ENCODE; ENCBS802AYH
DR ENCODE; ENCBS803KFY
DR ENCODE; ENCBS808AAA
DR ENCODE; ENCBS808FZK
DR ENCODE; ENCBS808ZQB
DR ENCODE; ENCBS809AAA
DR ENCODE; ENCBS809UHL
DR ENCODE; ENCBS810AAA
DR ENCODE; ENCBS811AAA
DR ENCODE; ENCBS812AAA
DR ENCODE; ENCBS812OIJ
DR ENCODE; ENCBS813AAA
DR ENCODE; ENCBS813JVE
DR ENCODE; ENCBS814AAA
DR ENCODE; ENCBS815AAA
DR ENCODE; ENCBS815LSY
DR ENCODE; ENCBS816AAA
DR ENCODE; ENCBS818EBR
DR ENCODE; ENCBS818WVG
DR ENCODE; ENCBS820QHU
DR ENCODE; ENCBS821KLW
DR ENCODE; ENCBS822TRA
DR ENCODE; ENCBS823LKQ
DR ENCODE; ENCBS824PND
DR ENCODE; ENCBS827AAA
DR ENCODE; ENCBS827YSZ
DR ENCODE; ENCBS828AAA
DR ENCODE; ENCBS828OIW
DR ENCODE; ENCBS829AAA
DR ENCODE; ENCBS829QEL
DR ENCODE; ENCBS829VJO
DR ENCODE; ENCBS830AAA
DR ENCODE; ENCBS830FSQ
DR ENCODE; ENCBS831AAA
DR ENCODE; ENCBS831ATS
DR ENCODE; ENCBS831COV
DR ENCODE; ENCBS831RAD
DR ENCODE; ENCBS832AAA
DR ENCODE; ENCBS833AAA
DR ENCODE; ENCBS833OVZ
DR ENCODE; ENCBS836YTS
DR ENCODE; ENCBS839CNN
DR ENCODE; ENCBS839VND
DR ENCODE; ENCBS840AAA
DR ENCODE; ENCBS841AAA
DR ENCODE; ENCBS841YJV
DR ENCODE; ENCBS842AAA
DR ENCODE; ENCBS843AAA
DR ENCODE; ENCBS843LHE
DR ENCODE; ENCBS843ZIK
DR ENCODE; ENCBS844AAA
DR ENCODE; ENCBS846HWI
DR ENCODE; ENCBS847CMA
DR ENCODE; ENCBS849TDY
DR ENCODE; ENCBS850BRB
DR ENCODE; ENCBS850LWJ
DR ENCODE; ENCBS850QNJ
DR ENCODE; ENCBS851FLL
DR ENCODE; ENCBS851WPL
DR ENCODE; ENCBS852AAA
DR ENCODE; ENCBS852JTF
DR ENCODE; ENCBS852VOH
DR ENCODE; ENCBS854WQM
DR ENCODE; ENCBS855MYK
DR ENCODE; ENCBS855ZEG
DR ENCODE; ENCBS857RNB
DR ENCODE; ENCBS861PFY
DR ENCODE; ENCBS862RBC
DR ENCODE; ENCBS863CBS
DR ENCODE; ENCBS863MAI
DR ENCODE; ENCBS864MCX
DR ENCODE; ENCBS864OKZ
DR ENCODE; ENCBS865CZC
DR ENCODE; ENCBS865HYV
DR ENCODE; ENCBS865KGU
DR ENCODE; ENCBS865VEQ
DR ENCODE; ENCBS869IGF
DR ENCODE; ENCBS870PSR
DR ENCODE; ENCBS870VQI
DR ENCODE; ENCBS871KRX
DR ENCODE; ENCBS871MOK
DR ENCODE; ENCBS871QLJ
DR ENCODE; ENCBS872JXE
DR ENCODE; ENCBS873YKY
DR ENCODE; ENCBS877QTV
DR ENCODE; ENCBS877RXF
DR ENCODE; ENCBS878WRC
DR ENCODE; ENCBS884PXY
DR ENCODE; ENCBS885HUO
DR ENCODE; ENCBS885ULI
DR ENCODE; ENCBS886PEW
DR ENCODE; ENCBS889HPN
DR ENCODE; ENCBS889HVK
DR ENCODE; ENCBS889MQU
DR ENCODE; ENCBS891EMR
DR ENCODE; ENCBS894CLK
DR ENCODE; ENCBS895IMG
DR ENCODE; ENCBS895KNQ
DR ENCODE; ENCBS897EVB
DR ENCODE; ENCBS897PRR
DR ENCODE; ENCBS903OGK
DR ENCODE; ENCBS904ISV
DR ENCODE; ENCBS904ULB
DR ENCODE; ENCBS905JDP
DR ENCODE; ENCBS905KZI
DR ENCODE; ENCBS905LQS
DR ENCODE; ENCBS906KIP
DR ENCODE; ENCBS907QMF
DR ENCODE; ENCBS910WHE
DR ENCODE; ENCBS917PHA
DR ENCODE; ENCBS918DLF
DR ENCODE; ENCBS922LYA
DR ENCODE; ENCBS922RYG
DR ENCODE; ENCBS923TYZ
DR ENCODE; ENCBS926CWO
DR ENCODE; ENCBS931MQO
DR ENCODE; ENCBS934FPI
DR ENCODE; ENCBS936VOR
DR ENCODE; ENCBS937ULR
DR ENCODE; ENCBS941WQP
DR ENCODE; ENCBS943ICN
DR ENCODE; ENCBS943ODH
DR ENCODE; ENCBS946FNG
DR ENCODE; ENCBS946SUX
DR ENCODE; ENCBS946YFO
DR ENCODE; ENCBS947EGW
DR ENCODE; ENCBS947VKK
DR ENCODE; ENCBS947YKG
DR ENCODE; ENCBS948HVW
DR ENCODE; ENCBS948PVM
DR ENCODE; ENCBS948QXW
DR ENCODE; ENCBS949ESX
DR ENCODE; ENCBS949FLF
DR ENCODE; ENCBS953HJY
DR ENCODE; ENCBS953YBZ
DR ENCODE; ENCBS954RIE
DR ENCODE; ENCBS957NCU
DR ENCODE; ENCBS958BUA
DR ENCODE; ENCBS960IYL
DR ENCODE; ENCBS962ZXU
DR ENCODE; ENCBS963QYF
DR ENCODE; ENCBS963XMS
DR ENCODE; ENCBS964MCW
DR ENCODE; ENCBS964YGP
DR ENCODE; ENCBS967BUS
DR ENCODE; ENCBS967GAK
DR ENCODE; ENCBS969AZO
DR ENCODE; ENCBS972JLR
DR ENCODE; ENCBS972KMH
DR ENCODE; ENCBS973CSB
DR ENCODE; ENCBS973MAW
DR ENCODE; ENCBS973NFP
DR ENCODE; ENCBS975JQF
DR ENCODE; ENCBS978JIM
DR ENCODE; ENCBS982AOH
DR ENCODE; ENCBS983KMD
DR ENCODE; ENCBS983TNS
DR ENCODE; ENCBS984GCA
DR ENCODE; ENCBS985INM
DR ENCODE; ENCBS990XUV
DR ENCODE; ENCBS992SGT
DR ENCODE; ENCBS993NMB
DR ENCODE; ENCBS994EIH
DR ENCODE; ENCBS994NNW
DR ENCODE; ENCBS994WPS
DR ENCODE; ENCBS995UMN
DR ENCODE; ENCBS997MUA
DR ENCODE; ENCBS998FPD
DR ENCODE; ENCBS998ZJJ
DR ENCODE; ENCBS999HDT
DR GDSC; 905940
DR GEO; GSM50195
DR GEO; GSM50259
DR GEO; GSM236784
DR GEO; GSM236820
DR GEO; GSM472910
DR GEO; GSM472926
DR GEO; GSM472927
DR GEO; GSM482508
DR GEO; GSM750811
DR GEO; GSM799347
DR GEO; GSM799410
DR GEO; GSM816655
DR GEO; GSM887193
DR GEO; GSM888266
DR GEO; GSM945165
DR GEO; GSM945228
DR GEO; GSM945294
DR GEO; GSM945302
DR GEO; GSM1008567
DR GEO; GSM1008558
DR GEO; GSM1008580
DR GEO; GSM1008601
DR GEO; GSM1008602
DR GEO; GSM1153418
DR GEO; GSM1181317
DR GEO; GSM1181332
DR GEO; GSM1374583
DR GEO; GSM1669971
DR ICLC; HTL94001
DR IGRhCellID; K562
DR IZSLER; BS TCL 33
DR JCRB; JCRB0019
DR KCB; KCB 90029YJ
DR KCLB; 10243
DR Lonza; 101
DR MeSH; D020014
DR NCBI_Iran; C122
DR PRIDE; PRD000229
DR PRIDE; PXD000216
DR PRIDE; PXD001352
DR PRIDE; PXD002395
DR PRIDE; PXD002836
DR PRIDE; PXD003664
DR RCB; RCB0027
DR RCB; RCB1635
DR RCB; RCB1897
DR SKY/M-FISH/CGH; 2811
DR TKG; TKG 0210
DR TOKU-E; 2086
DR TOKU-E; 3631
DR Wikidata; Q6324626
RX PubMed=163658;
RX PubMed=2041050;
RX PubMed=3023859;
RX PubMed=3332852;
RX PubMed=3856862;
RX PubMed=3857109;
RX PubMed=6091813;
RX PubMed=6582512;
RX PubMed=6996765;
RX PubMed=7194480;
RX PubMed=9290701;
RX PubMed=9738977;
RX PubMed=11021758;
RX PubMed=12506034;
RX PubMed=14642717;
RX PubMed=15637111;
RX PubMed=15843827;
RX PubMed=16408098;
RX PubMed=17088437;
RX PubMed=19372543;
RX PubMed=21269460;
RX PubMed=22278370;
RX PubMed=22460905;
RX PubMed=23325432;
RX PubMed=23671654;
RX PubMed=23856246;
RX PubMed=23933261;
RX PubMed=23955599;
RX PubMed=24618588;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=27397505;
RX PubMed=27807467;
RX PubMed=28196595;
WW https://en.wikipedia.org/wiki/K562_cells
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW https://strap.nci.nih.gov/celline_detail.php?sample_id=30
WW http://www.proteinatlas.org/learn/cellines
WW http://141.61.102.20/mxdb/project/show/9191407937500
WW http://genome.ucsc.edu/ENCODE/protocols/cell/human/K562_protocol.pdf
WW http://www.addexbio.com/productdetail?pid=52
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/k/cell-lines-detail-69.html
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: ENCODE project common cell types; tier 1.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: NCI60 cancer cell line panel.
CC Doubling time: 47 hours (PubMed=25984343); 19.6 hours (DTP); ~30-40 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
CC Omics: Deep antibody staining analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep proteome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: H3K27me3 ChIP-seq epigenome analysis.
CC Omics: H3K36me3 ChIP-seq epigenome analysis.
CC Omics: H3K4me3 ChIP-seq epigenome analysis.
CC Omics: H3K9ac ChIP-seq epigenome analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Omics: Virome analysis using proteomics.
CC Misspelling: 'K-652' in Cosmic 1523829.
CC Misspelling: 'K652' in Cosmic 1516632 and Cosmic 2024372.
ST Source(s): ATCC; CLS; Cosmic-CLP; COG; DSMZ; JCRB; KCLB; PubMed=11416159; PubMed=14642717; PubMed=15637111; PubMed=19372543; PubMed=25877200; RCB; TKG
ST Amelogenin: X
ST CSF1PO: 9,10
ST D12S391: 23
ST D13S317: 8
ST D16S539: 11,12 (ATCC; CLS; Cosmic-CLP; COG; ECACC; JCRB; PubMed=14642717; PubMed=15637111; PubMed=19372543; PubMed=25877200; TKG)
ST D16S539: 11,12,13 (DSMZ; RCB)
ST D18S51: 15 (CLS)
ST D18S51: 15,16 (PubMed=14642717; PubMed=15637111; PubMed=19372543)
ST D19S433: 14,14.2
ST D21S11: 29,30 (CLS; PubMed=15637111)
ST D21S11: 29,30,31 (PubMed=14642717; PubMed=19372543; PubMed=25877200)
ST D2S1338: 17
ST D3S1358: 16
ST D5S818: 11,12 (ATCC; CLS; Cosmic-CLP; COG; DSMZ; ECACC; JCRB; KCLB; PubMed=14642717; PubMed=15637111; PubMed=19372543; PubMed=25877200; TKG)
ST D5S818: 11,12,13 (RCB)
ST D7S820: 9,11
ST D8S1179: 12
ST DXS101: 23,24
ST FGA: 21,24
ST Penta D: 9,13
ST Penta E: 5,14
ST SE33: 26.2,28.2
ST TH01: 9.3
ST TPOX: 8,9
ST vWA: 16
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID K-562 SimpleCell O-GalNAc
AC CVCL_S029
SY K562 SimpleCell; K562 SC
RX PubMed=21983924;
RX PubMed=23399548;
RX PubMed=23584533;
CC Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans.
CC Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1.
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K-562R
AC CVCL_5950
SY K562R; K562-R
DR BTO; BTO:0004462
CC Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K-9
AC CVCL_4614
SY Clone 9
DR CLO; CLO_0002504
DR CLDB; cl798
DR ATCC; CRL-1439
DR BCRC; 60201
DR ECACC; 88072203
DR TOKU-E; 971
RX PubMed=162864;
CC Breed/subspecies: Sprague-Dawley.
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Male
CA Finite cell line
//
ID K-BALB
AC CVCL_4350
SY KBALB; K-234; K234
DR CLO; CLO_0007078
DR CLDB; cl2987
DR ATCC; CCL-163.3
DR BCRC; 60090
DR ChEMBL-Cells; CHEMBL3307846
DR ChEMBL-Targets; CHEMBL614009
DR ECACC; 89092101
DR KCLB; 10163.3
RX PubMed=4550769;
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0184 ! BALB/3T3 clone A31
CA Transformed cell line
//
ID K-KT
AC CVCL_J419
DR IMGT/HLA; 10892
RX PubMed=10372549;
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID K-MFH-1
AC CVCL_M820
RX PubMed=1710493;
DI NCIt; C4247; Unclassified pleomorphic sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K-T1
AC CVCL_F690
RX PubMed=3004618;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID K#1 50K
AC CVCL_1H11
SY K#1 50k; K #1 50K; CD8+ K#1 50K
RX Patent=US6358511;
RX PubMed=11752148;
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID K.I.
AC CVCL_F564
SY TER137; TER286
DR IMGT/HLA; 10886
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID K:Molv NIH/3T3
AC CVCL_6662
DR CLO; CLO_0007051
DR ATCC; CRL-6361
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Breed/subspecies: NIH Swiss.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0594 ! NIH 3T3
SX Male
CA Spontaneously immortalized cell line
//
ID K008
AC CVCL_5142
DR Cosmic; 1178186
DR GEO; GSM202004
DR IGRhCellID; K008%20GEO
RX PubMed=23418523;
DI NCIt; C3510; Cutaneous melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K028
AC CVCL_M764
RX PubMed=23418523;
DI NCIt; C3510; Cutaneous melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K029
AC CVCL_5143
DR Cosmic; 1244760
DR GEO; GSM202032
DR IGRhCellID; K029%20GEO
RX PubMed=23418523;
DI NCIt; C3510; Cutaneous melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K029AX
AC CVCL_8784
DR CCLE; K029AX_SKIN
DR GEO; GSM887192
DR GEO; GSM888265
RX PubMed=22460905;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
DI NCIt; C3510; Cutaneous melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5143 ! K029
CA Cancer cell line
//
ID K033
AC CVCL_8785
RX PubMed=23418523;
DI NCIt; C3510; Cutaneous melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K1
AC CVCL_2537
DR CLO; CLO_0007052
DR CLDB; cl2988
DR BCRJ; 0292
DR BioSample; SAMN03151643
DR Cosmic; 928833
DR Cosmic; 1084280
DR Cosmic; 1132597
DR Cosmic; 1162845
DR Cosmic; 1239966
DR Cosmic; 1280046
DR Cosmic; 1507368
DR Cosmic; 1533546
DR Cosmic; 1536121
DR Cosmic; 1889001
DR Cosmic; 2036691
DR Cosmic; 2319846
DR ECACC; 92030501
RX PubMed=9054892;
RX PubMed=17725429;
RX PubMed=18713817;
RX PubMed=19087340;
RX PubMed=20143388;
RX PubMed=22087789;
RX PubMed=23162534;
WW http://www.addexbio.com/productdetail?pid=51
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a GLAG-66 derivative (PubMed=19087340, PubMed=20143388).
ST Source(s): ECACC; PubMed=18713817
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 11,14
ST D16S539: 11,12
ST D18S51: 18
ST D21S11: 30,31.2
ST D3S1358: 18
ST D5S818: 10,11
ST D7S820: 11
ST D8S1179: 15
ST FGA: 21,24
ST TH01: 6,9
ST TPOX: 8
ST vWA: 17,18
DI NCIt; C4035; Thyroid gland papillary carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9918 ! GLAG-66
SX Male
CA Cancer cell line
//
ID K1-Mel
AC CVCL_V409
SY K1-MEL; K1
DR Cosmic; 888855
DR Cosmic; 897497
DR GDSC; 1298158
RX PubMed=15009714;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K107946
AC CVCL_V375
DR IMGT/HLA; 14471
RX PubMed=16948657;
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID K10M17
AC CVCL_T830
SY K10-M17
DR RCB; HPS0104
DR SKIP; SKIP000135
RX PubMed=21347327;
DI NCIt; C85045; Retinitis pigmentosa
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_T832 ! K10M5
OI CVCL_T831 ! K10M19
SX Male
CA Induced pluripotent stem cell
//
ID K10M19
AC CVCL_T831
SY K10-M19
DR RCB; HPS0105
DR SKIP; SKIP000136
RX PubMed=21347327;
DI NCIt; C85045; Retinitis pigmentosa
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_T832 ! K10M5
OI CVCL_T830 ! K10M17
SX Male
CA Induced pluripotent stem cell
//
ID K10M5
AC CVCL_T832
SY K10-M05
DR RCB; HPS0062
DR SKIP; SKIP000134
RX PubMed=21347327;
DI NCIt; C85045; Retinitis pigmentosa
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_T830 ! K10M17
OI CVCL_T831 ! K10M19
SX Male
CA Induced pluripotent stem cell
//
ID K117 [Human ESC]
AC CVCL_C945
DR ISCR; 2301
WW http://grants.nih.gov/stem_cells/registry/not_approved.htm
WW http://acd.od.nih.gov/reports/Stem-Cell-Working-Group-Reports-June-2011.pdf
CC From: VistaGen Therapeutics, Inc.
CC Registration: NIH Human Embryonic Stem Cell Registry; not approved.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID K117 [Mouse hybridoma]
AC CVCL_G226
DR CLO; CLO_0007053
DR ATCC; HB-8553
RX Patent=US5059523;
CC Monoclonal antibody target: UniProtKB; P04216; Human THY1/CD90.
OX NCBI_TaxID=10090; ! Mus musculus
CA Hybridoma
//
ID K11M4
AC CVCL_T833
SY K11-M4
DR RCB; HPS0107
DR SKIP; SKIP000137
RX PubMed=21347327;
DI NCIt; C85045; Retinitis pigmentosa
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_T834 ! K11PD17
OI CVCL_T835 ! K11PD18
SX Female
CA Induced pluripotent stem cell
//
ID K11PD17
AC CVCL_T834
SY K11-P17
DR RCB; HPS0072
DR SKIP; SKIP000138
RX Patent=US20130224156;
RX PubMed=21347327;
DI NCIt; C85045; Retinitis pigmentosa
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_T833 ! K11M4
OI CVCL_T835 ! K11PD18
SX Female
CA Induced pluripotent stem cell
//
ID K11PD18
AC CVCL_T835
SY K11-P18
DR RCB; HPS0106
DR SKIP; SKIP000139
RX PubMed=21347327;
DI NCIt; C85045; Retinitis pigmentosa
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_T833 ! K11M4
OI CVCL_T834 ! K11PD17
SX Female
CA Induced pluripotent stem cell
//
ID K12 [Hamster]
AC CVCL_0F73
RX PubMed=762193;
RX PubMed=4359531;
RX PubMed=7085753;
RX PubMed=7204505;
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0F72 ! Wg-1A
SX Male
CA Spontaneously immortalized cell line
//
ID K12 [Mouse osteosarcoma]
AC CVCL_W625
SY K 12
RX PubMed=3243385;
RX PubMed=10841188;
CC Breed/subspecies: BALB/c.
DI NCIt; C24021; Mouse osteosarcoma
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_W626 ! K14
OI CVCL_W627 ! K37
OI CVCL_W624 ! K7 [Mouse osteosarcoma]
OI CVCL_W628 ! K8 [Mouse osteosarcoma]
SX Female
CA Cancer cell line
//
ID K129SV
AC CVCL_F270
DR CLO; CLO_0007054
DR CLDB; cl2989
RX PubMed=87443;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: 129/Sv.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID K14
AC CVCL_W626
SY K 14
RX PubMed=3243385;
RX PubMed=10841188;
CC Breed/subspecies: BALB/c.
DI NCIt; C24021; Mouse osteosarcoma
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_W624 ! K7 [Mouse osteosarcoma]
OI CVCL_W628 ! K8 [Mouse osteosarcoma]
OI CVCL_W625 ! K12 [Mouse osteosarcoma]
OI CVCL_W627 ! K37
SX Female
CA Cancer cell line
//
ID K1735
AC CVCL_F828
SY K-1735
DR KCLB; 80013
RX PubMed=6944560;
CC Breed/subspecies: C3H/HeN.
DI NCIt; C21790; Mouse melanoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID K1735-C11
AC CVCL_0J42
SY K1735-Cl.11; K1735-Cl11; K-1735 clone 11
RX PubMed=6944560;
CC Breed/subspecies: C3H/HeN.
DI NCIt; C21790; Mouse melanoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F828 ! K1735
CA Cancer cell line
//
ID K1735-C16
AC CVCL_0J45
SY K1735-Cl16; K-1735 clone 16; K1735-C116; K1735c116
RX PubMed=2703275;
RX PubMed=6944560;
RX PubMed=11820393;
CC Breed/subspecies: C3H/HeN.
DI NCIt; C21790; Mouse melanoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F828 ! K1735
CA Cancer cell line
//
ID K1735-C23
AC CVCL_F829
SY K-1735 C-23; K1735C23; K1735-Cl23; K-1735 clone 23; K1735-C123
RX PubMed=6944560;
RX PubMed=11820393;
CC Breed/subspecies: C3H/HeN.
DI NCIt; C21790; Mouse melanoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F828 ! K1735
CA Cancer cell line
//
ID K1735-C26
AC CVCL_0J43
SY K-1735 cl26; K-1735 clone 26
RX PubMed=6944560;
CC Breed/subspecies: C3H/HeN.
DI NCIt; C21790; Mouse melanoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F828 ! K1735
CA Cancer cell line
//
ID K1735-M1
AC CVCL_0J41
SY K1735M1
RX PubMed=2703275;
RX PubMed=6750200;
CC Breed/subspecies: C3H/HeN.
DI NCIt; C21790; Mouse melanoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F828 ! K1735
CA Cancer cell line
//
ID K1735-M2
AC CVCL_F684
SY K-1735 M2; K-1735 M-2; K1735M2; K-1735 subclone M2; K1735 Met 2
RX PubMed=6750200;
RX PubMed=11820393;
CC Breed/subspecies: C3H/HeN.
DI NCIt; C21790; Mouse melanoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_F828 ! K1735
CA Cancer cell line
//
ID K177
AC CVCL_5I63
SY K-177
DR ChEMBL-Cells; CHEMBL3308619
DR ChEMBL-Targets; CHEMBL614687
RX PubMed=8558445;
RX PubMed=11245666;
CC Transfected with: HGNC; 1958; CHRNA4.
CC Transfected with: HGNC; 1962; CHRNB2.
CC Transformant: NCBI_TaxID; 28285; Adenovirus 5.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0045 ! HEK293
SX Female
CA Transformed cell line
//
ID K19
AC CVCL_W796
DR Cosmic; 706092
DR Cosmic; 888836
DR Cosmic; 897475
DR GDSC; 1298159
RX PubMed=10766161;
RX PubMed=15009714;
DI NCIt; C3510; Cutaneous melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K1K
AC CVCL_S935
RX DOI=10.1139/f81-125;
RX Patent=US4219543;
CC Group: Fish cell line.
OX NCBI_TaxID=59899; ! Clarias batrachus
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID K2 [Human melanoma]
AC CVCL_AT85
DR Cosmic; 888867
DR Cosmic-CLP; 1298160
DR GDSC; 1298160
DR LINCS; 51100
RX PubMed=15009714;
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
ST Source(s): Cosmic-CLP
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 10,13
ST D16S539: 10,13
ST D5S818: 11
ST D7S820: 10,11
ST TH01: 7
ST TPOX: 11
ST vWA: 17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K2 [Human thyroid carcinoma]
AC CVCL_6308
DR BioSample; SAMN03151644
DR Cosmic; 928834
DR Cosmic; 1162846
DR Cosmic; 1789443
RX PubMed=9054892;
RX PubMed=10646882;
RX PubMed=18713817;
RX PubMed=20143388;
RX PubMed=21868764;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a GLAG-66 derivative (PubMed=20143388).
ST Source(s): PubMed=18713817; PubMed=21868764
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 11,14
ST D16S539: 11,12
ST D18S51: 18
ST D21S11: 30,31.2
ST D3S1358: 18
ST D5S818: 10,11
ST D7S820: 11
ST D8S1179: 15
ST FGA: 21,24
ST TH01: 6,9
ST TPOX: 8
ST vWA: 17,18
DI NCIt; C4035; Thyroid gland papillary carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9918 ! GLAG-66
SX Male
CA Cancer cell line
//
ID K20-iPSC
AC CVCL_DD62
RX PubMed=27191603;
ST Source(s): PubMed=27191603
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 9,12
ST D16S539: 8,13
ST D21S11: 29,30
ST D5S818: 11,12
ST D7S820: 10,11
ST TH01: 7,9
ST TPOX: 8,9
ST vWA: 17,18
DI NCIt; C26845; Parkinson's disease
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_DD50 ! ND29802
SX Male
CA Induced pluripotent stem cell
//
ID K204
AC CVCL_8961
DR CLO; CLO_0007055
DR ATCC; HB-221
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_4342 ! Y3-Ag 1.2.3
CA Hybridoma
//
ID K209
AC CVCL_W340
SY A549 (K209)
RX PubMed=11991756;
CC Group: Adeno-associated virus packaging cell line.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0023 ! A-549
SX Male
CA Cancer cell line
//
ID K21
AC CVCL_CW35
SY K 21
DR ATCC; HB-8549
RX Patent=US4762800;
RX Patent=US5168043;
CC Discontinued: ATCC; HB-8549; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID K21S4
AC CVCL_T836
SY K21-S04
DR RCB; HPS0073
DR SKIP; SKIP000140
RX Patent=US20130224156;
RX PubMed=21347327;
DI NCIt; C85045; Retinitis pigmentosa
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Induced pluripotent stem cell
//
ID K24-3b
AC CVCL_DC94
RX Patent=US6190871;
RX PubMed=1694449;
CC Monoclonal antibody target: HIV-1 gp120.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID K248C
AC CVCL_T998
RX PubMed=1649697;
CC Breed/subspecies: Siamese.
OX NCBI_TaxID=9685; ! Felis catus
OI CVCL_T999 ! K248P
SX Female
CA Cancer cell line
//
ID K248P
AC CVCL_T999
RX PubMed=1649697;
CC Breed/subspecies: Siamese.
OX NCBI_TaxID=9685; ! Felis catus
OI CVCL_T998 ! K248C
SX Female
CA Cancer cell line
//
ID K25-iPSC
AC CVCL_DD63
RX PubMed=27191603;
ST Source(s): PubMed=27191603
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 9,12
ST D16S539: 8,13
ST D21S11: 29,30
ST D5S818: 11,12
ST D7S820: 10,11
ST TH01: 7,9
ST TPOX: 8,9
ST vWA: 17,18
DI NCIt; C26845; Parkinson's disease
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_DD50 ! ND29802
SX Male
CA Induced pluripotent stem cell
//
ID K2B-12H
AC CVCL_V088
SY K2B-12H-G7
DR CLO; CLO_0007058
DR CLDB; cl2992
DR IHW; IHW8008
RX PubMed=1655684;
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Transfected with: HGNC; 4931; HLA-A (allele HLA-A24).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID K31M28
AC CVCL_T838
DR RCB; HPS0074
DR SKIP; SKIP000141
RX Patent=US20130224156;
DI NCIt; C85045; Retinitis pigmentosa
OX NCBI_TaxID=9606; ! Homo sapiens
CA Induced pluripotent stem cell
//
ID K32M17
AC CVCL_T839
DR RCB; HPS0075
DR SKIP; SKIP000142
RX Patent=US20130224156;
DI NCIt; C85045; Retinitis pigmentosa
OX NCBI_TaxID=9606; ! Homo sapiens
CA Induced pluripotent stem cell
//
ID K37
AC CVCL_W627
SY K 37
RX PubMed=3243385;
RX PubMed=10841188;
CC Breed/subspecies: BALB/c.
DI NCIt; C24021; Mouse osteosarcoma
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_W624 ! K7 [Mouse osteosarcoma]
OI CVCL_W628 ! K8 [Mouse osteosarcoma]
OI CVCL_W625 ! K12 [Mouse osteosarcoma]
OI CVCL_W626 ! K14
SX Female
CA Cancer cell line
//
ID K38
AC CVCL_W141
DR ECACC; 11090602
DR Ximbio; 151682
RX PubMed=19907996;
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Spontaneously immortalized cell line
//
ID K3T103
AC CVCL_IU36
RX PubMed=3710619;
RX PubMed=6591445;
CC Selected for resistance to: ChEBI; CHEBI:472805; Ouabain.
CC Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC Transformant: ChEBI; CHEBI:23994; Ethyl methanesulfonate (Methylsulfonic acid ethyl ester; MSEE).
CC Breed/subspecies: DBA/2.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_IU35 ! KD2.3
CA Cancer cell line
//
ID K4 [Human melanoma]
AC CVCL_AT86
DR Cosmic; 888865
DR Cosmic; 897479
DR GDSC; 1298161
RX PubMed=15009714;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K4 [Mouse hybridoma]
AC CVCL_CW36
DR ATCC; HB-8550
RX Patent=US4762800;
CC Discontinued: ATCC; HB-8550; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID K457
AC CVCL_IP01
SY K-457
DR BTO; BTO:0005848
RX PubMed=22249266;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K46
AC CVCL_K163
RX PubMed=310843;
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/k/cell-lines-detail-44.html
CC Breed/subspecies: BALB/cAnN.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID K4IM
AC CVCL_9V29
SY K4 IM
DR NCBI_Iran; C616
RX PubMed=9106935;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID K5
AC CVCL_1322
DR ChEMBL-Cells; CHEMBL3308144
DR ChEMBL-Targets; CHEMBL2366152
DR Cosmic; 924238
DR Cosmic; 928832
DR Cosmic; 1162843
DR Cosmic; 1507370
DR Cosmic; 1533547
DR Cosmic; 1536123
DR Cosmic; 1789444
DR Cosmic; 1889002
DR Cosmic-CLP; 924238
DR GDSC; 924238
DR GEO; GSM1669970
RX PubMed=10646882;
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
ST Source(s): Cosmic-CLP
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 11,14
ST D16S539: 11,12
ST D5S818: 10,11
ST D7S820: 11
ST TH01: 6,9
ST TPOX: 8
ST vWA: 17,18
DI NCIt; C8054; Thyroid gland follicular carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID K562 AZQR
AC CVCL_2967
SY K562AZQR; AZQR
DR ECACC; 93112521
DR Ximbio; 153252
RX PubMed=7646550;
CC Selected for resistance to: ChEBI; CHEBI:90185; Diaziquone (AZQ).
ST Source(s): PubMed=11416159
ST Amelogenin: X
ST D18S51: 15,17
ST D21S11: 29,30
ST D8S1179: 12
ST FGA: 21,24
ST TH01: 9.3
ST vWA: 16
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 BZQR
AC CVCL_B502
SY K562BZQR; BZQR
RX PubMed=7646550;
CC Selected for resistance to: ChEBI; CHEBI:90193; NSC-224070 (BZQ; 2,5-bis(2-hydroxyethylamino)-3,6-diaziridinyl-1,4-benzoquinone).
ST Source(s): PubMed=11416159
ST Amelogenin: X
ST D18S51: 16
ST D21S11: 29,30
ST D8S1179: 12
ST FGA: 21,24
ST TH01: 9.3
ST vWA: 16
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 cl.6
AC CVCL_2968
DR CLO; CLO_0007060
DR CLDB; cl2993
DR ECACC; 85011407
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ADNP
AC CVCL_GZ75
DR ENCODE; ENCBS037KCN
DR ENCODE; ENCBS559UBQ
DR ENCODE; ENCBS995QNX
CC Transfected with: HGNC; 15766; ADNP.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ATF1
AC CVCL_AW13
DR ENCODE; ENCBS377AAA
DR ENCODE; ENCBS405AAA
DR ENCODE; ENCBS821FOP
CC Transfected with: HGNC; 783; ATF1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ATF3
AC CVCL_GZ76
DR ENCODE; ENCBS397AAA
DR ENCODE; ENCBS458AAA
DR ENCODE; ENCBS660SLH
CC Transfected with: HGNC; 785; ATF3.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-BACH1
AC CVCL_AW14
DR ENCODE; ENCBS024CCL
DR ENCODE; ENCBS083LQN
DR ENCODE; ENCBS706JJD
DR ENCODE; ENCBS746PBJ
CC Transfected with: HGNC; 935; BACH1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-CEBPB
AC CVCL_AW15
DR ENCODE; ENCBS378AAA
DR ENCODE; ENCBS406AAA
DR ENCODE; ENCBS818FPM
CC Transfected with: HGNC; 1834; CEBPB.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-CEBPG
AC CVCL_GZ77
DR ENCODE; ENCBS008URG
DR ENCODE; ENCBS054WRH
DR ENCODE; ENCBS274CBC
DR ENCODE; ENCBS476TFU
DR ENCODE; ENCBS760ONP
DR ENCODE; ENCBS788JQH
CC Transfected with: HGNC; 1837; CEBPG.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-CREB3
AC CVCL_AW16
DR ENCODE; ENCBS312MPK
DR ENCODE; ENCBS411NIF
DR ENCODE; ENCBS753IIO
CC Transfected with: HGNC; 2347; CREB3.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-CUX1
AC CVCL_GZ78
DR ENCODE; ENCBS544POC
DR ENCODE; ENCBS613PZU
DR ENCODE; ENCBS846OZP
CC Transfected with: HGNC; 2557; CUX1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-DDX20
AC CVCL_AW17
DR ENCODE; ENCBS026JDH
DR ENCODE; ENCBS196WDN
DR ENCODE; ENCBS216ZMH
CC Transfected with: HGNC; 2743; DDX20.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-DIDO1
AC CVCL_AW18
DR ENCODE; ENCBS055YUW
DR ENCODE; ENCBS197ROV
DR ENCODE; ENCBS454ZTQ
CC Transfected with: HGNC; 2680; DIDO1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-E2F1
AC CVCL_AW19
DR ENCODE; ENCBS062QLP
DR ENCODE; ENCBS554TJR
CC Transfected with: HGNC; 3113; E2F1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-E2F4
AC CVCL_GZ79
DR ENCODE; ENCBS107UAM
CC Transfected with: HGNC; 3118; E2F4.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-E2F5
AC CVCL_GZ80
DR ENCODE; ENCBS165WTA
DR ENCODE; ENCBS889YTW
DR ENCODE; ENCBS925NOW
CC Transfected with: HGNC; 3119; E2F5.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ELF1
AC CVCL_GZ81
DR ENCODE; ENCBS556OQY
DR ENCODE; ENCBS861JYZ
DR ENCODE; ENCBS872CIK
CC Transfected with: HGNC; 3316; ELF1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ELK1
AC CVCL_GZ82
DR ENCODE; ENCBS168TVX
DR ENCODE; ENCBS913AGK
DR ENCODE; ENCBS996OLB
CC Transfected with: HGNC; 3321; ELK1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ETS2
AC CVCL_GZ83
DR ENCODE; ENCBS381AAA
DR ENCODE; ENCBS413AAA
DR ENCODE; ENCBS506IZD
CC Transfected with: HGNC; 3489; ETS2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ETV1
AC CVCL_AW20
DR ENCODE; ENCBS302KJF
DR ENCODE; ENCBS398XYI
DR ENCODE; ENCBS750HFY
CC Transfected with: HGNC; 3490; ETV1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-FOS
AC CVCL_AW21
DR ENCODE; ENCBS366WZA
DR ENCODE; ENCBS607WST
DR ENCODE; ENCBS799VSJ
CC Transfected with: HGNC; 3796; FOS.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-FOSL1
AC CVCL_GZ84
DR ENCODE; ENCBS129EER
DR ENCODE; ENCBS392SQX
DR ENCODE; ENCBS894HTX
CC Transfected with: HGNC; 13718; FOSL1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-FOXJ2
AC CVCL_GZ85
DR ENCODE; ENCBS032TNV
DR ENCODE; ENCBS039TGQ
DR ENCODE; ENCBS507YTF
CC Transfected with: HGNC; 24818; FOXJ2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-GABPA
AC CVCL_GZ86
DR ENCODE; ENCBS021UXC
DR ENCODE; ENCBS084QBR
DR ENCODE; ENCBS164UBJ
CC Transfected with: HGNC; 4071; GABPA.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-GATA2
AC CVCL_AW22
DR ENCODE; ENCBS746ASY
DR ENCODE; ENCBS903OXA
CC Transfected with: HGNC; 4171; GATA2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-GTF2A2
AC CVCL_GZ87
DR ENCODE; ENCBS656LOQ
DR ENCODE; ENCBS725FFW
DR ENCODE; ENCBS839DWI
CC Transfected with: HGNC; 4647; GTF2A2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-GTF2E2
AC CVCL_GZ88
DR ENCODE; ENCBS182OZC
DR ENCODE; ENCBS231GMV
DR ENCODE; ENCBS936ECY
CC Transfected with: HGNC; 4651; GTF2E2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-HDAC8
AC CVCL_AW23
DR ENCODE; ENCBS055CUX
DR ENCODE; ENCBS383AAA
DR ENCODE; ENCBS422AAA
DR ENCODE; ENCBS443JHG
DR ENCODE; ENCBS903WFV
CC Transfected with: HGNC; 13315; HDAC8.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-HINFP
AC CVCL_AW24
DR ENCODE; ENCBS422ZTW
DR ENCODE; ENCBS436RZW
DR ENCODE; ENCBS595XIW
CC Transfected with: HGNC; 17850; HINFP.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-HMGB1
AC CVCL_AW25
DR ENCODE; ENCBS332OKQ
DR ENCODE; ENCBS772IOG
CC Transfected with: HGNC; 4983; HMGB1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ID3
AC CVCL_AW26
DR ENCODE; ENCBS384AAA
DR ENCODE; ENCBS425AAA
DR ENCODE; ENCBS579QSJ
CC Transfected with: HGNC; 5362; ID3.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ILK
AC CVCL_AW27
DR ENCODE; ENCBS002PZY
DR ENCODE; ENCBS076AAA
DR ENCODE; ENCBS428AAA
CC Transfected with: HGNC; 6040; ILK.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-IRF1
AC CVCL_AW28
DR ENCODE; ENCBS329CYL
DR ENCODE; ENCBS385AAA
DR ENCODE; ENCBS429AAA
CC Transfected with: HGNC; 6116; IRF1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-IRF9
AC CVCL_AW29
DR ENCODE; ENCBS134NRZ
DR ENCODE; ENCBS264ETB
DR ENCODE; ENCBS951JJK
CC Transfected with: HGNC; 6131; IRF9.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-JUNB
AC CVCL_AW30
DR ENCODE; ENCBS038ENC
DR ENCODE; ENCBS353XCU
DR ENCODE; ENCBS775URE
CC Transfected with: HGNC; 6205; JUNB.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-JUND
AC CVCL_AW31
DR ENCODE; ENCBS349TGF
DR ENCODE; ENCBS770RPE
DR ENCODE; ENCBS919IGK
CC Transfected with: HGNC; 6206; JUND.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-KLF1
AC CVCL_AW32
DR ENCODE; ENCBS386AAA
DR ENCODE; ENCBS431AAA
DR ENCODE; ENCBS481LVE
CC Transfected with: HGNC; 6345; KLF1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-KLF13
AC CVCL_AW33
DR ENCODE; ENCBS078AAA
DR ENCODE; ENCBS432AAA
DR ENCODE; ENCBS703NZF
CC Transfected with: HGNC; 13672; KLF13.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-MAFG
AC CVCL_AW34
DR ENCODE; ENCBS062KUE
DR ENCODE; ENCBS584ZNF
DR ENCODE; ENCBS683EBC
CC Transfected with: HGNC; 6781; MAFG.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-MEF2D
AC CVCL_GZ89
DR ENCODE; ENCBS163FHT
DR ENCODE; ENCBS207FBE
DR ENCODE; ENCBS902TFF
CC Transfected with: HGNC; 6997; MEF2D.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-NFE2
AC CVCL_GZ90
DR ENCODE; ENCBS085AAA
DR ENCODE; ENCBS443AAA
DR ENCODE; ENCBS903THP
CC Transfected with: HGNC; 7780; NFE2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-NFE2L1
AC CVCL_AW35
DR ENCODE; ENCBS108AEM
DR ENCODE; ENCBS151LVY
DR ENCODE; ENCBS378YNT
DR ENCODE; ENCBS500RHB
DR ENCODE; ENCBS670PDV
DR ENCODE; ENCBS918KOX
CC Transfected with: HGNC; 7781; NFE2L1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-NR2C1
AC CVCL_AW36
DR ENCODE; ENCBS706YBL
DR ENCODE; ENCBS707WFI
DR ENCODE; ENCBS936SUX
CC Transfected with: HGNC; 7971; NR2C1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-NR2C2
AC CVCL_GZ91
DR ENCODE; ENCBS168GXP
DR ENCODE; ENCBS250NTO
DR ENCODE; ENCBS923ZGZ
CC Transfected with: HGNC; 7972; NR2C2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-NR4A1
AC CVCL_AW37
DR ENCODE; ENCBS392AAA
DR ENCODE; ENCBS445AAA
DR ENCODE; ENCBS715EUG
DR ENCODE; ENCBS862GKZ
DR ENCODE; ENCBS875VQC
CC Transfected with: HGNC; 7980; NR4A1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-PBX2
AC CVCL_GZ92
DR ENCODE; ENCBS655BEX
DR ENCODE; ENCBS753ZIZ
DR ENCODE; ENCBS860ULO
CC Transfected with: HGNC; 8633; PBX2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-POLR2H
AC CVCL_GZ93
DR ENCODE; ENCBS188WMP
DR ENCODE; ENCBS420IWT
DR ENCODE; ENCBS687TWN
CC Transfected with: HGNC; 9195; POLR2H.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-PTRF
AC CVCL_AW38
DR ENCODE; ENCBS258BIP
DR ENCODE; ENCBS544EAP
DR ENCODE; ENCBS931QBF
CC Transfected with: HGNC; 9688; PTRF.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-PTTG1
AC CVCL_AW39
DR ENCODE; ENCBS405IFW
DR ENCODE; ENCBS430AYP
DR ENCODE; ENCBS473LEX
CC Transfected with: HGNC; 9690; PTTG1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-PYGO2
AC CVCL_AW40
DR ENCODE; ENCBS102NQC
DR ENCODE; ENCBS203NBV
DR ENCODE; ENCBS500RNP
CC Transfected with: HGNC; 30257; PYGO2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-RELA
AC CVCL_AW41
DR ENCODE; ENCBS394AAA
DR ENCODE; ENCBS450AAA
DR ENCODE; ENCBS557OXO
CC Transfected with: HGNC; 9955; RELA.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-SMARCA1
AC CVCL_AW42
DR ENCODE; ENCBS334LCL
DR ENCODE; ENCBS927HXP
CC Transfected with: HGNC; 11097; SMARCA1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-SMARCA2
AC CVCL_AW43
DR ENCODE; ENCBS776EGG
DR ENCODE; ENCBS961JJQ
CC Transfected with: HGNC; 11098; SMARCA2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-TAF7
AC CVCL_AW44
DR ENCODE; ENCBS115OID
DR ENCODE; ENCBS350VSG
DR ENCODE; ENCBS360JZL
CC Transfected with: HGNC; 11541; TAF7.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-TEAD2
AC CVCL_AW45
DR ENCODE; ENCBS528ZIT
DR ENCODE; ENCBS661EXX
DR ENCODE; ENCBS723GLY
CC Transfected with: HGNC; 11715; TEAD2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-TFDP1
AC CVCL_GZ94
DR ENCODE; ENCBS546RMD
DR ENCODE; ENCBS670LTO
DR ENCODE; ENCBS931GIA
CC Transfected with: HGNC; 11749; TFDP1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-TSC22D4
AC CVCL_AW46
DR ENCODE; ENCBS340PVD
DR ENCODE; ENCBS528FGG
DR ENCODE; ENCBS587AHU
CC Transfected with: HGNC; 21696; TSC22D4.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-USF2
AC CVCL_GZ95
DR ENCODE; ENCBS105RVN
DR ENCODE; ENCBS266WUA
DR ENCODE; ENCBS889FGM
CC Transfected with: HGNC; 12594; USF2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZBTB11
AC CVCL_GZ96
DR ENCODE; ENCBS075MLD
DR ENCODE; ENCBS170SCN
DR ENCODE; ENCBS991MRU
CC Transfected with: HGNC; 16740; ZBTB11.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZFX
AC CVCL_GZ97
DR ENCODE; ENCBS205YAO
DR ENCODE; ENCBS458HHF
DR ENCODE; ENCBS675IUA
CC Transfected with: HGNC; 12869; ZFX.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZKSCAN8
AC CVCL_GZ98
DR ENCODE; ENCBS539IPB
DR ENCODE; ENCBS541VKI
DR ENCODE; ENCBS669BXB
CC Transfected with: HGNC; 12983; ZKSCAN8.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF148
AC CVCL_GZ99
DR ENCODE; ENCBS091XYE
CC Transfected with: HGNC; 12933; ZNF148.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF175
AC CVCL_HA00
DR ENCODE; ENCBS098BHX
DR ENCODE; ENCBS200VWP
DR ENCODE; ENCBS241XDL
CC Transfected with: HGNC; 12964; ZNF175.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF197
AC CVCL_HA01
DR ENCODE; ENCBS261OYC
DR ENCODE; ENCBS309IBB
DR ENCODE; ENCBS437BJN
CC Transfected with: HGNC; 12988; ZNF197.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF24
AC CVCL_AW47
DR ENCODE; ENCBS016MLC
DR ENCODE; ENCBS778QBL
DR ENCODE; ENCBS985SCL
CC Transfected with: HGNC; 13032; ZNF24.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF395
AC CVCL_HA02
DR ENCODE; ENCBS343LRB
CC Transfected with: HGNC; 18737; ZNF395.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF512
AC CVCL_HA03
DR ENCODE; ENCBS259DFK
DR ENCODE; ENCBS725WFV
DR ENCODE; ENCBS874FAG
CC Transfected with: HGNC; 29380; ZNF512.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF584
AC CVCL_HA04
DR ENCODE; ENCBS027DJL
DR ENCODE; ENCBS101CXP
DR ENCODE; ENCBS922MVL
CC Transfected with: HGNC; 27318; ZNF584.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF589
AC CVCL_HA05
DR ENCODE; ENCBS070CNU
DR ENCODE; ENCBS609DLP
DR ENCODE; ENCBS912VQO
CC Transfected with: HGNC; 16747; ZNF589.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF639
AC CVCL_HA06
DR ENCODE; ENCBS215BGQ
DR ENCODE; ENCBS851CNL
DR ENCODE; ENCBS967JDE
CC Transfected with: HGNC; 30950; ZNF639.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF644
AC CVCL_HA07
DR ENCODE; ENCBS204XMM
DR ENCODE; ENCBS885SBO
DR ENCODE; ENCBS923DEI
CC Transfected with: HGNC; 29222; ZNF644.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF740
AC CVCL_HA08
DR ENCODE; ENCBS020CGZ
DR ENCODE; ENCBS160YCN
DR ENCODE; ENCBS353NLF
DR ENCODE; ENCBS450DNI
DR ENCODE; ENCBS523ORN
DR ENCODE; ENCBS928AAC
CC Transfected with: HGNC; 27465; ZNF740.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF766
AC CVCL_HA09
DR ENCODE; ENCBS105ZBV
DR ENCODE; ENCBS570ZDR
DR ENCODE; ENCBS605NSN
CC Transfected with: HGNC; 28063; ZNF766.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZNF83
AC CVCL_HA10
DR ENCODE; ENCBS285PHZ
DR ENCODE; ENCBS340DSB
DR ENCODE; ENCBS949ZPT
CC Transfected with: HGNC; 13158; ZNF83.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 eGFP-ZSCAN9
AC CVCL_AW48
DR ENCODE; ENCBS371OXN
DR ENCODE; ENCBS458HON
CC Transfected with: HGNC; 12984; ZSCAN9.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562 HHT
AC CVCL_IM25
SY K562-HHT
RX PubMed=7987716;
CC Selected for resistance to: ChEBI; CHEBI:71019; Omacetaxine mepesuccinate (Homoharringtonine; HHT).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-ARA-C
AC CVCL_Z732
SY K/araC
RX PubMed=10500836;
CC Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-BMS-R
AC CVCL_4V54
SY K562 BMS-R
RX PubMed=18829496;
CC Selected for resistance to: ChEBI; CHEBI:49375; Dasatinib (BMS-354825).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-CdA
AC CVCL_Z733
SY K/2cdA
RX PubMed=10500836;
CC Selected for resistance to: ChEBI; CHEBI:567361; Cladribine (2-chlorodeoxyadenosine; CdA).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-DAS[r]
AC CVCL_4V59
WW http://www.chemoscreen.com/product/k562-dasr-cells
CC Selected for resistance to: ChEBI; CHEBI:49375; Dasatinib (BMS-354825).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-FLUD
AC CVCL_Z734
SY K/flud; K/fluda
RX PubMed=10500836;
CC Selected for resistance to: ChEBI; CHEBI:63599; Fludarabine phosphate.
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-GEM
AC CVCL_Z735
SY K562/Gem; K/gem
RX PubMed=10500836;
RX PubMed=11802204;
CC Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-H
AC CVCL_9121
RX PubMed=7689892;
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-IMA[r]
AC CVCL_4V60
WW http://www.chemoscreen.com/product/k562-imar-cells
CC Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-IMA[r]+DAS[r]
AC CVCL_4V61
WW http://www.chemoscreen.com/product/k562-imardasr-cells
CC Selected for resistance to: ChEBI; CHEBI:49375; Dasatinib (BMS-354825).
CC Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-IMA[r]+PON[r]
AC CVCL_4V62
WW http://www.chemoscreen.com/product/k562-imarponr-cells
CC Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
CC Selected for resistance to: ChEBI; CHEBI:78543; Ponatinib (AP24534; Iclusig).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-IMR
AC CVCL_D201
SY K562-IM-R; K562 IMR; K562/IMR
RX PubMed=18829496;
CC Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-L
AC CVCL_9122
RX PubMed=7689892;
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-Luc
AC CVCL_J257
SY K-562-Luc
DR JCRB; JCRB1402
DR JCRB; NIHS0657
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Discontinued: JCRB; NIHS0657; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 8
ST D16S539: 11,12
ST D5S818: 11,12
ST D7S820: 9,11
ST TH01: 9.3
ST TPOX: 8,9
ST vWA: 16
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-luc2
AC CVCL_5J21
SY K-562-luc2
CC Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression).
CC Discontinued: PerkinElmer; Catalog number 124735.
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-Lucena 1
AC CVCL_D162
SY K562-Lucena; K562-LUCENA; Lucena 1; Lucena
DR BCRJ; 0127
RX PubMed=11246270;
CC Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC Discontinued: BCRJ; 0127; probable.
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-NIL[r]
AC CVCL_4V63
WW http://www.chemoscreen.com/product/k562-nilr-cells
CC Selected for resistance to: ChEBI; CHEBI:52172; Nilotinib (AMN107; Tasigna).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-PON[r]
AC CVCL_4V64
WW http://www.chemoscreen.com/product/k562-ponr-cells
CC Selected for resistance to: ChEBI; CHEBI:78543; Ponatinib (AP24534; Iclusig).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-Red-FLuc
AC CVCL_5J01
WW http://www.perkinelmer.com/Catalog/Product/ID/BW124735
CC Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase.
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562-rn
AC CVCL_DP55
RX PubMed=19047160;
CC Selected for resistance to: ChEBI; CHEBI:52172; Nilotinib (AMN107; Tasigna).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/A02
AC CVCL_0368
DR MCCL; MCC:0000262
RX PubMed=7668104;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/AC
AC CVCL_Y198
DR CGH-DB; 9121-4
RX PubMed=10781689;
RX PubMed=14973057;
CC Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/Adr
AC CVCL_3827
AS CVCL_2808
SY K562/adr; K-562adr; K562adr; K562/ADM
DR BTO; BTO:0002554
DR CLO; CLO_0050121
DR GEO; GSM827221
DR JCRB; JCRB1002
DR RCB; RCB1898
DR TKG; TKG 0211
RX PubMed=3091555;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
ST Source(s): JCRB; RCB; TKG
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 8
ST D16S539: 11,12
ST D5S818: 11,12
ST D7S820: 9,11
ST TH01: 9.3
ST TPOX: 8,9
ST vWA: 16
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/ara-C
AC CVCL_4V20
RX PubMed=21290089;
CC Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/AS-3
AC CVCL_4V84
RX PubMed=17261498;
CC Selected for resistance to: ChEBI; CHEBI:30621; Diarsenic trioxide (ATO; As2O3).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/AS2
AC CVCL_4V85
RX CelloPub=CLPUB00269;
CC Selected for resistance to: ChEBI; CHEBI:30621; Diarsenic trioxide (ATO; As2O3).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/CP
AC CVCL_AZ73
SY K-562/CP
DR BTO; BTO:0005801
RX PubMed=25356864;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/D1-9
AC CVCL_D205
RX PubMed=8687117;
CC Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/DNR
AC CVCL_4T87
RX PubMed=8787550;
CC Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/etop20
AC CVCL_Y168
DR CGH-DB; 9122-4
RX PubMed=14973057;
CC Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/etop80
AC CVCL_Y169
DR CGH-DB; 9123-4
RX PubMed=14973057;
CC Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/G01
AC CVCL_4V47
RX PubMed=15308010;
CC Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/MTX-2
AC CVCL_5144
DR CLO; CLO_0050119
DR BioSample; SAMN03472320
DR RCB; RCB0474
RX PubMed=2465288;
CC Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX).
ST Source(s): RCB
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 8
ST D16S539: 11,12
ST D5S818: 11,12
ST D7S820: 9,11
ST TH01: 6,9.3
ST TPOX: 8,9
ST vWA: 16
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/NIL-50
AC CVCL_4V51
RX PubMed=22712605;
CC Selected for resistance to: ChEBI; CHEBI:52172; Nilotinib (AMN107; Tasigna).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/R7
AC CVCL_D573
SY K-562/R7
DR BTO; BTO:0005195
RX CelloPub=CLPUB00273;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/Vin
AC CVCL_5145
SY K562/VCR; K562 H-1
DR CLO; CLO_0050125
DR RCB; RCB2111
DR TKG; TKG 0212
RX PubMed=6580255;
RX PubMed=6684716;
CC Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
ST Source(s): RCB; TKG
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 8
ST D16S539: 11,12
ST D5S818: 11,12
ST D7S820: 9,11
ST TH01: 9.3
ST TPOX: 8,9
ST vWA: 16
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562/ZD1694.C
AC CVCL_S663
SY K562/ZD1694 x C
RX PubMed=8576277;
CC Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; ZD1694).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562(A)
AC CVCL_9120
SY K-562 clone A; K-562, clone A
DR CLO; CLO_0007061
DR CLDB; cl2985
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562(S)
AC CVCL_9119
SY K-562 clone S; K-562, clone S
DR CLO; CLO_0007062
DR CLDB; cl2986
RX PubMed=6934848;
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K562YO
AC CVCL_0369
DR MCCL; MCC:0000263
RX PubMed=7506674;
RX PubMed=7534132;
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID K6-2
AC CVCL_DB44
WW http://www.creative-diagnostics.com/Anti-J5-EndoToxin-Core-Hybridoma-136717-197.htm
CC Monoclonal antibody target: Escherichia coli J5 endotoxin core.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID K63
AC CVCL_6D69
RX PubMed=21706466;
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Spontaneously immortalized cell line
//
ID K66
AC CVCL_G227
DR CLO; CLO_0007063
DR ATCC; HB-8767
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID K6H6/B5
AC CVCL_2538
SY K6H6B5
DR BTO; BTO:0002208
DR CLO; CLO_0007064
DR CLDB; cl2994
DR ATCC; CRL-1823
DR ECACC; 89101606
RX PubMed=3084658;
CC Group: Hybridoma fusion partner cell line.
OX NCBI_TaxID=9606; ! Homo sapiens
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybrid cell line
//
ID K7 [Human thyroid carcinoma]
AC CVCL_6307
DR Cosmic; 1789445
RX PubMed=9054892;
RX PubMed=10646882;
DI NCIt; C8054; Thyroid gland follicular carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K7 [Mouse osteosarcoma]
AC CVCL_W624
SY K 7
RX PubMed=3243385;
RX PubMed=10841188;
CC Breed/subspecies: BALB/c.
DI NCIt; C24021; Mouse osteosarcoma
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_W628 ! K8 [Mouse osteosarcoma]
OI CVCL_W625 ! K12 [Mouse osteosarcoma]
OI CVCL_W626 ! K14
OI CVCL_W627 ! K37
SX Female
CA Cancer cell line
//
ID K7M2-pCI Neo
AC CVCL_V454
DR ATCC; CRL-2837
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Derived from metastatic site: Lung.
CC Breed/subspecies: BALB/c.
DI NCIt; C24021; Mouse osteosarcoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_V455 ! K7M2-WT
SX Female
CA Cancer cell line
//
ID K7M2-WT
AC CVCL_V455
SY K7M2 wt; K7M2
DR ATCC; CRL-2836
DR CCRID; 3131C0001001200021
RX PubMed=11315100;
CC Derived from metastatic site: Lung.
CC Breed/subspecies: BALB/c.
DI NCIt; C24021; Mouse osteosarcoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_W624 ! K7 [Mouse osteosarcoma]
SX Female
CA Cancer cell line
//
ID K8 [Human melanoma]
AC CVCL_EQ75
DR GDSC; 1298162
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K8 [Human thyroid carcinoma]
AC CVCL_EI75
DR Cosmic; 1789446
RX PubMed=10646882;
DI NCIt; C8054; Thyroid gland follicular carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID K8 [Mouse osteosarcoma]
AC CVCL_W628
SY K 8
RX PubMed=3243385;
RX PubMed=10841188;
DI NCIt; C24021; Mouse osteosarcoma
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_W624 ! K7 [Mouse osteosarcoma]
OI CVCL_W625 ! K12 [Mouse osteosarcoma]
OI CVCL_W626 ! K14
OI CVCL_W627 ! K37
SX Female
CA Cancer cell line
//
ID K9TCC
AC CVCL_DN18
DR GEO; GSM1974792
RX PubMed=7653891;
RX PubMed=18562222;
RX PubMed=26401343;
RX PubMed=27197945;
RX PubMed=27257868;
CC Part of: FACC canine tumor cell line panel.
CC Omics: Array-based CGH.
CC Omics: CNV analysis.
CC Omics: Transcriptome analysis.
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID K9TCC-PU-An
AC CVCL_DN19
RX PubMed=26401343;
CC Breed/subspecies: Scottish Terrier.
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID K9TCC-PU-AxA
AC CVCL_DN20
SY K9TCC-AxA
RX PubMed=18562222;
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
OI CVCL_DN21 ! K9TCC-PU-AxC
SX Female
CA Cancer cell line
//
ID K9TCC-PU-AxC
AC CVCL_DN21
RX PubMed=18562222;
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
OI CVCL_DN20 ! K9TCC-PU-AxA
SX Female
CA Cancer cell line
//
ID K9TCC-PU-In
AC CVCL_DN22
SY K9TCC-In
RX PubMed=18562222;
RX PubMed=26401343;
CC Omics: Array-based CGH.
CC Omics: CNV analysis.
CC Breed/subspecies: German Shepherd.
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID K9TCC-PU-Mx
AC CVCL_DN23
RX PubMed=18562222;
RX PubMed=26401343;
CC Omics: Array-based CGH.
CC Omics: CNV analysis.
CC Breed/subspecies: German Shepherd.
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID K9TCC-PU-Nk
AC CVCL_DN24
SY K9TCC-NK
RX PubMed=18562222;
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID K9TCC-PU-Pu
AC CVCL_DN25
RX PubMed=18562222;
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID K9TCC-PU-Sh
AC CVCL_DN26
SY K9TCC-Sh
RX PubMed=18562222;
RX PubMed=26401343;
CC Omics: Array-based CGH.
CC Omics: CNV analysis.
CC Breed/subspecies: Collie.
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID K9TCC#1Lillie
AC CVCL_1R35
RX PubMed=24964787;
CC Doubling time: 47.4 hours (PubMed=24964787).
CC Breed/subspecies: Pointer.
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID K9TCC#2Dakota
AC CVCL_1R36
RX PubMed=24964787;
CC Doubling time: 31.96 hours (PubMed=24964787).
CC Breed/subspecies: Bichon Fries.
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID K9TCC#4Molly
AC CVCL_1R37
RX PubMed=24964787;
CC Doubling time: 44.69 hours (PubMed=24964787).
CC Breed/subspecies: Maltese.
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID K9TCC#5Lilly
AC CVCL_1R38
RX PubMed=24964787;
CC Doubling time: 48.3 hours (PubMed=24964787).
CC Breed/subspecies: Mixed breed.
DI NCIt; C128126; Canine transitional cell carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID Ka Dan
AC CVCL_U780
DR ATCC; CRL-1137
CC Discontinued: ATCC; CRL-1137; true.
DI NCIt; C2975; Cystic fibrosis
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID Ka-LCL
AC CVCL_6D79
RX PubMed=8127151;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KA-S1
AC CVCL_8363
DR JCRB; JCRB1013
WW http://cellbank.nibiohn.go.jp/legacy/celldata/jcrb1013.htm
CC Problematic cell line: Misidentified. Originally thought to be of human origin but found to be from mouse.
CC Discontinued: JCRB; JCRB1013; true.
OX NCBI_TaxID=10090; ! Mus musculus
SX Sex undetermined
CA Undefined cell line type
//
ID KA31
AC CVCL_0A31
SY KA 31; KA-31
RX PubMed=6245299;
RX PubMed=6409394;
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4350 ! K-BALB
CA Transformed cell line
//
ID KAI3
AC CVCL_2969
DR BioSample; SAMN03472803
DR Cosmic; 1542077
DR Cosmic; 2390216
DR GEO; GSM471999
DR IFO; IFO50518
RX PubMed=10193407;
RX PubMed=19194464;
RX PubMed=21052088;
RX PubMed=25586472;
CC Characteristics: IL2 dependent.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Omics: Transcriptome analysis.
CC Misspelling: 'KA13' in Cosmic 2390216.
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 8,11
ST D16S539: 9,10
ST D5S818: 11
ST D7S820: 10,12
ST TH01: 8,9
ST TPOX: 8,11
ST vWA: 17,18
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KAK-1
AC CVCL_6301
SY KAK1
DR BioSample; SAMN03151788
DR Cosmic; 886555
DR Cosmic; 888090
DR Cosmic; 913245
RX PubMed=9177396;
RX PubMed=17804723;
RX PubMed=18713817;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=18713817, PubMed=20143388). Originally thought to originate from a thyroid gland follicular carcinoma.
CC Omics: Transcriptome analysis.
DI NCIt; C43584; Rectosigmoid adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0320 ! HT-29
SX Female
CA Cancer cell line
//
ID KALS-1
AC CVCL_1323
SY KALS1
DR BioSample; SAMN03470951
DR CCLE; KALS1_CENTRAL_NERVOUS_SYSTEM
DR CGH-DB; 142-1
DR ChEMBL-Cells; CHEMBL3308235
DR ChEMBL-Targets; CHEMBL2366155
DR Cosmic; 687572
DR Cosmic; 907271
DR Cosmic; 2367530
DR Cosmic; 2516020
DR Cosmic-CLP; 907271
DR GDSC; 907271
DR GEO; GSM887194
DR GEO; GSM888267
DR GEO; GSM1669972
DR IFO; IFO50434
RX CelloPub=CLPUB00062;
RX PubMed=16232199;
RX PubMed=22460905;
RX PubMed=25984343;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: 90 hours (PubMed=25984343).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 9
ST D13S317: 10
ST D16S539: 11,13
ST D18S51: 14,19
ST D19S433: 13,15.2
ST D21S11: 29,32
ST D2S1338: 18,22
ST D3S1358: 16,18
ST D5S818: 9
ST D7S820: 10,12
ST D8S1179: 12,13
ST FGA: 21,23
ST Penta D: 9,10
ST Penta E: 12,15
ST TH01: 9
ST TPOX: 8
ST vWA: 14,17
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KaMi
AC CVCL_W532
RX PubMed=1279943;
DI NCIt; C4450; Large cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kamoti
AC CVCL_IU58
RX PubMed=170370;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C27694; Epstein-Barr virus-related Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Kampong
AC CVCL_6F59
RX PubMed=1690682;
CC Group: Non-human primate cell line.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9600; ! Pongo pygmaeus
SX Male
CA Transformed cell line
//
ID Kan-BL
AC CVCL_7198
SY Kan
RX PubMed=9882297;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C27694; Epstein-Barr virus-related Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KAN-ES
AC CVCL_1F87
RX PubMed=10795747;
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KAO
AC CVCL_W455
SY Kao
DR Cosmic; 1093167
RX PubMed=9247632;
RX PubMed=12966428;
RX PubMed=15150091;
DI NCIt; C3745; Clear cell sarcoma of soft tissue
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Karpas-1106P
AC CVCL_1821
SY Karpas-1106p; KARPAS-1106P; Karpas 1106P; KARPAS 1106P; KARPAS1106P; Karpas1106P; Karpas-1106; Karpas 1106; Karpas1106; K1106
DR EFO; EFO_0006606
DR BioSample; SAMN03470811
DR Cosmic; 1013890
DR Cosmic; 1278829
DR Cosmic; 1289975
DR Cosmic; 2276324
DR Cosmic; 2297035
DR Cosmic; 2437271
DR Cosmic; 2479248
DR Cosmic-CLP; 1327773
DR DSMZ; ACC-545
DR ECACC; 06072607
DR GDSC; 1327773
DR GEO; GSM119503
DR GEO; GSM157143
DR GEO; GSM380128
DR GEO; GSM552445
DR GEO; GSM1374584
DR GEO; GSM1374585
DR GEO; GSM1669973
RX PubMed=7849311;
RX PubMed=7949096;
RX PubMed=9724100;
RX PubMed=16960149;
RX PubMed=19278952;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: ~60-100 hours (ECACC).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Array-based CGH.
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: DSMZ; ACC-545; true.
ST Source(s): Cosmic-CLP; DSMZ; ECACC; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 9,11
ST D16S539: 9
ST D18S51: 21
ST D21S11: 29,30
ST D3S1358: 15
ST D5S818: 8,14
ST D7S820: 9,13
ST D8S1179: 8,15
ST FGA: 21,22
ST Penta D: 8,11
ST Penta E: 7
ST TH01: 6
ST TPOX: 9,11
ST vWA: 18,20
DI NCIt; C9280; Mediastinal (thymic) large B-cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Karpas-120
AC CVCL_9Y63
SY Karpas 120
RX DOI=10.1016/0145-2126(77)90063-7;
DI NCIt; C9154; Adult acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Karpas-1272
AC CVCL_9554
SY Karpas 1272
DR Cosmic; 720772
RX PubMed=10936422;
RX PubMed=15621787;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Karpas-1718
AC CVCL_2539
SY KARPAS-1718; Karpas 1718; KARPAS 1718; K1718
DR Cosmic; 1291155
DR Cosmic; 2297034
DR ECACC; 08072401
DR GEO; GSM115991
DR GEO; GSM866164
DR Ximbio; 152423
RX PubMed=16960149;
CC Misspelling: 'Kapas 1718' in Cosmic 1291155.
ST Source(s): ECACC
ST Amelogenin: X,Y
ST CSF1PO: 11,13
ST D13S317: 8,13
ST D16S539: 11,13
ST D5S818: 11,12
ST D7S820: 8
ST TH01: 6
ST TPOX: 8,11
ST vWA: 14
DI NCIt; C4341; Marginal zone lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Karpas-230
AC CVCL_7705
SY Karpas 230; KARPAS 230; Line 230
RX PubMed=272914;
DI NCIt; C9154; Adult acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Karpas-231
AC CVCL_1822
SY KARPAS-231; Karpas 231; KARPAS 231; KARPAS231
DR EFO; EFO_0005389
DR BioSample; SAMN03473540
DR Cosmic; 1281371
DR Cosmic; 2297008
DR Cosmic-CLP; 1327774
DR DSMZ; ACC-562
DR ECACC; 06120601
DR GDSC; 1327774
DR GEO; GSM115820
DR GEO; GSM1374586
DR GEO; GSM1374587
DR GEO; GSM1669974
RX PubMed=7849311;
RX PubMed=8324225;
RX PubMed=16960149;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: ~30-40 hours (DSMZ); ~60 hours (ECACC).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: Transcriptome analysis.
CC Discontinued: DSMZ; ACC-562; true.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X
ST CSF1PO: 11,14
ST D13S317: 8,12
ST D16S539: 11,13
ST D5S818: 12
ST D7S820: 8,9
ST TH01: 8,9.3
ST TPOX: 8,9
ST vWA: 18
DI NCIt; C8851; Diffuse large B-cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Karpas-241
AC CVCL_7706
SY Karpas 241; KARPAS 241
RX DOI=10.1016/0739-6260(87)90032-3;
WW http://www.enterprise.cam.ac.uk/industry/reagents/2011/9/karpas-241/
DI NCIt; C3457; B-cell non-Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Karpas-247
AC CVCL_0T65
SY Karpas 247
RX PubMed=7849311;
DI NCIt; C4753; B-cell prolymphocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Karpas-25
AC CVCL_2540
SY KARPAS-25; Karpas 25; KARPAS 25
DR ECACC; 06072601
DR Ximbio; 152420
RX PubMed=10936422;
RX PubMed=15621787;
CC Doubling time: ~30 hours (ECACC).
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Karpas-299
AC CVCL_1324
SY KARPAS-299; Karpas 299; KARPAS 299; Karpas299; KARPAS299; K299
DR BTO; BTO:0002829
DR CLO; CLO_0007065
DR EFO; EFO_0005390
DR CLDB; cl2995
DR BioSample; SAMN03473348
DR CCLE; KARPAS299_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR ChEMBL-Cells; CHEMBL3308327
DR ChEMBL-Targets; CHEMBL2366156
DR Cosmic; 850199
DR Cosmic; 907273
DR Cosmic; 1086364
DR Cosmic; 1086752
DR Cosmic; 1509203
DR Cosmic; 1995466
DR Cosmic-CLP; 907273
DR DSMZ; ACC-31
DR ECACC; 06072604
DR GDSC; 907273
DR GEO; GSM887195
DR GEO; GSM888268
DR GEO; GSM1217153
DR GEO; GSM1669975
DR Lonza; 18
DR Ximbio; 152418
RX PubMed=3260522;
RX PubMed=9738977;
RX PubMed=11021758;
RX PubMed=11494142;
RX PubMed=15356658;
RX PubMed=22460905;
RX PubMed=25355872;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://www.cogcell.org/cellreqs-ncipptp.php
WW http://www.pptpinvitro.org/cell_lines_panel.php
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC Doubling time: ~30 hours (ECACC).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Omics: Virome analysis using RNAseq.
CC Discontinued: DSMZ; ACC-31; true.
ST Source(s): Cosmic-CLP; COG; DSMZ; ECACC
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 8,12
ST D16S539: 12
ST D18S51: 16,18
ST D19S433: 14,15.2
ST D21S11: 27,29
ST D2S1338: 16,17
ST D3S1358: 16,18
ST D5S818: 11,12
ST D7S820: 10,11
ST D8S1179: 12
ST FGA: 21,22
ST TH01: 7,8.3 (COG; ECACC)
ST TH01: 7,9 (Cosmic-CLP; DSMZ)
ST TPOX: 8
ST vWA: 17,19
DI NCIt; C3720; Anaplastic large cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KARPAS-299-CR06
AC CVCL_V404
SY K299CR06
DR Cosmic; 1849569
RX PubMed=23239810;
CC Selected for resistance to: ChEBI; CHEBI:64310; Crizotinib (Xalkori).
DI NCIt; C3720; Anaplastic large cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1324 ! Karpas-299
SX Male
CA Cancer cell line
//
ID Karpas-353
AC CVCL_9553
SY KARPAS-353; Karpas 353; KARPAS 353
DR Cosmic; 2297005
DR GEO; GSM119483
RX PubMed=7849311;
RX PubMed=8324225;
RX PubMed=16960149;
DI NCIt; C8851; Diffuse large B-cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Karpas-384
AC CVCL_2541
SY Karpas 384; KARPAS 384
DR ECACC; 06120602
RX PubMed=7849311;
RX PubMed=8391614;
CC Doubling time: ~60 hours (ECACC).
DI NCIt; C3467; Cutaneous T-cell non-Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Karpas-417
AC CVCL_2542
SY Karpas 417; KARPAS 417
DR ECACC; 06100302
DR Ximbio; 152421
RX PubMed=15621787;
CC Doubling time: ~60 hours (ECACC).
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Karpas-422
AC CVCL_1325
SY KARPAS-422; Karpas 422; KARPAS 422; Karpas422; KARPAS422; K422
DR BTO; BTO:0004981
DR CLO; CLO_0007066
DR EFO; EFO_0005719
DR CLDB; cl2996
DR CLDB; cl4975
DR BioSample; SAMN03471099
DR CCLE; KARPAS422_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR ChEMBL-Cells; CHEMBL3308328
DR ChEMBL-Targets; CHEMBL2366368
DR Cosmic; 907274
DR Cosmic; 1086338
DR Cosmic; 1329088
DR Cosmic; 1629930
DR Cosmic; 1714156
DR Cosmic; 1945182
DR Cosmic; 1995467
DR Cosmic; 2276323
DR Cosmic; 2297003
DR Cosmic; 2361372
DR Cosmic; 2437320
DR Cosmic-CLP; 907274
DR DSMZ; ACC-32
DR ECACC; 06101702
DR ENCODE; ENCBS530UDH
DR ENCODE; ENCBS171YVY
DR ENCODE; ENCBS301UOD
DR ENCODE; ENCBS850UIV
DR ENCODE; ENCBS869AAA
DR ENCODE; ENCBS870AAA
DR ENCODE; ENCBS992KXS
DR GDSC; 907274
DR GEO; GSM115821
DR GEO; GSM201346
DR GEO; GSM380129
DR GEO; GSM552444
DR GEO; GSM907518
DR GEO; GSM1059807
DR GEO; GSM1374588
DR GEO; GSM1669976
DR ICLC; HTL99023
DR Ximbio; 152419
RX PubMed=1465024;
RX PubMed=2297573;
RX PubMed=7849311;
RX PubMed=8547074;
RX PubMed=9738977;
RX PubMed=16960149;
RX PubMed=19278952;
RX PubMed=19358282;
RX PubMed=23292937;
RX PubMed=23699601;
RX PubMed=25355872;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: ~60-90 hours (ECACC).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Array-based CGH.
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Genome sequenced.
CC Omics: H3K9ac ChIP-seq epigenome analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Omics: Virome analysis using RNAseq.
CC Misspelling: 'Karpass422' in PubMed=23292937.
CC Discontinued: DSMZ; ACC-32; true.
ST Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 12
ST D16S539: 13
ST D18S51: 12,14
ST D21S11: 29,32.2
ST D3S1358: 15,18
ST D5S818: 11,12
ST D7S820: 12,13
ST D8S1179: 11,15
ST FGA: 23,27
ST Penta D: 9,12
ST Penta E: 7,17
ST TH01: 6,9
ST TPOX: 8
ST vWA: 19
DI NCIt; C8851; Diffuse large B-cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Karpas-45
AC CVCL_1326
SY KARPAS-45; Karpas 45; KARPAS 45; KARPAS45; T-45; T45
DR CLO; CLO_0007067
DR CLDB; cl35
DR BioSample; SAMN03473409
DR ChEMBL-Cells; CHEMBL3308305
DR ChEMBL-Targets; CHEMBL2366305
DR Cosmic; 907272
DR Cosmic; 913413
DR Cosmic; 1012075
DR Cosmic; 1151781
DR Cosmic; 1175130
DR Cosmic; 1191704
DR Cosmic; 1281370
DR Cosmic; 1330505
DR Cosmic; 1524799
DR Cosmic; 1664523
DR Cosmic; 1760525
DR Cosmic; 2165714
DR Cosmic; 2391812
DR Cosmic-CLP; 907272
DR DSMZ; ACC-105
DR ECACC; 06072602
DR GDSC; 907272
DR GEO; GSM1669977
DR NCBI_Iran; C180
RX DOI=10.1016/0145-2126(77)90063-7;
RX PubMed=3264071;
RX PubMed=9933131;
RX PubMed=15843827;
RX PubMed=16408098;
RX PubMed=22675565;
RX PubMed=27397505;
CC Doubling time: 50-100 hours (ECACC).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Discontinued: DSMZ; ACC-105; true.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X,Y
ST CSF1PO: 11,14
ST D13S317: 9,14
ST D16S539: 9,13
ST D5S818: 11,12
ST D7S820: 8,11
ST TH01: 9
ST TPOX: 8
ST vWA: 14,18
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Karpas-620
AC CVCL_1823
SY KARPAS-620; Karpas 620; KARPAS 620; Karpas620; K620
DR EFO; EFO_0006449
DR BioSample; SAMN03473162
DR CCLE; KARPAS620_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR Cosmic; 720777
DR Cosmic; 2081387
DR Cosmic; 2131564
DR Cosmic; 2367275
DR Cosmic-CLP; 1327775
DR DSMZ; ACC-514
DR GDSC; 1327775
DR GEO; GSM887196
DR GEO; GSM888269
DR GEO; GSM1374589
DR GEO; GSM1669978
DR Ximbio; 152425
RX PubMed=2310698;
RX PubMed=10936422;
RX PubMed=16956823;
RX PubMed=19064000;
RX PubMed=21173094;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: DSMZ; ACC-514; true.
ST Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 12,14
ST D16S539: 11,12
ST D18S51: 13,18
ST D21S11: 29,31.2
ST D3S1358: 14,16
ST D5S818: 9,11
ST D7S820: 9
ST D8S1179: 10,15
ST FGA: 26
ST Penta D: 10,13
ST Penta E: 14,15
ST TH01: 6,7
ST TPOX: 11,12
ST vWA: 17,19
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Karpas-707
AC CVCL_0010
SY KARPAS-707; Karpas 707; KARPAS 707; Karpas707
DR NCBI_Iran; C505
RX PubMed=3332852;
RX PubMed=7079750;
RX PubMed=10936422;
RX PubMed=17254797;
RX PubMed=23074853;
WW http://www.proteinatlas.org/learn/cellines
CC Omics: Deep antibody staining analysis.
CC Omics: Deep RNAseq analysis.
CC Misspelling: 'CARPAS 707' in PubMed=17254797.
ST Source(s): PubMed=17254797
ST Amelogenin: X
ST CSF1PO: 10,13
ST D13S317: 12,13
ST D16S539: 11
ST D18S51: 12
ST D21S11: 16,18
ST D3S1358: 30,31
ST D5S818: 15
ST D7S820: 11
ST D8S1179: 8
ST FGA: 18,26
ST TH01: 6,10
ST TPOX: 8
ST vWA: 17,18
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Karpas-707H
AC CVCL_9552
SY Karpas 707H; KARPAS 707H
DR Ximbio; 152424
RX PubMed=11172031;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0010 ! Karpas-707
SX Male
CA Cancer cell line
//
ID Karpas-929
AC CVCL_2543
SY KARPAS-929; Karpas 929; KARPAS 929
DR ECACC; 06072606
DR Ximbio; 152422
RX PubMed=15621787;
CC Doubling time: ~30 hours (ECACC).
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KAS-6/1
AC CVCL_9544
SY KAS 6/1; KAS6/1
RX CelloPub=CLPUB00252;
RX PubMed=8656685;
RX PubMed=10936422;
CC Characteristics: IL6 dependent.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_M524 ! KAS-6/2
SX Female
CA Cancer cell line
//
ID KAS-6/2
AC CVCL_M524
RX CelloPub=CLPUB00252;
RX PubMed=8656685;
RX PubMed=10936422;
CC Characteristics: IL6 dependent.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_9544 ! KAS-6/1
SX Female
CA Cancer cell line
//
ID KAS01 #2
AC CVCL_T900
SY KAS01-#2
RX PubMed=23364790;
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Induced pluripotent stem cell
//
ID KAS01 #3
AC CVCL_T901
SY KAS01-#3
DR SKIP; SKIP000224
RX PubMed=23364790;
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Induced pluripotent stem cell
//
ID KAS011
AC CVCL_E720
SY KASOII
DR dbMHC; 48918
DR ECACC; 94070704
DR IHW; IHW9009
DR IMGT/HLA; 10901
WW http://bioinformatics.hsanmartino.it/ecbr/cl9.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KAS116
AC CVCL_E721
DR dbMHC; 48919
DR ECACC; 88052003
DR IHW; IHW9003
DR IMGT/HLA; 10902
WW http://bioinformatics.hsanmartino.it/ecbr/cl3.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID Kasey
AC CVCL_6F64
RX PubMed=1690682;
CC Group: Non-human primate cell line.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9598; ! Pan troglodytes
SX Male
CA Transformed cell line
//
ID Kasumi-1
AC CVCL_0589
SY KASUMI-1; Kasumi 1; KASUMI1; Kasumi1
DR BTO; BTO:0004136
DR CLO; CLO_0007068
DR CLO; CLO_0007069
DR EFO; EFO_0006607
DR MCCL; MCC:0000264
DR CLDB; cl2998
DR ATCC; CRL-2724
DR BCRC; 60505
DR BCRJ; 0305
DR BioSample; SAMN01821572
DR BioSample; SAMN01821642
DR BioSample; SAMN01821688
DR BioSample; SAMN03473161
DR CCLE; KASUMI1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR ChEMBL-Cells; CHEMBL3307835
DR ChEMBL-Cells; CHEMBL3308850
DR ChEMBL-Targets; CHEMBL613988
DR ChEMBL-Targets; CHEMBL2366321
DR CLS; 300226/p633_Kasumi-1
DR Cosmic; 787441
DR Cosmic; 907275
DR Cosmic; 975258
DR Cosmic; 981579
DR Cosmic; 987968
DR Cosmic; 1012076
DR Cosmic; 1078725
DR Cosmic; 1149336
DR Cosmic; 1181600
DR Cosmic; 1451847
DR Cosmic; 1476423
DR Cosmic; 1509202
DR Cosmic; 1516633
DR Cosmic; 1524831
DR Cosmic; 1623636
DR Cosmic; 1779131
DR Cosmic; 2089650
DR Cosmic; 2131540
DR Cosmic; 2306211
DR Cosmic-CLP; 907275
DR DSMZ; ACC-220
DR GDSC; 907275
DR GEO; GSM236785
DR GEO; GSM236821
DR GEO; GSM482490
DR GEO; GSM506744
DR GEO; GSM506867
DR GEO; GSM506973
DR GEO; GSM887197
DR GEO; GSM888270
DR GEO; GSM1374590
DR GEO; GSM1669979
DR IZSLER; BS TCL 242
DR JCRB; JCRB1003
DR JCRB; NIHS0235
DR PRIDE; PXD000185
RX PubMed=2018839;
RX PubMed=9738977;
RX PubMed=15621809;
RX PubMed=15843827;
RX PubMed=16408098;
RX PubMed=16523483;
RX PubMed=18385756;
RX PubMed=22460905;
RX PubMed=23955599;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://www.cogcell.org/cellreqs-ncipptp.php
WW http://www.pptpinvitro.org/cell_lines_panel.php
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC Doubling time: 40 hours (PubMed=25984343); ~48-72 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Array-based CGH.
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Misspelling: 'Kusami-1' in Cosmic 1516633 and Cosmic 1623636.
CC Misspelling: 'KUSAMI-1' in Cosmic 2306211.
CC Discontinued: JCRB; NIHS0235; true.
ST Source(s): ATCC; CLS; Cosmic-CLP; COG; DSMZ; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 11,13
ST D16S539: 9,12
ST D18S51: 15,16
ST D19S433: 13,15.2
ST D21S11: 30,31
ST D2S1338: 19
ST D3S1358: 15,17
ST D5S818: 9,11
ST D7S820: 8,11
ST D8S1179: 13,14
ST FGA: 22,24
ST Penta D: 12
ST Penta E: 11
ST TH01: 6,9
ST TPOX: 8,9
ST vWA: 14 (ATCC; CLS; Cosmic-CLP; DSMZ; JCRB; PubMed=25877200)
ST vWA: 14,18 (COG)
DI NCIt; C9381; Childhood acute myeloid leukemia with maturation
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kasumi-10
AC CVCL_8485
DR JCRB; JCRB1410
CC Problematic cell line: Possibly misidentified. Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile).
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 8,11
ST D16S539: 9,10
ST D5S818: 10,12
ST D7S820: 8,10
ST TH01: 6,9
ST TPOX: 11,12
ST vWA: 17,19
DI NCIt; C80342; B acute lymphoblastic leukemia with t(v;11q23) MLL rearranged
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Kasumi-2
AC CVCL_0590
SY KASUMI-2; KASUMI2; Kasumi2
DR EFO; EFO_0002224
DR BioSample; SAMN03473522
DR CCLE; KASUMI2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR Cosmic; 1130249
DR Cosmic; 1524843
DR DSMZ; ACC-526
DR GEO; GSM236786
DR GEO; GSM236822
DR GEO; GSM887198
DR GEO; GSM888271
DR IGRhCellID; Kasumi2
DR JCRB; JCRB1395
RX PubMed=22460905;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: ~30 hours (DSMZ).
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): DSMZ; JCRB
ST Amelogenin: X (DSMZ)
ST Amelogenin: X,Y (JCRB)
ST CSF1PO: 10,11
ST D13S317: 8,12,13
ST D16S539: 9,13
ST D5S818: 11,12
ST D7S820: 11,12
ST TH01: 8,10
ST TPOX: 8,11
ST vWA: 17,18
DI NCIt; C80347; B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1)
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kasumi-3
AC CVCL_0612
SY KASUMI-3; Kasumi 3; Kasumi3; KASUMI3
DR CLO; CLO_0007070
DR ATCC; CRL-2725
DR BioSample; SAMN01821573
DR BioSample; SAMN01821689
DR BioSample; SAMN03471777
DR BioSample; SAMN03472527
DR BioSample; SAMN03473397
DR Cosmic; 787442
DR Cosmic; 975259
DR Cosmic; 996310
DR Cosmic; 1037659
DR Cosmic; 2089647
DR DSMZ; ACC-714
DR GDSC; 1327776
DR GEO; GSM1374591
DR JCRB; JCRB1004
DR JCRB; NIHS0236
RX PubMed=8613429;
RX PubMed=23955599;
RX PubMed=28196595;
WW http://www.infarktforschung.de/macrophages_cell_lines.html
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: ~3-4 days (DSMZ).
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0236; true.
ST Source(s): ATCC; DSMZ; JCRB
ST Amelogenin: X,Y
ST CSF1PO: 11
ST D13S317: 11,12
ST D16S539: 9,11 (ATCC; JCRB)
ST D16S539: 11 (DSMZ)
ST D5S818: 12
ST D7S820: 10,11
ST TH01: 6,9,11 (ATCC)
ST TH01: 6,9 (DSMZ; JCRB)
ST TPOX: 8
ST vWA: 16,18
DI NCIt; C8303; Adult acute myeloid leukemia with minimal differentiation
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kasumi-4
AC CVCL_0613
SY KASUMI-4; Kasumi 4
DR CLO; CLO_0007071
DR ATCC; CRL-2726
DR BioSample; SAMN03471778
DR DSMZ; ACC-715
DR JCRB; JCRB0161
DR JCRB; NIHS0237
RX PubMed=8611478;
CC Discontinued: DSMZ; ACC-715; true.
CC Discontinued: JCRB; NIHS0237; true.
ST Source(s): ATCC; DSMZ; JCRB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 10,12
ST D16S539: 9,13
ST D5S818: 11,12
ST D7S820: 8,10
ST TH01: 8,9
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Kasumi-5
AC CVCL_6864
DR Cosmic; 981580
DR JCRB; JCRB1398
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 10
ST D16S539: 10,11
ST D5S818: 10,13
ST D7S820: 8,11
ST TH01: 6,9
ST TPOX: 8
ST vWA: 14
DI NCIt; C9142; Adult T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kasumi-6
AC CVCL_0614
SY KASUMI-6; KASUMI6
DR CLO; CLO_0007072
DR ATCC; CRL-2775
DR BioSample; SAMN03471785
DR CCLE; KASUMI6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR DSMZ; ACC-686
DR GEO; GSM887199
DR GEO; GSM888272
DR GEO; GSM1374592
DR JCRB; JCRB1024
DR JCRB; NIHS0314
RX PubMed=12508245;
RX PubMed=22460905;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~70 hours (DSMZ).
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0314; true.
ST Source(s): ATCC; DSMZ; JCRB
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 8,12
ST D16S539: 9,10
ST D5S818: 11
ST D7S820: 9,11
ST TH01: 6,9
ST TPOX: 8,9
ST vWA: 17
DI NCIt; C9154; Adult acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kasumi-7
AC CVCL_8486
SY Kasumi 7
DR JCRB; JCRB1401
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 8,10
ST D16S539: 9
ST D5S818: 12,13
ST D7S820: 9,10
ST TH01: 6
ST TPOX: 8,11
ST vWA: 14,18
DI NCIt; C9143; Adult B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Kasumi-8
AC CVCL_8487
DR JCRB; JCRB1403
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 8,9
ST D16S539: 10,11
ST D5S818: 10,12
ST D7S820: 10,11
ST TH01: 9
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C9143; Adult B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kasumi-9
AC CVCL_8488
DR JCRB; JCRB1409
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 11
ST D13S317: 8,9
ST D16S539: 11,13
ST D5S818: 12
ST D7S820: 8,10
ST TH01: 7,9
ST TPOX: 8
ST vWA: 17
DI NCIt; C9143; Adult B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KasumiA-541
AC CVCL_8523
DR JCRB; JCRB1411
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 9,11
ST D16S539: 10,12
ST D5S818: 10,11
ST D7S820: 10,12
ST TH01: 7
ST TPOX: 8,11
ST vWA: 14
DI NCIt; C82179; Mixed phenotype acute leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KasumiA-554
AC CVCL_8524
DR JCRB; JCRB1416
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 12
ST D16S539: 9,12
ST D5S818: 11,12
ST D7S820: 11
ST TH01: 6,9
ST TPOX: 11,12
ST vWA: 16,18
DI NCIt; C25765; Secondary acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KasumiA-568
AC CVCL_8525
DR JCRB; JCRB1415
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 12,13
ST D13S317: 8,12
ST D16S539: 9,11
ST D5S818: 10,11
ST D7S820: 12
ST TH01: 7
ST TPOX: 8
ST vWA: 17
DI NCIt; C8923; Acute erythroid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KAT-10
AC CVCL_6302
SY KAT10
DR BioSample; SAMN03151789
DR Cosmic; 886546
DR Cosmic; 888093
DR Cosmic; 913248
RX PubMed=17804723;
RX PubMed=18713817;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=18713817, PubMed=20143388). Originally thought to originate from a thyroid gland papillary carcinoma.
CC Omics: Transcriptome analysis.
ST Source(s): PubMed=18713817
ST Amelogenin: X
ST D13S317: 11
ST D18S51: 12,13
ST D21S11: 30
ST D3S1358: 15,17
ST D5S818: 11,12
ST D7S820: 10
ST D8S1179: 10,16
ST FGA: 20,22
ST vWA: 17,19
DI NCIt; C43584; Rectosigmoid adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0320 ! HT-29
SX Female
CA Cancer cell line
//
ID KAT-18
AC CVCL_6303
SY KAT18; Kat18
DR BTO; BTO:0005161
DR Cosmic; 886552
DR Cosmic; 1152121
DR Cosmic; 1239983
DR Cosmic; 1280049
DR Cosmic; 1507378
DR Cosmic; 1533555
DR Cosmic; 1536131
DR Cosmic; 1889010
DR Cosmic; 2054101
DR Cosmic; 2319854
RX PubMed=18713817;
RX PubMed=21868764;
RX PubMed=23833040;
ST Source(s): PubMed=18713817; PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 11
ST D16S539: 11,12
ST D18S51: 14
ST D21S11: 30,31
ST D3S1358: 15
ST D5S818: 10,12
ST D7S820: 10
ST D8S1179: 14,16
ST FGA: 20,21
ST TH01: 7,9.3
ST TPOX: 8,11
ST vWA: 16
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KAT-4
AC CVCL_6304
SY KAT4
DR BioSample; SAMN03151790
DR ChEMBL-Cells; CHEMBL3307845
DR ChEMBL-Targets; CHEMBL614008
DR Cosmic; 886548
DR Cosmic; 891253
DR Cosmic; 1068626
DR Cosmic; 1162839
DR Cosmic; 2050372
RX PubMed=12481943;
RX PubMed=17465858;
RX PubMed=17804723;
RX PubMed=18713817;
RX PubMed=20143388;
RX PubMed=21868764;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=18713817, PubMed=20143388, PubMed=21868764). Originally thought to originate from a thyroid gland anaplastic carcinoma.
CC Omics: Transcriptome analysis.
ST Source(s): PubMed=18713817; PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 11 (PubMed=18713817)
ST D13S317: 11,13 (PubMed=21868764)
ST D16S539: 9,11,12
ST D18S51: 13
ST D21S11: 30
ST D3S1358: 15,17
ST D5S818: 11,12
ST D7S820: 10 (PubMed=18713817)
ST D7S820: 8,10,12 (PubMed=21868764)
ST D8S1179: 10,16
ST FGA: 20,22
ST TH01: 6,7
ST TPOX: 8,9,11
ST vWA: 17,19 (PubMed=18713817)
ST vWA: 16,17,18,19 (PubMed=21868764)
DI NCIt; C43584; Rectosigmoid adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0320 ! HT-29
SX Female
CA Cancer cell line
//
ID KAT-5
AC CVCL_0370
SY KAT5
DR MCCL; MCC:0000265
DR BioSample; SAMN03151791
DR Cosmic; 888091
DR Cosmic; 913246
RX PubMed=18713817;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=18713817, PubMed=20143388). Originally thought to originate from a thyroid gland papillary carcinoma.
ST Source(s): PubMed=18713817
ST Amelogenin: X
ST D13S317: 11
ST D18S51: 13
ST D21S11: 30
ST D3S1358: 15,17
ST D5S818: 11,12
ST D7S820: 10
ST D8S1179: 10,16
ST FGA: 20,22
ST vWA: 17,19
DI NCIt; C43584; Rectosigmoid adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0320 ! HT-29
SX Female
CA Cancer cell line
//
ID KAT-50
AC CVCL_6305
SY KAT50
DR BioSample; SAMN03151792
RX PubMed=18713817;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=18713817, PubMed=20143388).
DI NCIt; C43584; Rectosigmoid adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0320 ! HT-29
SX Female
CA Cancer cell line
//
ID KAT-7
AC CVCL_6306
SY KAT7
DR BioSample; SAMN03151793
DR Cosmic; 888092
DR Cosmic; 913247
RX PubMed=18713817;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=18713817, PubMed=20143388).
DI NCIt; C43584; Rectosigmoid adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0320 ! HT-29
SX Female
CA Cancer cell line
//
ID KAT45
AC CVCL_S308
RX PubMed=9449645;
RX PubMed=9629269;
RX PubMed=15541571;
DI NCIt; C3326; Adrenal gland pheochromocytoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Katata
AC CVCL_M551
RX PubMed=9242553;
RX PubMed=9753061;
CC Characteristics: Contains a chromosomally integrated HHV-6B (CI-HHV-6B).
CC Doubling time: 24 hours (PubMed=9242553).
CC Transformant: NCBI_TaxID; 1592561; Human herpes virus 6B (HHV-6B).
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KATO II
AC CVCL_M882
SY KATO-II
RX PubMed=209229;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C2993; Down syndrome
DI NCIt; C5250; Signet ring cell gastric adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KATO III
AC CVCL_0371
SY Kato III; Kato-III; KATO-III; KATOIII; KatoIII; KATO 3; JTC-28; Japanese Tissue Culture-28
DR BTO; BTO:0001092
DR CLO; CLO_0007073
DR CLO; CLO_0050790
DR EFO; EFO_0002217
DR MCCL; MCC:0000266
DR CLDB; cl5214
DR CLDB; cl3000
DR ATCC; HTB-103
DR BCRC; 60200
DR BCRJ; 0318
DR BioSample; SAMN01821574
DR BioSample; SAMN01821690
DR BioSample; SAMN03471089
DR BioSample; SAMN03473264
DR CCLE; KATOIII_STOMACH
DR CCRID; 3131C0001001200014
DR CGH-DB; 122-1
DR CGH-DB; 9024-4
DR ChEMBL-Cells; CHEMBL3308432
DR ChEMBL-Targets; CHEMBL612700
DR CLS; 300381/p610_KATO-III
DR Cosmic; 685595
DR Cosmic; 687555
DR Cosmic; 755614
DR Cosmic; 801336
DR Cosmic; 848150
DR Cosmic; 848375
DR Cosmic; 877044
DR Cosmic; 887248
DR Cosmic; 888823
DR Cosmic; 889107
DR Cosmic; 907276
DR Cosmic; 922690
DR Cosmic; 926118
DR Cosmic; 968350
DR Cosmic; 1001657
DR Cosmic; 1067210
DR Cosmic; 1090464
DR Cosmic; 1187279
DR Cosmic; 1223583
DR Cosmic; 1518254
DR Cosmic; 1571766
DR Cosmic; 1627262
DR Cosmic; 1890472
DR Cosmic; 2009529
DR Cosmic; 2036664
DR Cosmic; 2069771
DR Cosmic; 2484964
DR Cosmic-CLP; 907276
DR ECACC; 86093004
DR GDSC; 907276
DR GEO; GSM267419
DR GEO; GSM267426
DR GEO; GSM267433
DR GEO; GSM267440
DR GEO; GSM562404
DR GEO; GSM827547
DR GEO; GSM828835
DR GEO; GSM844573
DR GEO; GSM887200
DR GEO; GSM888273
DR GEO; GSM1237676
DR GEO; GSM1237701
DR GEO; GSM1374593
DR GEO; GSM1374594
DR GEO; GSM1669980
DR IGRhCellID; KATOIII
DR IZSLER; BS TCL 151
DR JCRB; JCRB0611
DR KCB; KCB 2014045YJ
DR KCLB; 30103
DR LINCS; 50022
DR NCBI_Iran; C640
DR RCB; RCB2088
DR TKG; TKG 0213
RX PubMed=209229;
RX PubMed=1778766;
RX PubMed=3962675;
RX PubMed=9290701;
RX PubMed=11107048;
RX PubMed=15723654;
RX PubMed=22460905;
RX PubMed=24807215;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://www.addexbio.com/productdetail?pid=53
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 32-34 hours (PubMed=3962675).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC; CLS; ECACC; JCRB; KCLB; PubMed=25877200; RCB; TKG
ST Amelogenin: X
ST CSF1PO: 7,11
ST D13S317: 8,12
ST D16S539: 10,12
ST D18S51: 12
ST D21S11: 30,31
ST D3S1358: 15,16
ST D5S818: 10,11
ST D7S820: 8,12 (ATCC; CLS; Cosmic-CLP; ECACC; JCRB; KCLB; RCB; TKG)
ST D7S820: 12 (PubMed=25877200)
ST D8S1179: 13,14
ST FGA: 23,24 (CLS; KCLB)
ST FGA: 23,25 (PubMed=25877200)
ST Penta D: 13,14
ST Penta E: 13,18,19
ST TH01: 7,9
ST TPOX: 11
ST vWA: 14,16
DI NCIt; C2993; Down syndrome
DI NCIt; C5250; Signet ring cell gastric adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M882 ! KATO II
SX Male
CA Cancer cell line
//
ID KATOIII/CMV-Luc
AC CVCL_M251
DR JCRB; JCRB1487
DR JCRB; NIHS0713
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 7,11
ST D13S317: 8,12
ST D16S539: 10,12
ST D5S818: 10,11
ST D7S820: 8,12
ST TH01: 7,9
ST TPOX: 11
ST vWA: 14,16
DI NCIt; C2993; Down syndrome
DI NCIt; C5250; Signet ring cell gastric adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0371 ! KATO III
SX Male
CA Cancer cell line
//
ID KAWASAKI
AC CVCL_E722
DR dbMHC; 48920
DR ECACC; 94082243
DR IHW; IHW9143
DR IMGT/HLA; 11686
RX PubMed=8307784;
WW http://bioinformatics.hsanmartino.it/ecbr/cl143.html
CC Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID KB
AC CVCL_0372
SY Strain KB
DR BTO; BTO:0000665
DR CLO; CLO_0007074
DR MCCL; MCC:0000267
DR CLDB; cl3001
DR CLDB; cl3002
DR CLDB; cl3003
DR CLDB; cl3004
DR CLDB; cl3005
DR CLDB; cl3006
DR ATCC; CCL-17
DR BCRJ; 0128
DR BioSample; SAMN03151730
DR CCRID; 3111C0001CCC000163
DR CCRID; 3131C0001000700073
DR CCRID; 3153C0001000000018
DR ChEMBL-Cells; CHEMBL3307959
DR ChEMBL-Targets; CHEMBL398
DR CLS; 300446/p501_KB_(HeLa)
DR Cosmic; 753567
DR Cosmic; 1042301
DR Cosmic; 1339927
DR Cosmic; 1969496
DR Cosmic; 2301581
DR Cosmic; 2546843
DR DSMZ; ACC-136
DR ECACC; 86103004
DR ECACC; 94050408
DR GEO; GSM1374595
DR GEO; GSM1374596
DR ICLC; HTL96014
DR IZSLER; BS TCL 34
DR JCRB; JCRB9027
DR KCB; KCB 94020YJ
DR KCLB; 10017
DR MeSH; D007624
DR NCBI_Iran; C152
DR TKG; TKG 0401
DR TOKU-E; 2094
DR Wikidata; Q28334825
RX DOI=10.1007/978-1-4757-1647-4_13;
RX PubMed=1246601;
RX PubMed=4203458;
RX PubMed=13254761;
RX PubMed=13322936;
RX PubMed=17254797;
RX PubMed=17325662;
RX PubMed=20143388;
RX PubMed=23925245;
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/k/cell-lines-detail-494.html
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=1246601, PubMed=20143388). Was originally thought to originate from an epidermal carcinoma of the mouth.
CC Part of: KuDOS 95 cell line panel.
CC Doubling time: ~30 hours (DSMZ).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC Omics: Genome sequenced (low read coverage).
CC Omics: Transcriptome analysis.
CC Discontinued: ECACC; 86103004; probable.
CC Discontinued: ICLC; HTL96014; true.
ST Source(s): ATCC; CLS; DSMZ; JCRB; KCLB; PubMed=11416159; PubMed=17254797; TKG
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 12,13.3 (ATCC; CLS; DSMZ; JCRB; KCLB; TKG)
ST D13S317: 12,14 (PubMed=17254797)
ST D16S539: 9,10
ST D18S51: 16
ST D21S11: 27,28
ST D3S1358: 15,18
ST D5S818: 11,12
ST D7S820: 8,12
ST D8S1179: 12,13
ST FGA: 21
ST Penta D: 8,15
ST Penta E: 7,17
ST TH01: 7
ST TPOX: 8,12
ST vWA: 16,18
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID KB 16
AC CVCL_D680
DR BCRJ; 0129
CC Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
ST Source(s): BCRJ
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 12,13.3
ST D16S539: 9,10
ST D5S818: 11,12
ST D7S820: 8,12
ST TH01: 7
ST TPOX: 8,12
ST vWA: 16,18
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0372 ! KB
SX Female
CA Cancer cell line
//
ID KB 18
AC CVCL_D681
DR BCRJ; 0130
CC Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
ST Source(s): BCRJ
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 12,13.3
ST D16S539: 9,10
ST D5S818: 11,12
ST D7S820: 8,12
ST TH01: 7
ST TPOX: 8,12
ST vWA: 16,18
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0372 ! KB
SX Female
CA Cancer cell line
//
ID KB-3-1
AC CVCL_2088
SY KB 3-1; KB3-1; KB31
DR BTO; BTO:0003918
DR CLO; CLO_0007076
DR CLDB; cl3008
DR BioSample; SAMN03151731
DR ChEMBL-Cells; CHEMBL3307659
DR ChEMBL-Targets; CHEMBL614590
DR DSMZ; ACC-158
DR TOKU-E; 4096
RX PubMed=3856953;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
WW http://www.ott.nih.gov/erma/multidrug-resistant-epidermal-carcinoma-cell-line-kb-3-1
CC Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC Doubling time: ~40 hours (DSMZ).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
ST Source(s): DSMZ
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 12,14
ST D16S539: 9,10
ST D5S818: 11,12
ST D7S820: 8,12
ST TH01: 7
ST TPOX: 8,12
ST vWA: 16,18
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0372 ! KB
SX Female
CA Cancer cell line
//
ID KB-A1
AC CVCL_1D82
SY KB-A-1; KBA 1; KBA1
RX PubMed=3711108;
RX PubMed=15202936;
CC Problematic cell line: Contaminated. Grand-parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2088 ! KB-3-1
SX Female
CA Cancer cell line
//
ID KB-C1.5
AC CVCL_1D80
SY KBC1.5
RX PubMed=3711108;
CC Problematic cell line: Contaminated. Ancestral cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:23359; Colchicine.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M125 ! KB-ChR-8-5-11-24
SX Female
CA Cancer cell line
//
ID KB-C1-R1
AC CVCL_1D83
RX PubMed=3711108;
CC Problematic cell line: Contaminated. Ancestral cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:23359; Colchicine.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M125 ! KB-ChR-8-5-11-24
SX Female
CA Cancer cell line
//
ID KB-C2
AC CVCL_D600
SY KBC2
DR BTO; BTO:0005215
RX PubMed=3711108;
RX PubMed=3857583;
RX PubMed=11509122;
CC Problematic cell line: Contaminated. Ancestral cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:23359; Colchicine.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D80 ! KB-C1.5
SX Female
CA Cancer cell line
//
ID KB-C2.5
AC CVCL_1D81
SY KBC2.5
RX PubMed=3711108;
CC Problematic cell line: Contaminated. Ancestral cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:23359; Colchicine.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D600 ! KB-C2
SX Female
CA Cancer cell line
//
ID KB-ChR-8-5
AC CVCL_5994
SY KB-CH[R]-8-5; KBCh(R)-8-5; KB-8-5; KB8-5
DR BTO; BTO:0003919
RX PubMed=3711108;
RX PubMed=3856953;
WW http://www.ott.nih.gov/erma/multidrug-resistant-epidermal-carcinoma-cell-line-kb-8-5-and-kb-8-11
CC Problematic cell line: Contaminated. Grand-parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:23359; Colchicine.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2088 ! KB-3-1
SX Female
CA Cancer cell line
//
ID KB-ChR-8-5-11
AC CVCL_5997
SY KB-8-5-11
RX PubMed=3711108;
RX PubMed=3856953;
CC Problematic cell line: Contaminated. Ancestral cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:23359; Colchicine.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5994 ! KB-ChR-8-5
SX Female
CA Cancer cell line
//
ID KB-ChR-8-5-11-24
AC CVCL_M125
SY KB-ChR-24; KB-8-5-11-24; KB-C1; KBC-1
RX PubMed=3711108;
RX PubMed=3856953;
CC Problematic cell line: Contaminated. Ancestral cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:23359; Colchicine.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5997 ! KB-ChR-8-5-11
SX Female
CA Cancer cell line
//
ID KB-CP.5
AC CVCL_IP04
SY KCP.5
DR BTO; BTO:0005849
RX PubMed=22571463;
CC Problematic cell line: Contaminated. Grand-parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2088 ! KB-3-1
SX Female
CA Cancer cell line
//
ID KB-CP10
AC CVCL_IP05
RX PubMed=7710928;
CC Problematic cell line: Contaminated. Ancestral cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_IP17 ! KB-CP5
SX Female
CA Cancer cell line
//
ID KB-CP20
AC CVCL_IP06
RX PubMed=7710928;
RX PubMed=9443404;
RX PubMed=22571463;
CC Problematic cell line: Contaminated. Ancestral cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_IP05 ! KB-CP10
SX Female
CA Cancer cell line
//
ID KB-CP5
AC CVCL_IP17
RX PubMed=7710928;
CC Problematic cell line: Contaminated. Grand-parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2088 ! KB-3-1
SX Female
CA Cancer cell line
//
ID KB-CV60
AC CVCL_X335
SY KBCV60; CV60
RX PubMed=11509122;
CC Problematic cell line: Contaminated. Grand-parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2088 ! KB-3-1
SX Female
CA Cancer cell line
//
ID KB-D8
AC CVCL_1Q75
DR RCB; RCB2724
RX PubMed=12070602;
CC Doubling time: 19.1 hours (PubMed=12070602).
CC Breed/subspecies: Fischer 344/DuCrj.
DI NCIt; C60505; Rat sarcoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_1Q74 ! KB-P
SX Male
CA Cancer cell line
//
ID KB-P
AC CVCL_1Q74
RX PubMed=12070602;
CC Doubling time: 20.3 hours (PubMed=12070602).
CC Breed/subspecies: Fischer 344/DuCrj.
DI NCIt; C60505; Rat sarcoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Male
CA Cancer cell line
//
ID KB-R
AC CVCL_M096
RX PubMed=17487352;
CC Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0372 ! KB
SX Female
CA Cancer cell line
//
ID KB-V1
AC CVCL_2089
SY KB-v1; KB-V-1; KBV1
DR BTO; BTO:0003917
DR CLO; CLO_0007077
DR CLDB; cl3009
DR BioSample; SAMN03151732
DR DSMZ; ACC-149
RX PubMed=3711108;
WW http://www.ott.nih.gov/erma/multidrug-resistant-epidermal-carcinoma-cell-line-kb-v-1
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Grand-parent cell line (KB) has been shown to be a HeLa derivative.
CC Doubling time: ~50 hours (DSMZ).
CC Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
ST Source(s): DSMZ
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 12,14
ST D16S539: 9,10
ST D5S818: 11,12
ST D7S820: 8,12
ST TH01: 7
ST TPOX: 8,12
ST vWA: 16,18
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2088 ! KB-3-1
SX Female
CA Cancer cell line
//
ID KB/BF-1
AC CVCL_HA90
RX PubMed=1597488;
CC Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:48080; Brefeldin A (BFA).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0372 ! KB
SX Female
CA Cancer cell line
//
ID KB/BF-2
AC CVCL_HA91
RX PubMed=1597488;
CC Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:48080; Brefeldin A (BFA).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0372 ! KB
SX Female
CA Cancer cell line
//
ID KB/cSV
AC CVCL_0I92
DR CLO; CLO_0007075
DR CLDB; cl3010
RX PubMed=87443;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID KB/STP-1
AC CVCL_AE00
RX PubMed=8625310;
CC Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:91276; Saintopin.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0372 ! KB
SX Female
CA Cancer cell line
//
ID KB/STP-2
AC CVCL_AE01
RX PubMed=8625310;
CC Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:91276; Saintopin.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0372 ! KB
SX Female
CA Cancer cell line
//
ID KB10460 iPSC colony 1
AC CVCL_DA13
RX PubMed=26475477;
CC Group: Non-human primate cell line.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9601; ! Pongo abelii
OI CVCL_DA14 ! KB10460 iPSC colony 2
OI CVCL_DA15 ! KB10460 iPSC colony 3
SX Female
CA Induced pluripotent stem cell
//
ID KB10460 iPSC colony 2
AC CVCL_DA14
RX PubMed=26475477;
CC Group: Non-human primate cell line.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9601; ! Pongo abelii
OI CVCL_DA13 ! KB10460 iPSC colony 1
OI CVCL_DA15 ! KB10460 iPSC colony 3
SX Female
CA Induced pluripotent stem cell
//
ID KB10460 iPSC colony 3
AC CVCL_DA15
RX PubMed=26475477;
CC Group: Non-human primate cell line.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9601; ! Pongo abelii
OI CVCL_DA13 ! KB10460 iPSC colony 1
OI CVCL_DA14 ! KB10460 iPSC colony 2
SX Female
CA Induced pluripotent stem cell
//
ID KB10973 iPSC colony 1
AC CVCL_DA16
RX PubMed=26475477;
CC Group: Non-human primate cell line.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9601; ! Pongo abelii
OI CVCL_DA17 ! KB10973 iPSC colony 2
OI CVCL_DA18 ! KB10973 iPSC colony 3
SX Male
CA Induced pluripotent stem cell
//
ID KB10973 iPSC colony 2
AC CVCL_DA17
RX PubMed=26475477;
CC Group: Non-human primate cell line.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9601; ! Pongo abelii
OI CVCL_DA16 ! KB10973 iPSC colony 1
OI CVCL_DA18 ! KB10973 iPSC colony 3
SX Male
CA Induced pluripotent stem cell
//
ID KB10973 iPSC colony 3
AC CVCL_DA18
RX PubMed=26475477;
CC Group: Non-human primate cell line.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9601; ! Pongo abelii
OI CVCL_DA16 ! KB10973 iPSC colony 1
OI CVCL_DA17 ! KB10973 iPSC colony 2
SX Male
CA Induced pluripotent stem cell
//
ID KB521
AC CVCL_0A32
RX PubMed=6245299;
RX PubMed=6409394;
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4350 ! K-BALB
CA Transformed cell line
//
ID KBF11
AC CVCL_0F75
SY KBF 11
DR ATCC; CRL-2788
RX PubMed=2612208;
CC Group: Human/rodent somatic cell hybrid.
CC Discontinued: ATCC; CRL-2788; true.
OX NCBI_TaxID=9606; ! Homo sapiens
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_9116 ! NIH 3T3-TK-
CA Hybrid cell line
//
ID KBH5.0
AC CVCL_D644
DR BTO; BTO:0005296
RX PubMed=14679002;
CC Problematic cell line: Contaminated. Grand-parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:51232; 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole (Hoechst 33342; Hoe 33342).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2088 ! KB-3-1
SX Female
CA Cancer cell line
//
ID KBM-3
AC CVCL_A425
SY KBM3
DR ChEMBL-Cells; CHEMBL3307847
DR ChEMBL-Targets; CHEMBL614010
DR Cosmic; 975260
RX PubMed=1568450;
RX PubMed=1995877;
CC Doubling time: 22.9 hours, at 255th passage (PubMed=1568450).
DI NCIt; C7463; Acute myelomonocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KBM-3/AMSA
AC CVCL_IP19
RX PubMed=1311390;
CC Characteristics: Has a TOP2A p.Arg487Lys mutation.
CC Selected for resistance to: ChEBI; CHEBI:2687; Amsacrine.
DI NCIt; C7463; Acute myelomonocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_A425 ! KBM-3
SX Female
CA Cancer cell line
//
ID KBM-3/DOX
AC CVCL_H688
DR ChEMBL-Cells; CHEMBL3307838
DR ChEMBL-Targets; CHEMBL613994
RX PubMed=1995877;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI NCIt; C7463; Acute myelomonocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_A425 ! KBM-3
SX Female
CA Cancer cell line
//
ID KBM-5
AC CVCL_0373
SY KBM5
DR BTO; BTO:0002546
DR MCCL; MCC:0000268
RX PubMed=3332852;
RX PubMed=8339266;
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KBM-7
AC CVCL_A426
SY KBM7; KBM-7/Hap8
DR BTO; BTO:0005775
DR EFO; EFO_0005903
DR BioSample; SAMN03473259
DR Cosmic; 787496
DR ENCODE; ENCBS322FGS
DR ENCODE; ENCBS815EDC
DR Wikidata; Q18392835
RX PubMed=8609723;
RX PubMed=23861985;
RX PubMed=24161985;
RX PubMed=24644259;
WW https://en.wikipedia.org/wiki/KBM-7_cells
WW https://www.horizondiscovery.com/kbm-7-cell-lines-c628
CC Group: Haploid karyotype cell line.
CC Characteristics: Haploid except for a disomy of chromosome 8.
CC Omics: Deep exome analysis.
CC Omics: Deep proteome analysis.
CC Misspelling: Occasionally 'KMB-7'.
ST Source(s): PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 11
ST D18S51: 18
ST D21S11: 30
ST D3S1358: 15
ST D5S818: 12
ST D7S820: 9
ST D8S1179: 8,14
ST FGA: 21
ST Penta D: 9
ST Penta E: 10
ST TH01: 7
ST TPOX: 8
ST vWA: 18
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KBM-7 P1-55
AC CVCL_B253
SY P1-55
RX PubMed=10527618;
CC Group: Haploid karyotype cell line.
CC Characteristics: Haploid except for a disomy of chromosome 8.
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_A426 ! KBM-7
SX Male
CA Cancer cell line
//
ID KBM-7/B5
AC CVCL_B254
SY KBM-7-B5; KBM7B5
RX PubMed=8609723;
RX PubMed=9783811;
CC Group: Haploid karyotype cell line.
CC Characteristics: Haploid except for a disomy of chromosome 8.
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_A426 ! KBM-7
SX Male
CA Cancer cell line
//
ID KBM-7/B5-1803
AC CVCL_8Z14
SY KBM7-B5-1803; KBM-7/B5 clone 1803
RX PubMed=9783811;
CC Group: Haploid karyotype cell line.
CC Characteristics: Haploid except for a disomy of chromosome 8.
CC Selected for resistance to: ChEBI; CHEBI:4027; Cyclophosphamide (CP; Endoxan).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B254 ! KBM-7/B5
SX Male
CA Cancer cell line
//
ID KBv200
AC CVCL_D599
SY KBV200
DR BTO; BTO:0005196
RX PubMed=7909748;
CC Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0372 ! KB
SX Female
CA Cancer cell line
//
ID Kc
AC CVCL_Z833
SY KC; K C
DR CLO; CLO_0007079
DR EFO; EFO_0002068
DR CLDB; cl3011
DR ECACC; 90070550
RX DOI=10.1016/B978-012229460-0/50004-X;
RX PubMed=5577860;
RX PubMed=24434506;
WW http://www.rccc.cytspb.rssi.ru/ecellbank/spinless/skc.htm
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/d/cell-lines-detail-283.html
CC Group: Insect cell line.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z832 ! Line K
SX Female
CA Spontaneously immortalized cell line
//
ID KC
AC CVCL_S097
SY KC-R; KC RAND
DR ATCC; CRL-7719
RX PubMed=4313504;
RX PubMed=4351391;
RX PubMed=6500159;
CC Problematic cell line: Contaminated. Parent cell line (U-118MG) has been shown to be a U-138MG derivative.
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-7719; true.
DI NCIt; C60781; Astrocytoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0633 ! U-118MG
SX Male
CA Cancer cell line
//
ID KC-1 [Human colon carcinoma]
AC CVCL_W475
RX PubMed=7873502;
DI NCIt; C7966; Colon mucinous adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KC-1 [Koala]
AC CVCL_IK54
SY Koala Conjunctiva-1
RX PubMed=14505439;
CC Doubling time: 16.5 hours (in 10% FCS), 26.5 hours (in 2% FCS), 86 hours (in absence of FCS) (PubMed=14505439).
OX NCBI_TaxID=38626; ! Phascolarctos cinereus
CA Finite cell line
//
ID KC-4G3
AC CVCL_G228
SY KC-4(IgG3); HB KC-4G3
DR CLO; CLO_0007080
DR ATCC; HB-8709
DR CCRID; 3142C0001000000401
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KC-4M1
AC CVCL_G229
SY KC-4(IgM)
DR CLO; CLO_0007081
DR ATCC; HB-8710
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID Kc-H
AC CVCL_Z837
SY KC-H; KcH
RX DOI=10.1016/B978-012229460-0/50004-X;
RX PubMed=877552;
RX PubMed=6780196;
CC Group: Insect cell line.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z833 ! Kc
SX Female
CA Spontaneously immortalized cell line
//
ID Kc-HP
AC CVCL_Z838
SY Kc HP; KcHP; KcAlo
RX PubMed=886199;
CC Group: Insect cell line.
CC Caution: We are not certain that Kc-HP and KcAlo are the same cell line.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z833 ! Kc
SX Female
CA Spontaneously immortalized cell line
//
ID Kc0
AC CVCL_Z840
SY KcO; KC-O
DR CLO; CLO_0007086
DR CLDB; cl3015
RX DOI=10.1016/B978-012229460-0/50004-X;
CC Group: Insect cell line.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z833 ! Kc
SX Female
CA Spontaneously immortalized cell line
//
ID KC02-44D
AC CVCL_E224
RX PubMed=21801462;
CC Transfected with: HGNC; 11730; TERT.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Telomerase immortalized cell line
//
ID KC12
AC CVCL_X904
SY KC 12
DR CGH-DB; 9334-4
DR Cosmic; 849373
DR Cosmic; 2520638
DR GEO; GSM374460
RX PubMed=8105119;
RX PubMed=10761702;
RX PubMed=11146448;
DI NCIt; C9385; Renal cell carcinoma
DI NCIt; C3105; Von Hippel-Lindau syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kc167
AC CVCL_Z834
SY KC167; Kc 167; Kc-167; Kc(167); Kc clone 167
DR EFO; EFO_0005819
DR DGRC; 1
DR ENCODE; ENCBS135ZQF
DR ENCODE; ENCBS182VSZ
DR ENCODE; ENCBS205EQM
DR ENCODE; ENCBS329ISE
DR ENCODE; ENCBS382VFL
DR ENCODE; ENCBS394RBY
DR ENCODE; ENCBS478PEU
DR ENCODE; ENCBS486FOA
DR ENCODE; ENCBS539YYB
DR ENCODE; ENCBS675YSX
DR ENCODE; ENCBS719PGH
DR ENCODE; ENCBS780AES
DR ENCODE; ENCBS836UXA
DR ENCODE; ENCBS851EXM
DR ENCODE; ENCBS931HGX
DR ENCODE; ENCBS942QVO
DR ENCODE; ENCBS985UDR
RX DOI=10.1016/B978-012229460-0/50004-X;
RX DOI=10.4172/2472-1115.1000103;
RX PubMed=6194991;
RX PubMed=21177962;
RX PubMed=21958154;
RX PubMed=24434506;
RX PubMed=24985917;
RX PubMed=25262759;
WW http://www.entu.cas.cz/zurovec/eng/research/cultures.html
CC Group: Insect cell line.
CC Part of: modENCODE project cell lines.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z833 ! Kc
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-IPPI-66D
AC CVCL_5I02
DR DGRC; 233
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z834 ! Kc167
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-IPPI-66D-Mt-mCherry
AC CVCL_5I03
DR DGRC; 244
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; X5DSL3; mCherry fluorescent protein.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_5I02 ! Kc167-IPPI-66D
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-Mt-mCherry-c1
AC CVCL_5I04
DR DGRC; 246
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; X5DSL3; mCherry fluorescent protein.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_5I15 ! Kc167-PP-93E
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-Mt-mCherry-c2
AC CVCL_5I05
DR DGRC; 247
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; X5DSL3; mCherry fluorescent protein.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_5I15 ! Kc167-PP-93E
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-Mt-mCherry-c3
AC CVCL_5I06
DR DGRC; 248
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; X5DSL3; mCherry fluorescent protein.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_5I15 ! Kc167-PP-93E
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-PP-16F
AC CVCL_5I07
DR DGRC; 219
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z834 ! Kc167
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-PP-21B
AC CVCL_5I08
DR DGRC; 220
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z834 ! Kc167
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-PP-21D
AC CVCL_5I09
DR DGRC; 221
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z834 ! Kc167
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-PP-50Aa
AC CVCL_5I10
DR DGRC; 222
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z834 ! Kc167
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-PP-50Ab
AC CVCL_5I11
DR DGRC; 223
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z834 ! Kc167
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-PP-52E
AC CVCL_5I12
DR DGRC; 224
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z834 ! Kc167
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-PP-61C
AC CVCL_5I13
DR DGRC; 225
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z834 ! Kc167
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-PP-89B
AC CVCL_5I14
DR DGRC; 226
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z834 ! Kc167
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-PP-93E
AC CVCL_5I15
DR DGRC; 227
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z834 ! Kc167
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-PP-93E-Mt-mCherry
AC CVCL_5I16
DR DGRC; 245
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; X5DSL3; mCherry fluorescent protein.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_5I15 ! Kc167-PP-93E
SX Female
CA Spontaneously immortalized cell line
//
ID Kc167-PP-99A
AC CVCL_5I17
DR DGRC; 228
RX PubMed=26450921;
CC Group: Insect cell line.
CC Transfected with: UniProtKB; P42212; GFP.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z834 ! Kc167
SX Female
CA Spontaneously immortalized cell line
//
ID Kc23
AC CVCL_Z900
SY Kc 23
RX PubMed=2515901;
CC Group: Insect cell line.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z833 ! Kc
SX Female
CA Spontaneously immortalized cell line
//
ID KC2H3
AC CVCL_M608
RX PubMed=1836174;
DI NCIt; C2946; Chondrosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M605 ! 105KC
SX Male
CA Cancer cell line
//
ID Kc7E10
AC CVCL_Z835
SY Kc 7E10
DR DGRC; 182
RX PubMed=7760738;
RX PubMed=8062820;
WW http://flybase.org/reports/FBrf0205934.html
CC Group: Insect cell line.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z833 ! Kc
SX Female
CA Spontaneously immortalized cell line
//
ID KCB 2012053S
AC CVCL_BS82
SY KCB 201253S
RX PubMed=23266978;
CC Group: Bird cell line.
OX NCBI_TaxID=128390; ! Nipponia nippon
SX Male
CA Finite cell line
//
ID KCB 2012055S
AC CVCL_BS83
RX PubMed=23266978;
CC Group: Bird cell line.
OX NCBI_TaxID=128390; ! Nipponia nippon
SX Female
CA Finite cell line
//
ID KCB 89001
AC CVCL_4231
DR CLO; CLO_0007083
DR CLDB; cl3013
DR ECACC; 93052109
DR KCB; KCB 89001
OX NCBI_TaxID=662561; ! Rusa unicolor
SX Female
CA Finite cell line
//
ID KCB 90008
AC CVCL_4233
DR CLO; CLO_0007084
DR CLDB; cl3014
DR ECACC; 94042031
DR KCB; KCB 90008
CC Discontinued: ECACC; 94042031; probable.
OX NCBI_TaxID=9612; ! Canis lupus
CA Finite cell line
//
ID KCC-L871
AC CVCL_7961
DR Cosmic; 1136976
DR Cosmic; 1556192
RX PubMed=18097577;
CC From: Tsukuda M.; Yokohama City University; Yokohama; Japan.
DI NCIt; C4044; Laryngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KCC-M871
AC CVCL_7962
DR Cosmic; 1136973
DR Cosmic; 1556191
RX PubMed=18097577;
CC From: Tsukuda M.; Yokohama City University; Yokohama; Japan.
DI NCIt; C8181; Oropharyngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KCC-MS871
AC CVCL_7963
DR Cosmic; 1136971
DR Cosmic; 1556185
RX PubMed=18097577;
RX PubMed=26780976;
RX PubMed=26781072;
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26780976, PubMed=26781072). Originally thought to originate from a tongue squamous cell carcinoma.
CC From: Tsukuda M.; Yokohama City University; Yokohama; Japan.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID KCC-T871
AC CVCL_7964
DR Cosmic; 1136963
DR Cosmic; 1556184
RX PubMed=18097577;
CC From: Tsukuda M.; Yokohama City University; Yokohama; Japan.
DI NCIt; C4648; Tongue squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KCC-T873
AC CVCL_7965
DR Cosmic; 1136964
DR Cosmic; 1556193
RX PubMed=18097577;
CC From: Tsukuda M.; Yokohama City University; Yokohama; Japan.
DI NCIt; C4648; Tongue squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KCC-TCM901
AC CVCL_7966
DR Cosmic; 1136965
DR Cosmic; 1556194
RX PubMed=18097577;
RX PubMed=26780976;
RX PubMed=26781072;
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26780976, PubMed=26781072). Originally thought to originate from a tongue squamous cell carcinoma.
CC From: Tsukuda M.; Yokohama City University; Yokohama; Japan.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID KCC-TCM902
AC CVCL_7967
DR Cosmic; 1136966
DR Cosmic; 1556195
RX PubMed=18097577;
CC From: Tsukuda M.; Yokohama City University; Yokohama; Japan.
DI NCIt; C4648; Tongue squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KCC-TCM903
AC CVCL_7968
DR Cosmic; 1136967
DR Cosmic; 1556196
RX PubMed=18097577;
CC From: Tsukuda M.; Yokohama City University; Yokohama; Japan.
DI NCIt; C4648; Tongue squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KCCF1
AC CVCL_M157
SY Kids Cancer Care Foundation 1
RX PubMed=18651103;
WW http://medicine.ucalgary.ca/about/kids_cancer
DI NCIt; C6906; Atypical teratoid/rhabdoid tumor
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KCEK
AC CVCL_1L46
RX PubMed=21213599;
CC Group: Bird cell line.
CC Breed/subspecies: White Leghorn.
OX NCBI_TaxID=9031; ! Gallus gallus
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KCEL
AC CVCL_1L47
RX PubMed=21213599;
CC Group: Bird cell line.
CC Breed/subspecies: White Leghorn.
OX NCBI_TaxID=9031; ! Gallus gallus
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KCF-1
AC CVCL_W097
SY Koi Caudal Fin-1
RX PubMed=21839788;
CC Group: Fish cell line.
CC Breed/subspecies: Koi.
OX NCBI_TaxID=1045269; ! Cyprinus carpio haematopterus
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KCI-MENG1-HP
AC CVCL_2H42
RX PubMed=26174772;
DI NCIt; C3230; Meningioma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2H40 ! KCI-MENG1-LP
SX Female
CA Cancer cell line
//
ID KCI-MENG1-HPSX-CL
AC CVCL_2H43
RX PubMed=26174772;
DI NCIt; C3230; Meningioma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2H42 ! KCI-MENG1-HP
SX Female
CA Cancer cell line
//
ID KCI-MENG1-LP
AC CVCL_2H40
RX PubMed=26174772;
DI NCIt; C3230; Meningioma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KCI-MENG1-LPSX-CL
AC CVCL_2H41
RX PubMed=26174772;
DI NCIt; C3230; Meningioma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2H40 ! KCI-MENG1-LP
SX Female
CA Cancer cell line
//
ID KCI-MOH1
AC CVCL_2090
SY KCIMOH1; WSU-MOH1
DR EFO; EFO_0006608
DR BioSample; SAMN03151779
DR CCLE; KCIMOH1_PANCREAS
DR DSMZ; ACC-498
DR GEO; GSM887201
DR GEO; GSM888274
RX PubMed=9436858;
RX PubMed=20143388;
RX PubMed=22460905;
RX PubMed=25485619;
WW http://www.prnewswire.com/news-releases/asterand-introduces-nine-ways-to-accelerate-cancer-research-55450592.html
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HPAC derivative (PubMed=20143388).
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~70 hours (DSMZ).
CC Omics: Deep RNAseq analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): DSMZ
ST Amelogenin: X
ST CSF1PO: 13
ST D13S317: 11
ST D16S539: 9,10
ST D5S818: 12
ST D7S820: 10,12
ST TH01: 9.3
ST TPOX: 10,11
ST vWA: 15,17
DI NCIt; C8294; Pancreatic adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3517 ! HPAC
SX Female
CA Cancer cell line
//
ID KCL-22
AC CVCL_2091
SY KCL22; Kcl22; KCL22S
DR BTO; BTO:0004137
DR BioSample; SAMN03472399
DR BioSample; SAMN03473517
DR CCLE; KCL22_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR Cosmic; 919142
DR Cosmic; 924053
DR Cosmic; 1019832
DR Cosmic; 1026566
DR Cosmic; 1070700
DR Cosmic; 1078720
DR Cosmic; 1176585
DR Cosmic; 1436596
DR Cosmic; 1498417
DR Cosmic; 2009517
DR Cosmic-CLP; 1330931
DR DSMZ; ACC-519
DR GDSC; 1330931
DR GEO; GSM887202
DR GEO; GSM888275
DR GEO; GSM1669981
DR JCRB; JCRB1317
DR JCRB; NIHS0534
DR NCBI_Iran; C574
DR PRIDE; PXD000030
RX PubMed=3332852;
RX PubMed=6321612;
RX PubMed=6576961;
RX PubMed=20417730;
RX PubMed=22460905;
RX PubMed=23754495;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~24 hours (DSMZ).
CC Microsatellite instability: Instable (MSI-high) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: Proteome analysis by 2D-DE/MS.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0534; true.
ST Source(s): Cosmic-CLP; DSMZ; JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 8,11 (Cosmic-CLP; DSMZ)
ST D13S317: 8,12 (JCRB)
ST D16S539: 12
ST D5S818: 10,12 (Cosmic-CLP; DSMZ)
ST D5S818: 10,11 (JCRB)
ST D7S820: 12 (Cosmic-CLP; DSMZ)
ST D7S820: 11,12 (JCRB)
ST TH01: 7,9
ST TPOX: 8
ST vWA: 14
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KCL001
AC CVCL_A237
SY KCL-001; WT-3; WT3; KCLe001-A
DR hPSCreg; KCLe001-A
DR ISCR; 309
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
CC From: King's College London; London; UK.
CC Registration: Swiss research registry; BAG-hES-IMP-0019.
CC Registration: UK Stem Cell Bank (UKSCB); R-06-021, Steering comm. appl. SCSC05-05.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL002
AC CVCL_A238
SY KCL-002; WT-4; WT4; KCL002/WT4; KCLe002-A
DR hPSCreg; KCLe002-A
DR ISCR; 306
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://www.nibsc.org/science_and_research/advanced_therapies/uk_stem_cell_bank/cell_lines/available_human_cell_lines/laboratory_grade/kcl002-wt4.aspx
CC From: King's College London; London; UK.
CC Registration: Swiss research registry; BAG-hES-IMP-0018.
CC Registration: UK Stem Cell Bank (UKSCB); R-06-028, Steering comm. appl. SCSC06-28.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL003
AC CVCL_A239
SY KCL-003; CF-1; CF1; KCL003/CF-1; KCL-003-CF-1; KCL003_CF1; KCLe003-A
DR hPSCreg; KCLe003-A
DR ISCR; 319
RX PubMed=17572666;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://www.nibsc.org/science_and_research/advanced_therapies/uk_stem_cell_bank/cell_lines/available_human_cell_lines/laboratory_grade/kcl003-cf-1.aspx
CC From: King's College London; London; UK.
CC Registration: Swiss research registry; BAG-hES-IMP-0017.
CC Registration: UK Stem Cell Bank (UKSCB); R-08-030, Steering comm. appl. SCSC06-28.
DI NCIt; C2975; Cystic fibrosis
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL004
AC CVCL_A240
SY KCL-004; KCLe005-A
DR hPSCreg; KCLe005-A
DR ISCR; 1369
RX PubMed=20178004;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
CC From: King's College London; London; UK.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL005
AC CVCL_A241
SY KCL-005; HD-1; KCL005-HD1; KCL005_HD1; KCLe004-A
DR hPSCreg; KCLe004-A
DR ISCR; 1370
RX PubMed=20178004;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
CC From: King's College London; London; UK.
CC Registration: UK Stem Cell Bank (UKSCB); R-07-013, Steering comm. appl. SCSC07-11.
DI NCIt; C82342; Huntington's disease
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID KCL006
AC CVCL_A242
SY KCL-006; KCLe006-A
DR hPSCreg; KCLe006-A
DR ISCR; 1371
RX PubMed=20178004;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
CC From: King's College London; London; UK.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID KCL008
AC CVCL_A243
SY KCL-008; HD-2; KCL008-HD2; KCL008_HD2; KCLe007-A
DR hPSCreg; KCLe007-A
DR ISCR; 1372
DR Wikidata; Q27570645
RX PubMed=20178004;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
CC From: King's College London; London; UK.
CC Registration: UK Stem Cell Bank (UKSCB); R-08-010, Steering comm. appl. SCSC07-49.
DI NCIt; C82342; Huntington's disease
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex ambiguous
CA Embryonic stem cell
//
ID KCL009
AC CVCL_A244
SY KCL-009-trans1; KCL009-trans1; KCL009/trans-1; KCLe008-A
DR hPSCreg; KCLe008-A
DR ISCR; 1373
RX PubMed=20178004;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://www.nibsc.org/science_and_research/advanced_therapies/uk_stem_cell_bank/cell_lines/available_human_cell_lines/laboratory_grade/kcl009-trans-1.aspx
CC From: King's College London; London; UK.
CC Registration: UK Stem Cell Bank (UKSCB); R-08-011, Steering comm. appl. SCSC07-49.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KCL011
AC CVCL_A245
SY KCL-011; KCLe015-A
DR hPSCreg; KCLe015-A
DR ISCR; 1866
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=644
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0212.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC10-31.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KCL012
AC CVCL_A246
SY KCL-012; HD-3; HD3; KCL012_HD3; KCLe009-A
DR hPSCreg; KCLe009-A
DR ISCR; 1867
RX PubMed=27345979;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=650
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0213.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC10-32.
CC Miscellaneous: Sibling to KCL013 (CVCL_A247).
DI NCIt; C82342; Huntington's disease
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL013
AC CVCL_A247
SY KCL-013; HD-4; HD4; KCL013_HD4; KCLe010-A
DR hPSCreg; KCLe010-A
DR ISCR; 1868
RX PubMed=27345987;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=651
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0214.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC10-33.
CC Miscellaneous: Sibling to KCL012 (CVCL_A246).
DI NCIt; C82342; Huntington's disease
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL015
AC CVCL_A248
SY KCL-015; VHL2; KCL015_VHL2; KCLe011-A
DR hPSCreg; KCLe011-A
DR ISCR; 1869
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=655
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0215.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC10-36.
CC Miscellaneous: Sibling to KCL016 (CVCL_A249) and KCL017 (CVCL_A250).
DI NCIt; C3105; Von Hippel-Lindau syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL016
AC CVCL_A249
SY KCL-016; VHL3; KCL016_VHL3; KCLe012-A
DR hPSCreg; KCLe012-A
DR ISCR; 1870
RX PubMed=27345783;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=656
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0216.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC10-35.
CC Miscellaneous: Sibling to KCL015 (CVCL_A248) and KCL017 (CVCL_A250).
DI NCIt; C3105; Von Hippel-Lindau syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KCL017
AC CVCL_A250
SY KCL-017; VHL4; KCL017_VHL4; KCLe013-A
DR hPSCreg; KCLe013-A
DR ISCR; 1871
RX PubMed=27345980;
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=657
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0217.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC10-34.
CC Miscellaneous: Sibling to KCL015 (CVCL_A248) and KCL016 (CVCL_A249).
DI NCIt; C3105; Von Hippel-Lindau syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL018
AC CVCL_A251
SY KCL-018; KCL018_MD1; MD1; KCLe014-A
DR hPSCreg; KCLe014-A
DR ISCR; 1872
RX PubMed=27346000;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=658
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0218.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC10-30.
DI NCIt; C84679; Dystrophia myotonica 1
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KCL019
AC CVCL_A252
SY KCL-019
DR ISCR; 1873
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=676
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0270.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-13.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KCL020
AC CVCL_A253
SY KCL-020
DR ISCR; 1874
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=677
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0271.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-13.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL021
AC CVCL_A254
SY KCL-021; KCL021_CF2
DR ISCR; 1875
RX PubMed=27345808;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=659
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0219.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-14.
DI NCIt; C2975; Cystic fibrosis
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL022
AC CVCL_A255
SY KCL-022
DR ISCR; 1876
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=673
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0264.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-13.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL023
AC CVCL_A256
SY KCL-023
DR ISCR; 1877
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=671
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0262.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-13.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID KCL024
AC CVCL_A257
SY KCL-024; KCL024_NF1-1
DR ISCR; 1878
RX PubMed=27345975;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=660
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0220.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-48.
CC Miscellaneous: Sibling to KCL025 (CVCL_A258).
DI NCIt; C3273; Neurofibromatosis type 1
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Embryonic stem cell
//
ID KCL025
AC CVCL_A258
SY KCL-025; KCL024_NF1-2
DR ISCR; 1879
RX PubMed=27345978;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=661
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0221.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-48.
CC Miscellaneous: Sibling to KCL024 (CVCL_A257).
DI NCIt; C3273; Neurofibromatosis type 1
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL026
AC CVCL_A259
SY KCL-026; KCL026_SMA
DR ISCR; 1880
RX PubMed=27345977;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=662
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0222.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-49.
DI NCIt; C98670; Werdnig-Hoffmann disease
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL027
AC CVCL_A260
SY KCL-027; HD-5; HD5; KCL027_HD5
DR ISCR; 1881
RX PubMed=27345982;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=663
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0223.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-47.
DI NCIt; C82342; Huntington's disease
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL028
AC CVCL_A261
SY KCL-028; KCL028_HD6
DR ISCR; 1882
RX PubMed=27345983;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=664
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0224.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-47.
DI NCIt; C82342; Huntington's disease
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL029
AC CVCL_A262
SY KCL-029; KCL029_CFWAS
DR ISCR; 1883
RX PubMed=27345811;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=665
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0225.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-46.
DI NCIt; C3448; Wiskott-Aldrich syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL030
AC CVCL_A263
SY KCL-030; KCL030_BT1
DR ISCR; 1884
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=666
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0226.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-45.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KCL031
AC CVCL_A264
SY KCL-031
DR ISCR; 1885
RX PubMed=26607962;
RX PubMed=27345813;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=672
CC Group: Clinical grade hESC cell line.
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0263.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-37.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL032
AC CVCL_A265
SY KCL-032
DR ISCR; 1886
RX PubMed=26607962;
RX PubMed=27345778;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=652
CC Group: Clinical grade hESC cell line.
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0266.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-37.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KCL033
AC CVCL_A266
SY KCL-033
DR ISCR; 1887
RX PubMed=25122690;
RX PubMed=26607962;
RX PubMed=27345988;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=653
CC Group: Clinical grade hESC cell line.
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0267.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-54.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
CC Miscellaneous: Sibling to KCL034 (CVCL_A267).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KCL034
AC CVCL_A267
SY KCL-034
DR ISCR; 1888
RX PubMed=25122690;
RX PubMed=26607962;
RX PubMed=27345810;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=654
CC Group: Clinical grade hESC cell line.
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0268.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC11-54.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
CC Miscellaneous: Sibling to KCL033 (CVCL_A266).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL035
AC CVCL_A268
SY KCL-035
DR ISCR; 1889
RX PubMed=27345970;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=667
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0227.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-38.
DI NCIt; C34375; Thalassemia major
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KCL036
AC CVCL_A269
SY KCL-036
DR ISCR; 1890
RX PubMed=27346001;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=668
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0241.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-38.
DI NCIt; C82342; Huntington's disease
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL037
AC CVCL_A270
SY KCL-037
DR ISCR; 1891
RX PubMed=26607962;
RX PubMed=27345800;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=675
CC Group: Clinical grade hESC cell line.
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0269.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-37.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL038
AC CVCL_A271
SY KCL-038
DR ISCR; 1892
RX PubMed=26607962;
RX PubMed=27345799;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=674
CC Group: Clinical grade hESC cell line.
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0265.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-37.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL039
AC CVCL_A272
SY KCL-039
DR ISCR; 1893
RX PubMed=26607962;
RX PubMed=27345806;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=680
CC Group: Clinical grade hESC cell line.
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0274.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-37.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KCL040
AC CVCL_A273
SY KCL-040
DR ISCR; 1894
RX PubMed=26607962;
RX PubMed=27345807;
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=678
CC Group: Clinical grade hESC cell line.
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0272.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-37.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KCL041
AC CVCL_A274
SY KCL-041
DR ISCR; 2282
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=679
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0273.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-38.
DI NCIt; C26900; Turner syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KCL042
AC CVCL_E085
SY KCL-042
DR ISCR; 2283
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=669
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0242.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-38.
DI NCIt; C2975; Cystic fibrosis
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID KCL043
AC CVCL_E086
SY KCL-043
DR ISCR; 2284
WW http://www.kcl.ac.uk/lsm/research/divisions/wh/groups/medicine/hescell.aspx
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=670
CC From: King's College London; London; UK.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0243.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-38.
DI NCIt; C2975; Cystic fibrosis
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID KCL22-r
AC CVCL_DP58
SY KCL22R
DR PRIDE; PXD000030
RX PubMed=10910924;
RX PubMed=20417730;
RX PubMed=23754495;
CC Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
CC Omics: Proteome analysis by 2D-DE/MS.
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2091 ! KCL-22
SX Female
CA Cancer cell line
//
ID KCL22/SR
AC CVCL_4V46
RX PubMed=12743326;
CC Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2091 ! KCL-22
SX Female
CA Cancer cell line
//
ID KCMC-1379
AC CVCL_4W59
DR JCRB; JCRB1511
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 11,12
ST D16S539: 9,13
ST D5S818: 10,12
ST D7S820: 11
ST TH01: 9
ST TPOX: 11,12
ST vWA: 18
DI NCIt; C123813; Beare-Stevenson cutis gyrata syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID KCMC-1528
AC CVCL_4W60
DR JCRB; JCRB1541
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 11,12
ST D16S539: 9
ST D5S818: 10,11,12
ST D7S820: 12
ST TH01: 6,9
ST TPOX: 9
ST vWA: 17,18
DI NCIt; C75466; Rubinstein-Taybi syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KCMC-1694
AC CVCL_4W61
DR JCRB; JCRB1540
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 9,12
ST D13S317: 12
ST D16S539: 11,12
ST D5S818: 10
ST D7S820: 11,12
ST TH01: 7,9
ST TPOX: 8
ST vWA: 14
DI NCIt; C123815; Myhre syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
CA Finite cell line
//
ID KCMC-T
AC CVCL_A632
DR Cosmic; 996308
DR Cosmic; 1037694
DI NCIt; C3183; T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KCP-4
AC CVCL_M123
RX PubMed=8200854;
RX PubMed=22562377;
CC Problematic cell line: Contaminated. Grand-parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2088 ! KB-3-1
SX Female
CA Cancer cell line
//
ID KCSV
AC CVCL_5781
DR CLO; CLO_0007087
DR CLDB; cl3016
RX PubMed=87443;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: C57BL/6.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID KD [Human abdomen rhabdoid tumor]
AC CVCL_U757
DR Cosmic; 802251
RX PubMed=9671307;
DI NCIt; C6586; Extrarenal rhabdoid tumor
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KD [Human lip fibroblast]
AC CVCL_2970
SY Karen Day
DR ATCC; CRL-1295
DR JCRB; JCRB9103
RX PubMed=418410;
RX PubMed=3860870;
RX PubMed=4842250;
CC Discontinued: ATCC; CRL-1295; true.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID KD2.3
AC CVCL_IU35
SY KD2-3
RX PubMed=6591445;
CC Breed/subspecies: DBA/2.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_S411 ! MDAY-D2
CA Cancer cell line
//
ID KD2SV
AC CVCL_F243
DR CLO; CLO_0007088
DR CLDB; cl3017
RX PubMed=87443;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: C57BL/10 x DBA/2.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID KD83
AC CVCL_5300
RX PubMed=3871362;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KD83
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/k/cell-lines-detail-160.html
CC Breed/subspecies: BALB/c.
DI NCIt; C21631; Mouse plasmacytoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4001 ! MOPC-104E
CA Cancer cell line
//
ID KDH-8
AC CVCL_HX29
RX PubMed=8635193;
RX PubMed=12192538;
CC Transformant: ChEBI; CHEBI:76329; 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB).
CC Breed/subspecies: Wistar King Aptekman/Hok (WKA/Hok).
DI NCIt; C60416; Rat hepatocellular carcinoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Cancer cell line
//
ID KDI/20
AC CVCL_9V30
DR NCBI_Iran; C637
RX PubMed=17852455;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID KE 37.3.2
AC CVCL_L699
SY KE37.3.2; KE37 3.2
RX PubMed=6983562;
DI NCIt; C9142; Adult T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1327 ! KE-37
SX Male
CA Cancer cell line
//
ID Ke He
AC CVCL_U781
DR ATCC; CRL-1277
CC Discontinued: ATCC; CRL-1277; probable.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID KE-24
AC CVCL_W476
SY KE24
RX PubMed=1958633;
RX PubMed=15016319;
CC Doubling time: 32.4 hours (PubMed=15016319).
CC Microsatellite instability: Instable (MSI-low) (PubMed=15016319).
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KE-3
AC CVCL_D883
RX PubMed=7671230;
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KE-37
AC CVCL_1327
SY KE 37; KE37
DR BTO; BTO:0002547
DR CLO; CLO_0007089
DR CLDB; cl3018
DR CLDB; cl3019
DR CCLE; KE37_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR ChEMBL-Cells; CHEMBL3308872
DR ChEMBL-Targets; CHEMBL2366287
DR Cosmic; 907277
DR Cosmic; 998735
DR Cosmic; 1012077
DR Cosmic; 1151782
DR Cosmic; 1281372
DR Cosmic; 1330502
DR Cosmic; 1524800
DR Cosmic; 1664524
DR Cosmic; 1760526
DR Cosmic; 2165719
DR Cosmic-CLP; 907277
DR DSMZ; ACC-46
DR GDSC; 907277
DR GEO; GSM887203
DR GEO; GSM888276
DR GEO; GSM1669982
DR Lonza; 1260
DR NCBI_Iran; C181
RX PubMed=9933131;
RX PubMed=16408098;
RX PubMed=22460905;
RX PubMed=22675565;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~40 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 8,12
ST D16S539: 11,12
ST D5S818: 12,13
ST D7S820: 8,12
ST TH01: 6,9.3
ST TPOX: 8
ST vWA: 17,18
DI NCIt; C9142; Adult T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KE-39
AC CVCL_3385
SY KE39
DR CLO; CLO_0050802
DR BioSample; SAMN03470990
DR BioSample; SAMN03472139
DR CCLE; KE39_STOMACH
DR Cosmic; 1187280
DR GEO; GSM887204
DR GEO; GSM888277
DR RCB; RCB1434
RX PubMed=7599112;
RX PubMed=22460905;
RX PubMed=24807215;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): PubMed=25877200; RCB
ST Amelogenin: X
ST CSF1PO: 13
ST D13S317: 8,10
ST D16S539: 11
ST D18S51: 14,15
ST D19S433: 14.2,16.2
ST D21S11: 30
ST D2S1338: 22
ST D3S1358: 17
ST D5S818: 10
ST D7S820: 11
ST D8S1179: 11,16
ST FGA: 22,23
ST Penta D: 11
ST Penta E: 18,23
ST TH01: 7 (PubMed=25877200)
ST TH01: 7,9.3 (RCB)
ST TPOX: 9,11
ST vWA: 14
DI NCIt; C4004; Gastric adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KE-4
AC CVCL_D884
SY KE4
RX PubMed=7671230;
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KE-43
AC CVCL_W477
SY KE43
RX PubMed=1390419;
RX PubMed=15016319;
CC Doubling time: 22.5 hours, at 105th passage (PubMed=1390419); 33.6 hours (PubMed=15016319).
CC Microsatellite instability: Stable (MSS) (PubMed=15016319).
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KE-43C4
AC CVCL_W478
RX PubMed=15016319;
CC Doubling time: 63.6 hours (PubMed=15016319).
CC Microsatellite instability: Stable (MSS) (PubMed=15016319).
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_W477 ! KE-43
SX Female
CA Cancer cell line
//
ID KE-97
AC CVCL_3386
SY KE97
DR CLO; CLO_0050806
DR BioSample; SAMN03470997
DR CCLE; KE97_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR Cosmic; 1187281
DR GEO; GSM887205
DR GEO; GSM888278
DR RCB; RCB1435
RX PubMed=7861622;
RX PubMed=22460905;
RX PubMed=24807215;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): PubMed=25877200; RCB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8
ST D16S539: 11
ST D18S51: 16,17
ST D19S433: 12,14
ST D21S11: 31,32.2
ST D2S1338: 20
ST D3S1358: 15
ST D5S818: 11,13
ST D7S820: 8,12
ST D8S1179: 10,15
ST FGA: 18,24
ST Penta D: 9,13
ST Penta E: 5
ST TH01: 7,9
ST TPOX: 9,11
ST vWA: 16,18
DI NCIt; C5248; Mucinous gastric adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KE-F11
AC CVCL_1Q77
DR RCB; RCB2726
RX PubMed=12811582;
CC Doubling time: 20.0 hours (at 10th passage), 16.5 hours (at 20th passage), 19.0 hours (at 30th passage) (PubMed=12811582).
CC Breed/subspecies: Fischer 344/DuCrj.
DI NCIt; C60465; Rat malignant schwannoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_1Q76 ! KE-P
SX Male
CA Cancer cell line
//
ID KE-P
AC CVCL_1Q76
RX PubMed=12811582;
CC Doubling time: 20.9 hours (at 10th passage), 19.7 hours (at 20th passage), 20.5 hours (at 30th passage), 18.4 hours (at 50th passage) (PubMed=12811582).
CC Breed/subspecies: Fischer 344/DuCrj.
DI NCIt; C60465; Rat malignant schwannoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Male
CA Cancer cell line
//
ID KE-R
AC CVCL_0I57
DR CCLV; CCLV-RIE 0138
RX PubMed=19941903;
OX NCBI_TaxID=9685; ! Felis catus
CA Spontaneously immortalized cell line
//
ID KE2a
AC CVCL_U657
RX PubMed=8648763;
CC Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0372 ! KB
SX Female
CA Cancer cell line
//
ID KEL FIB
AC CVCL_3730
SY KELFIB; KEL-FIB; Keloid fibroblast
DR CLO; CLO_0007090
DR ATCC; CRL-1762
DR BCRC; 60345
DR BCRJ; 0279
DR BioSample; SAMN03471419
CC Discontinued: BCRJ; 0279; probable.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 8,12
ST D13S317: 11,13
ST D16S539: 9
ST D5S818: 12
ST D7S820: 8,10
ST TH01: 7,8
ST TPOX: 8,11
ST vWA: 14,16
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID Kelly
AC CVCL_2092
AS CVCL_B322
SY KELLY; NB19; NB-19; NB19-RIKEN
DR CLO; CLO_0007091
DR CLO; CLO_0051540
DR EFO; EFO_0002069
DR CLDB; cl3020
DR BioSample; SAMN03472324
DR BioSample; SAMN03473084
DR BioSample; SAMN03473316
DR CCLE; KELLY_AUTONOMIC_GANGLIA
DR CLS; 300317/p2447_Kelly
DR Cosmic; 688077
DR Cosmic; 753618
DR Cosmic; 801738
DR Cosmic; 920246
DR Cosmic; 947704
DR Cosmic; 1037341
DR Cosmic; 1099138
DR Cosmic; 1109365
DR Cosmic; 1153786
DR Cosmic; 1161990
DR Cosmic; 1167409
DR Cosmic; 1167987
DR Cosmic; 1212537
DR Cosmic; 1995468
DR Cosmic; 2058107
DR Cosmic; 2131576
DR Cosmic; 2393634
DR Cosmic; 2485945
DR Cosmic-CLP; 753618
DR DSMZ; ACC-355
DR ECACC; 92110411
DR GDSC; 753618
DR GEO; GSM313806
DR GEO; GSM333801
DR GEO; GSM313805
DR GEO; GSM563354
DR GEO; GSM887206
DR GEO; GSM888279
DR GEO; GSM1366407
DR GEO; GSM1669983
DR Lonza; 1024
DR PRIDE; PXD003596
DR RCB; RCB0479
RX DOI=10.1007/0-306-46872-7_2;
RX PubMed=2846152;
RX PubMed=6888561;
RX PubMed=7139592;
RX PubMed=18923524;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~30-40 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: RCB; RCB0479; probable.
ST Source(s): Cosmic-CLP; DSMZ; ECACC; PubMed=25877200; RCB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 14 (Cosmic-CLP; PubMed=25877200)
ST D13S317: 10,13,14 (DSMZ)
ST D13S317: 10,14 (ECACC; RCB)
ST D16S539: 12,13
ST D18S51: 14,17
ST D21S11: 28,30
ST D3S1358: 14,16
ST D5S818: 11,13
ST D7S820: 9
ST D8S1179: 14
ST FGA: 20,21
ST Penta D: 9,14
ST Penta E: 12,16
ST TH01: 9.3
ST TPOX: 8,10
ST vWA: 18 (Cosmic-CLP; DSMZ; PubMed=25877200)
ST vWA: 16,18 (ECACC; RCB)
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Kem-BL
AC CVCL_7199
SY Kem; Kem-I
DR GEO; GSM1604062
DR GEO; GSM1604063
DR GEO; GSM1604064
RX PubMed=9882297;
RX PubMed=12219084;
RX PubMed=21088132;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C27694; Epstein-Barr virus-related Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KEN-3
AC CVCL_W124
SY KEN3; Ken3
RX PubMed=1351514;
RX PubMed=8718548;
RX PubMed=15677628;
DI NCIt; C5233; Ovarian fibrosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KEP1
AC CVCL_DR13
SY Kep1
DR GEO; GSM1489214
DR GEO; GSM1489244
DR GEO; GSM1489454
CC From: Center for iPS Cell Research and Application; Kyoto University; Kyoto; Japan.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_DR14 ! KRV1
SX Female
CA Induced pluripotent stem cell
//
ID Ker-CT
AC CVCL_S877
DR ATCC; CRL-4048
RX PubMed=12545164;
RX PubMed=19936293;
CC Transfected with: HGNC; 1773; CDK4.
CC Transfected with: HGNC; 11730; TERT.
ST Source(s): ATCC
ST CSF1PO: 7,11
ST D13S317: 11,13
ST D16S539: 9,11
ST D5S818: 12
ST D7S820: 10,11
ST TH01: 6,9
ST TPOX: 8
ST vWA: 15,16
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Telomerase immortalized cell line
//
ID Ker-CT-Ras
AC CVCL_4T86
RX PubMed=19936293;
CC Transfected with: HGNC; 1773; CDK4.
CC Transfected with: HGNC; 5173; HRAS.
CC Transfected with: HGNC; 11730; TERT.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_S877 ! Ker-CT
SX Male
CA Telomerase immortalized cell line
//
ID Kera-308
AC CVCL_5782
AS CVCL_0116
SY KERA-308; 308; Line 308
DR MCCL; MCC:0000008
DR CLS; 400429/p808_Kera-308
RX PubMed=3121168;
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID KERA-BP4
AC CVCL_5783
SY BP-4; BALB/c Papilloma 4
RX PubMed=3121168;
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID KERA-LC14
AC CVCL_5784
SY LC14
RX PubMed=3121168;
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID KERA-SP1
AC CVCL_5785
SY SP-1; SP1
DR CLS; 400430/NA
RX PubMed=1711471;
RX PubMed=3121168;
CC Discontinued: CLS; 400430; true.
CC Breed/subspecies: SENCAR.
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID Kera5
AC CVCL_ER29
RX PubMed=27533138;
CC Transformant: ChEBI; CHEBI:75393; Y-27632.
OX NCBI_TaxID=35658; ! Mastomys coucha
CA Transformed cell line
//
ID Ketr-3
AC CVCL_H579
SY ketr 3; Ketr3; KETR3
DR ChEMBL-Cells; CHEMBL3307668
DR ChEMBL-Targets; CHEMBL614637
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KF
AC CVCL_5M20
RX PubMed=4735239;
OX NCBI_TaxID=10036; ! Mesocricetus auratus
OI CVCL_5M21 ! MB
OI CVCL_5M22 ! TD
OI CVCL_5M23 ! WE
CA Cancer cell line
//
ID KF-1
AC CVCL_F843
SY KF
DR Cosmic; 931367
RX PubMed=7844449;
DI NCIt; C7978; Ovarian serous cystadenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KF-101
AC CVCL_Z507
RX PubMed=23731143;
CC Group: Fish cell line.
CC Doubling time: ~41 hours (PubMed=23731143).
CC Breed/subspecies: Koi.
OX NCBI_TaxID=1045269; ! Cyprinus carpio haematopterus
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KF-RMS-1
AC CVCL_S636
RX PubMed=12670897;
RX PubMed=23882450;
CC Derived from metastatic site: Bone marrow.
DI NCIt; C8971; Embryonal rhabdomyosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KF1
AC CVCL_W095
SY Koi Fin-1; KF-1
DR CCLV; CCLV-RIE 0843
DR ECACC; 10072801
RX PubMed=19941903;
CC Group: Fish cell line.
CC Breed/subspecies: Koi.
OX NCBI_TaxID=1045269; ! Cyprinus carpio haematopterus
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KF1SV
AC CVCL_5786
DR CLO; CLO_0007092
DR CLDB; cl3021
RX PubMed=87443;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: C57BL/6 x BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID KF28
AC CVCL_V533
SY KF-28
DR CGH-DB; 340-2
RX PubMed=10741911;
RX PubMed=11185891;
RX PubMed=17671176;
RX PubMed=18319717;
RX PubMed=18483383;
DI NCIt; C7978; Ovarian serous cystadenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_F843 ! KF-1
SX Female
CA Cancer cell line
//
ID KF28Tx
AC CVCL_X936
SY KF28 TX
DR CGH-DB; 382-2
RX PubMed=10741911;
RX PubMed=18483383;
CC Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
DI NCIt; C7978; Ovarian serous cystadenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_V533 ! KF28
SX Female
CA Cancer cell line
//
ID KFC
AC CVCL_0I51
SY Koi Fin Cell line
DR CCLV; CCLV-RIE 1112
RX PubMed=19941903;
CC Group: Fish cell line.
CC Breed/subspecies: Koi.
OX NCBI_TaxID=1045269; ! Cyprinus carpio haematopterus
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KFR
AC CVCL_S637
RX PubMed=8180967;
RX PubMed=12670897;
RX PubMed=23882450;
DI NCIt; C3749; Alveolar rhabdomyosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
- 公告/新闻
